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Thesis Summary 
Alzheimer’s disease is a neurodegenerative disorder which has been characterised with 
genetic (apolipoproteins), protein (β-amyloid and tau) and lipid oxidation/metabolism 
alterations in its pathogenesis.  In conjunction with the Dementia Research Group, 
Bristol University, investigation into genetic, protein and lipid oxidation in Alzheimer’s 
disease was conducted. A large sample cohort using the double-blind criteria, along with 
various clinical and chemical data sets were used to improve the statistical analysis and 
therefore the strength of this particular study. Bristol University completed genetic and 
protein analysis with lipid oxidation assays performed at Aston University. Lipid 
oxidation is a complex process that creates various biomarkers, from transient 
intermediates, to short carbon chain products and cyclic ring structures. Quantification of 
these products was performed on lipid extracts of donated clinical diseased and non-
diseased frontal and temporal brain regions, from the Brain Bank within Frenchay 
Hospital. The initial unoxidised fatty acids, first transient oxidation intermediates the 
conjugated dienes and lipid hydroperoxides, the endpoint aldehyde biomarkers and 
finally the cyclic isoprostanes and neuroprostanes were determined to investigate lipid 
oxidation in Alzheimer’s. Antioxidant levels were also investigated to observe the effect 
of oxidation on the defence pathways. Assays utilised in this analysis included; fatty acid 
composition by GC-FID, conjugated diene levels by HPLC-UV and UV-spec, lipid 
hydroperoxide levels by FOX, aldehyde content by TBARs, antioxidant status by TEAC 
and finally isoprostane and neuroprostane quantification using a newly developed EI-MS 
method.  This method involved the SIM of specific ions from F-ring isoprostane and 
neuroprostane fragmentation, which enabled EI-MS to be used for their quantification. 
Analyses demonstrated that there was no significant difference between control and 
Alzheimer samples across all the oxidation biomarkers for both brain regions. 
Antioxidants were the only marker that showed a clear variance; with Alzheimer samples 
having higher levels than the age matched controls. This unique finding is supported with 
the observed lower levels of lipid oxidation biomarkers in Alzheimer brain region 
samples. The increased antioxidant levels indicate protection against oxidation which 
may be a host response to counteract the oxidative pathways, but this requires further 
investigation. In terms of lipid oxidation, no definitive markers or target site for 
therapeutic intervention have been revealed. This study concludes that dietary 
supplementation of omega-3 fatty acids or antioxidants would most likely be ineffective 
against Alzheimer disease, although it may support improvement in other areas of 
general health.  
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1    Introduction 
1.1 - Alzheimer’s disease 
“To achieve this goal, all the choir need to sing from the same hymn sheet [1]”  
In 1901, the German psychiatrist and neuropathologist Aloysius “Alois” Alzheimer first 
observed a 51-year-old patient, Auguste D., who was plagued by symptoms that did not 
fit any existing diagnosis. These symptoms included rapid failing memory, confusion, 
disorientation, trouble expressing her thoughts, progressive cognitive impairment, 
hallucinations, delusions and unfounded suspicions about her family and the hospital 
staff. His patient deterioated inexorably, stating to Dr. Alzheimer, “I have lost myself.” 
Her subsequent death on April 8, 1906, allowed Alzheimer to identify β-amyloid (Aβ) 
plaques, neurofibrillary tangles (NFTs), and arteriosclerotic changes after post-mortem in 
her brain [2, 3]. At the 37
th
 Assembly of the Society of Southwest German Psychiatrists 
in Tubingen 1906, Dr Alzheimer presented for the first time these observations about 
amyloid plaques, NFTs, and arteriosclerotic changes. The neuropathological hallmarks of 
what later was termed AD [4]. Alzheimer’s disease (AD) is a neurodegenerative disorder 
that is normally diagnosed in the elderly. Due to longer life expectancy in these modern 
times, the older population is growing but this means that the risk of AD increases also. 
Recently there has been significant media and research attention, from the open talks by 
Sir Terry Pratchett regarding his personal management of the disorder to current news 
and radio broadcasts discussing a potential drug cure [5] and vitamin B supplementation 
[6]. However, to date, no definitive cure or medical intervention has been able to reduce 
significantly the effects of this mental disorder. 
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Figure 1 – Depiction of tissue damage observed in AD [2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Timeline of AD pathogenesis [7]. 
 
 
 
AD is a destructive neurodegenerative disease that causes trauma to the patient but 
also for the patient’s friends and family. The image above shows a dramatic 
representation of the damage AD can inflict on brain size in comparison to a healthy, 
non-AD, brain. 
 
In the early stages of AD there are two main increases in amyloid plaques and NFTs 
as the process of AD evolves. Entwined with this is a marked reduction in neuronal 
integrity which is a consequence of Aβ and NFT formation. 
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1.1a - Symptoms and Statistical Prevalence 
AD symptoms often appear as subtle problems in remembering minor events of everyday 
life, such as forgetfulness and difficulties recalling new names or recent conversations. 
However, these particulars are synonymous with other neurological disorders [8]. Early 
in the disease process, depression and anxiety occur with psychiatric symptoms which 
increase as the disease progresses [9]. Delusions, hallucinations and agitation occur 
within the middle to late stages [9] and during this later stage; profound dementia 
develops affecting multiple cognitive abilities and behavioural aspects. This involves 
memory loss, disorientation and impairment of judgement and reasoning [10], resulting 
in the patient being unaware of time and place, but more importantly at times being 
unable to identify  close family members [8]. Death occurs, on average, 9 years after the 
initial clinical diagnosis and is usually caused by respiratory complications, such as 
aspiration pneumonia [8].  
 
There are two general types of AD. Familial AD is an autosomal dominant disease 
associated with genes and their mutation. This type of AD is defined as being early-
onset, linked to incorrect amyloid precursor protein (APP) production and presenilin-1 
and 2 genes. The sporadic form of AD occurs in the majority of cases, termed late-onset 
which affects people over the age of 65 years. Risk factors for late-onset include the 
presence of apolipoprotein E Ɛ 4 isoform (ApoE Ɛ 4) and other environmental factors 
[detailed in section 1.1d (iii)] [11]. AD is the most prevalent form of dementia and 
significantly impacts patients, families, caregivers, communities, and society as a whole 
[2].  
 
According to the 2003 World Health Report, dementia contributed to the most years 
lived with a disability in people aged 60 years and older, more than stroke, 
musculoskeletal disorders, cardiovascular disease, and all forms of cancer. In 2006, there 
were 26.6 million cases of AD in the world. By the year 2050, the worldwide prevalence 
of Alzheimer’s will grow fourfold, to 106.8 million, with 1 in 85 persons living with AD 
[12]. Furthermore, it is estimated that at least 4 million people in the United States have 
been diagnosed with AD [13]. Approximately 200,000 diagnosed with early-onset AD 
(familial 4%), with the remaining cases being late-onset AD (sporadic 96%) [2]. In 
Europe the number of people with dementia may increase from 7.6 million prevalent 
cases in 2000 to 16.2 million in 2050 [14]. Finanically, in the United Kingdom (UK),  
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224 000 of the 461 000 elderly people with cognitive impairment live in institutions at a 
cost of £4.6 billion [3]. In the US, 5.1 million people were estimated to be living with 
AD in 2007 and $148 billion is spent each year to provide health care for these 
individuals [11]. Delaying disease onset by an average of 2 years would decrease the 
worldwide prevalence of AD by 22.8 million cases. Even a modest 1-year delay in 
disease onset would result in 11.8 million fewer cases worldwide [12]. Until methods of 
preventing AD are discovered, it is not only the tens of millions of disease victims and 
their families that will suffer, but also our nation, our healthcare system, and our 
economy as a whole [15]. 
 
1.1b - Post-mortem classification of disease state (Figure 3) 
During post-mortem, AD brain samples are classified using a definitive scale known as 
Braak staging. There are six stages which are distinguishable from each other allowing 
for determination of disease progression, the higher the stage, the greater the AD 
severity.  
 
Stage I. The most mildly affected cases show an involvement of the cortex confined to 
the transentorhinal region, which is involved in memory. The transentorhinal neurons 
generally are the first nerve cells in the brain to develop NFTs. Stage I is characterised by 
a modest number of these changes [16]. 
 
Stage II. The next stage is an aggravation of stage I and exhibits numerous NFTs in the 
transentorhinal region. Their density decreases slightly when approaching the proper 
entorhinal region. Stages I and II are characterised by the transentorhinal region being 
preferentially affected with only mild involvement of the hippocampus [16]. 
 
Stage III The characteristic feature of the third stage is a severe involvement of both the 
transentorhinal and entorhinal region. The isocortex remains virtually devoid of changes 
or is only mildly affected [16]. 
 
Stage IV. The fourth stage exhibits large numbers of tangles which are present in both the 
transentorhinal and entorhinal region with the subiculum, found in the hippocampus, 
only mildly involved. The key feature of stages III and IV is that both the entorhinal and 
transentorhinal regions are conspicuously affected and this is supplemented by a mild to 
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moderate hippocampal and low isocortical damage. Consequently being summarised as 
the "limbic stages" [16]. 
 
Stage V. The main feature of stage V is the damage to the isocortex region. In cases 
where the isocortex is severely affected, these areas tend to show the highest packing 
density of NFTs with virtually all isocortical areas being affected. A new component 
appearing in stage V is a brushwork of argyrophilic cellular processes covering the 
anteroventral nucleus [16]. 
 
Stage VI. In stage VI all the previous changes are even more pronounced. The large 
number of NFTs-bearing granule cells in the fascia dentata facilitates differentiation of 
stage V from stage VI. The obvious hallmark of stages V and VI is that the isocortex has 
been devastatingly affected by NFTs and plaques. The pathology includes, of course, all 
the changes noted in earlier stages. Stages V and VI are, therefore, denoted as 
"isocortical stages" [16]. 
 
1.1c - Hypotheses in relation to Alzheimer’s disease 
Many questions about pathogenesis of this disease still remain unanswered and 
therapeutic options are few. Therefore research and development of different novel 
strategies which target the mechanisms leading to dementia are constantly being 
investigated. In this context, it becomes essential to identify the molecular constituents 
and pathways involved in AD pathogenesis [17]. Generally, there are three common 
areas under investigation in AD which include oxidation, genetic control of protein 
synthesis and dietary risk factors. 
 
Oxidative stress is caused by a relative increase in the ratio of free radicals to 
antioxidants [2] and has been implicated in multiple diseases, but importantly in the 
development of neurodegenerative diseases’ including AD [18]. Oxidative stress results 
in the destruction and death of neurons in the brain, contributing to the progression of the 
disease [13, 19]. The brain areas demonstrating the highest levels of oxidative stress are 
typically the hippocampus, amygdala and parietal cortex [2]. Measuring this stress 
involves analytical methods determining the damage to nucleic acids, proteins, DNA and 
RNA, monitoring the levels of reactive oxygen species (ROS) [20], biomarkers [21] and 
finally compounds of lipid peroxidation [19].  
[22] [23] 
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AD is also associated with two major protein synthesis pathological traits. First, there is 
an overproduction and accumulation of Aβ peptide produced by the proteolytic 
processing of APP. Aβ then folds incorrectly and aggregates to form senile plaques. The 
biological role of APP is undefined; however this protein has been linked with cell 
growth, cell adhesion and metal ion homeostasis but in AD the processing of APP 
becomes disregulated and produces Aβ [24]. Secondly, there is the formation of NFTs 
caused by the aggregation of phosphorylated tau protein within neurons resulting in 
neuronal cell loss [11, 25]. Tau proteins provide the scaffolding matrix for neurite growth 
and the conversion to phosphorylated tangles begins to twist the neurite structure 
affecting neuronal activity. Individuals with genetic alterations in the genes that code for 
three transmembrane proteins; APP, presenilin-1 and presenilin-2 all deposit large 
amounts of the amyloid fragment Aβ in the brain and develop AD [26-28]. Numerous 
studies and theories are covered in the literature regarding Aβ and tau in the pathogenesis 
of AD [15, 17, 29-32].  
 
Inheritance of APOE Ɛ 4 allele is a major risk factor for late-onset AD. APOE proteins 
belong to the family of plasma lipid-binding proteins involved in triacylglycerol and 
cholesterol transport and delivery, but also contribute to the clearance of Aβ through 
binding to lipoprotein receptors [17, 33, 34]. APOE is a 299-amino acid protein that 
exists as three common isoforms. APOE Ɛ 2, APOE Ɛ 3, and APOE Ɛ 4 are encoded by 
alleles, which are a form of gene (similar to blood typing where the alleles are defined as 
whether you are AO, AA etc) and the more alleles present, the greater the risk of AD 
onset [35]. In addition to the genetic association between APOE and susceptibility to 
AD, immunoreactive APOE can be observed within the NFTs and Aβ proteins in the 
senile plaques in the brains of AD patients [35].  
 
Besides age, gender, education level and social activities, dietary parameters represent 
common risk factors for neurodegenerative and cardiovascular diseases. This leads to the 
hypothesis that nutrition could delay the onset of AD or at least slow its progression [2, 
17, 36, 37]. Higher intake of vitamin C, vitamin E, flavonoids, unsaturated fatty acids, 
fish oil, vitamin B12 and folate; along with lower saturated fat intake have been related 
to a lower risk for AD or slower cognitive decline [34, 38]. While genetics play a major 
role in the risk of familial AD, the majority of AD is late onset and appears to involve the 
interplay of multiple risk factors. The Mediterranean diet which is high in vegetables, 
fruits, nuts, cereals, fish, and olive oil are low in saturated fats and is linked to reducing 
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the risk of AD onset [39]. Most observational studies report an association of high fish 
intake, rich in omega-3 fatty acids, with better cognition or lower risk of dementia [40]. 
People who consume 1 or more fish meals per week have 60% less risk of AD than 
people who reported eating fish rarely or never [41].  
 
1.2 – Fatty acids 
“For one simple molecule (DHA) to affect so many seemingly unrelated processes, it 
must function at a fundamental level common to most cells, such as transcription events, 
membrane structure and functions, and/or signal transduction [42]” 
A simple description of a fatty acid is a hydrocarbon chain with a carboxyl group at one 
end which provides a means of attachment and polarity, whilst at the other a methyl 
group creates a hydrophobic environment. PUFAs are fatty acids which contain two or 
more double bonds within their hydrocarbon chain [43, 44]. Polyunsaturates have two 
naming systems which are used to differentiate between multiple bond systems. One is 
the delta and the other omega. The delta nomemclature is used to attribute the position of 
the double bond from the carboxyl end group. The omega classification system uses the 
position of the double bond from the methyl end to denote the class. For example, α-
linolenic acid (LNA; eighteen carbons with three double bonds) using the delta system is 
presented as Δ9, 12, 15 as the double bonds are positioned on C-9, 12, 15 respectively. 
Using the omega system the same α-linolenic acid is called omega-3 as the last double 
bond in the fatty acid is three carbons from the terminal methyl end.   
 
1.2a – Fatty acid synthesis 
Synthesis of fatty acids occurs in mammals through systematic addition of smaller chain 
building blocks to an intermediate in order to form longer chains. The intermediate 
required is malonyl-CoA, a three carbon chain, which is made from acetyl-CoA (a two 
carbon fatty acid) in an enzymatic reaction by acetyl-CoA carboxylase [45]. Both acetyl 
and malonyl groups need to be activated by coenzyme A (CoA) so that these components 
can bind with the fatty acid synthase enzyme where fatty acid synthesis occurs. Acetyl-
CoA and malonyl-CoA are transferred to the ACP and ACP track sites of the synthase 
enzyme by transacylase activity.  These two esterified ACP components on the fatty acid 
synthesis enzyme enables for the initial stage of fatty acid synthesis to start, a process 
involving addition and condensation. Malonyl-ACP and acetyl-ACP groups combine 
forming a four carbon chain carbonyl, accompanied with the release of carbon dioxide 
from the reaction [45].  
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Figure 4 – Fatty acid structures 
 
 
 
 
 
 
 
 
 
 
 
 
 
These three images above are all examples of fatty acids. The first image shows a simple 
saturated fatty acid with no double bonds in its structure and a methyl and carboxyl group on 
either end, where n can represent any amount of carbon chain units. As stated in the text, 
unsaturated fatty acids are defined as being omega-3 or omega-6, denoted by the position of 
the nearest double bond to the terminal methyl group in the second picture. The final picture 
shows the structure of some PUFAs, linoleic acid (18:2), α- and γ-linolenic acids (LNA), 
arachidonic acid (AA), eicosapentaenoic acid (EPA) and finally docosahexaenoic acid 
(DHA). 
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Figure 5 – De novo fatty acid synthesis [45]. 
The fatty acid synthase acts as the mediator for palmitate formation. The synthase 
present in vertebrates carry all the necessary enzymatic activities in one large 
polypeptide, whereas in plants all the conversions are conducted by several 
independent polypeptides. Malonyl-CoA and acetyl-CoA have to be transferred to the 
fatty acid synthase through two enzymes, acetyl-CoA-ACP transacetylase and 
malonyl-CoA-ACP transferase which connects these fatty acids to the synthase 
enzyme. Condensation occurs which combines the attached malonyl and acetyl 
groups to form a four carbon chain, acetoacetyl-ACP, with a loss of carbon dioxide. 
The carbonyl in this structure then gets reduced to form a hydroxyl group which is 
then removed leaving a double bond in the growing fatty acid chain. The penultimate 
and final stages includes the reduction of the double bond formed between the 
repeating units and the relocation of the chain to β-ketoacyl-ACP site of the fatty acid 
synthase, where the first acetyl was attached [45]. Addition of subsequent two carbon 
chains, through this pathway, increases the length of the fatty acid chain accordingly.   
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The synthesised carbonyl is then reduced to form a hydroxyl group, which in turn is then 
dehydrated to form a four chain fatty acid with a double bond. The double bond is then 
reduced to create a saturated four carbon activated fatty acid. The newly synthesised four 
carbon fatty acid is on one site of ACP and addition of another malonyl-CoA occurs at 
the second position; thus initiating the above process which continues to add two carbon 
units. This process of de novo fatty acid synthesis is depicted in figure 5. When this 
growing chain reaches sixteen carbons long (palmitic acid), no more carbons can be 
added by this mammalian system. Longer chains have to be created by elongase 
enzymatic activity, which is separate to the fatty acid synthase, in order to generate 
stearic acid (18:0) from palmitic acid (16:0).  
 
Double bonds can be introduced by another set of enzymes which are called desaturases, 
generating unsaturated fatty acids. Desaturases insert double bonds into fatty acids by 
removal of protons from the acyl chain to molecular oxygen. This process requires 
NADH as a co-reductant in which electrons are shuttled through cytochrome b5 and the 
b5 reductase onto the terminal desaturase which ultimately converts molecular oxygen to 
water. Both CoA and phospholipid linked fatty acids can act as substrates for destaurases 
[46] .It must be noted that humans do not possess all types of desaturases, PUFAs like 
linoleic acid (LA), (omega-6) and α-LNA (omega-3) are classes as essential fatty acids. 
These are obtained through diet as they cannot be synthesised in mammals by the de 
novo pathway detailed above. This is because mammals lack the desaturase enzymes that 
insert double bonds after C-9; and consequently these lipids are defined as essential fatty 
acids. Major sources of omega-6 fatty acids include vegetable oils such as corn, 
sunflower and soybean oil, whereas omega-3 fatty acid sources are for example fish, such 
as salmon, trout and tuna [17, 42, 47, 48].   
 
1.2b – Metabolism of essential fatty acids 
DHA and eicosapentaenoic acid (EPA) are the most important products of omega-3 
PUFA metabolism, with AA and docosapentaenoic acid (ω-6 DPA) the equivalent 
omega-6 products [11, 49, 50]. Neurons in the brain lack the enzymes necessary for de 
novo PUFA synthesis, of DHA and AA. These fatty acids are derived either from the 
diet, or synthesised from two dietary precursors. The liver is considered to be the primary 
site for biosynthesis of these fatty acids, which are delivered to the brain through 
subsequent secretion into the circulating blood stream. To synthesise AA, the initial 
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precursor is ω-6 LA. This fatty acid is desaturated, introducing another double bond at 
Δ6 enzymatically, to form γ-LNA (Δ6, 9, 12 – ω-6, 18:3). A elongase enzyme converts ω-6 
γ-LNA to dihomo-γ-linolenic acid (Δ8, 11, 14 – ω-6, 20:3) and then a Δ5-desaturase adds 
another double bond creating AA (Δ5, 8, 11, 14 – ω-6, 20:4). This key intermediate can be 
enzymatically converted into prostaglandins (PGs), thromboxanes (TxBs), leukotrienes 
(LTs) and lipoxins (LXs) which all have inherent physiological, pharmacological and 
biological activities [51-53]. Elongation converts AA to adrenic acid (AdA; Δ7, 10, 13, 16 – 
ω-6, 22:4), then another elongase adds two more carbons making tetracosatetraenoic acid 
(Δ9, 12, 15, 18 – ω-6, 24:4). Insertion of a double bond at C-6 by a Δ6-desaturase synthesises 
tetracosapentaenoic acid (Δ6, 9, 12, 15, 18 – ω-6, 24:5), then β-oxidation removes two 
carbons forming DPA (Δ4, 7, 11, 13, 16 – ω-6, 22:5) [48, 54-56]. 
 
 It is well established that DHA can be biosynthesised from ω-3 α-LNA, through the 
same processes detailed above. Starting with ω-3 α-LNA, it is desaturated to 18:4 (Δ6, 9, 
12, 15
- ω-3, 18:4) by a Δ6-desaturase. Chain elongation creates 20:4 (Δ8, 11, 14, 17- ω-3, 
20:4), which is then converted to ω-3 EPA by a Δ5-desaturase in the endoplasmic 
reticulum (ER). In mammals, ω-3 EPA is twice elongated to 24:5 (Δ9, 12, 15, 18, 21- ω-3, 
24:5) via ω-3 DPA. A double bond is introduced by a Δ6-desaturase to produce 24:6 (Δ6, 
9, 12, 15, 18, 21
- ω-3, 24:6). Subsequently, ω-3 24:6 is transferred to peroxisomes and 
converted to DHA by removal of two carbon atoms by β-oxidation. The synthesised 
DHA is transferred back to the ER and quickly incorporated into phospholipids [46, 57-
60]. It has been suggested that the rate limiting step in the formation of DHA from α-
LNA is the final step, involving peroxisomal oxidation of 24:6 omega-3 to DHA [61].  
 
Due to its degree of unsaturation, DHA can undergo rapid inter-conversions between 
many torsional states. These conversions happen because of the rotation of the methylene 
carbon groups situated between the double bonds [42]. This chain flexibility allows for 
changes to the bilayer properties and also the short-range interactions with other 
membrane components, which can subsequently affect the function of integral membrane 
proteins [62]. The apparent structural simplicity of DHA belies its biological versatility. 
DHA membranes are actually quite thin and leaky [63]. Data from a series of model 
membranes with increasing levels of lipids containing unsaturated fatty acids, predicted 
that DHA behaves as if it is actually shorter than the 18-carbon fatty acid oleic acid 
(18:1) [63]. 
28 
 
Figure 6 – Sprecker pathway [48] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Sprecker pathway denotes the synthesis longer chain PUFAs from two essential fatty 
acids, ω-6 LA and ω-3 α-LNA from dietary intake. Both precursors are converted following 
the same enzymatic processes, yet yield different end products. Starting with ω-6 LA, Δ6 
desaturase activity introduces a double bond at Δ6 of ω-6 LA, creating ω-6 γ-LNA (Δ6, 9, 12). 
Elongase activity adds two carbon atoms to ω-6 γ-LNA, making ω-6 dihomo-γ-LNA (Δ8, 11, 
14
), which has a double bond inserted at Δ5 by a Δ5-desaturase resulting in the formation of 
AA. This fatty acid can be converted to potent lipid mediators by cyclooxygenase and 
lipoxygenase activity after phospholipase release, when required. Continuing with the 
pathway, AA is elongated twice more, first to form ω-6 AdA (Δ7, 10, 13, 16 – 22:4) then onto 
tetracosatetraenoic acid (Δ9, 12, 15, 18 – ω-6 24:4).  Introduction of another double bond at Δ6 by 
Δ6 desaturase activity yields tetracosapentaenoic acid (Δ6, 9, 12, 15, 18 – ω-6 24:5) before a final 
β-oxidation step removes two carbons creating ω-6 DPA (Δ4, 7, 10, 13, 16). In the ω-3 pathway, 
the precursor is ω-3 α-LNA. A double bond is inserted at Δ6 by a desaturase forming 
stearidonic acid (Δ6, 9, 12, 15 – ω-3 18:4), then an elongase enzyme adds two carbons creating 
eicosatetraenoic acid (Δ8, 11, 14, 17 – ω-3). Δ5 desaturase activity puts a double bond at Δ5 
creating ω-3 EPA, which can be converted to metabolites but are less potent than the 
previous AA metabolites. Double elongation steps on ω-3 EPA produce ω-3 DPA (Δ7, 10, 13, 16, 
19) first, which has different bond positions to ω-6 DPA, then into tetracosapentaenoic acid 
(Δ9, 12, 15, 18, 21 – ω-3 24:5). A final double bond is inserted at Δ6 by a desaturase to make 
tetracosahexaenoic acid (Δ6, 9, 12, 15, 18, 21 – ω-3 24:6) before β-oxidation removes two carbons 
yielding the main product ω-3 synthesis product, DHA. 
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The flexible chain of DHA results in rapid inter-conversion between conformational 
states that range from extended towards the inner layer of the membrane, to bent 
conformers where the terminal methyl approaches the outer layer. The fluctuating surface 
of a PUFA chain compared to the rigid moiety of a neighbouring cholesterol molecule 
deters close approach and creates lipid rafts within the membrane. These rafts comprise 
of saturated lipid classes including cholesterol, sphingolipids and ceramides which are 
depicted as isolated elements, or rafts in the membrane and are not as dynamic as 
PUFAs. The flexibility of the PUFA chain accounts for the high “fluidity”, permeability, 
elasticity, fusion, enhanced flip-flop and preference for non-lamellar phases observed in 
specialised neural membranes [63].  
 
To maintain basal DHA levels in the brain, Δ5 and Δ6 desaturase activities are only 
induced in the absence of the precursors (LA and α-LNA). Despite a strong capacity of 
the central nervous system (CNS) to retain its DHA, an animal study revealed that the 
dietary intake of DHA can significantly alter its levels in the brain [64]. Generally, it is 
difficult to deplete DHA from the neural membranes of adult mammals even with a diet 
low in this fatty acid, presumably because of preferential uptake of it to support the basal 
turnover in the brain [57]. Unlike other tissues, the brain uptake needs to overcome the 
blood–brain barrier (BBB), and the transport mechanisms involved for DHA uptake 
through this barrier are not understood [42]. Studies with whole animals as well as with 
in vitro systems, revealed that DHA and other long chain PUFAs are transported across 
the BBB more efficiently when they are esterified to lysophosphatidylcholine (lysoPC) 
[65]. Upon its entry, DHA is subsequently released and then activated by an acyl-CoA 
synthetase. This newly formed docosahexaenoyl-CoA can be esterified via an acyl-CoA 
transferase to the stereospecifically numbered sn-2 position of phospholipids [66]. 
However, as humans age,  the level of PUFAs in the brain decreases and this observation 
may be attributed to (a) poor passage rate via the BBB, or (b) decreased rate of 
incorporation into the membrane, or (c) a decrease in the activities of Δ6 and Δ9 
desaturase enzymes [67]. 
 
1.2c – Putative functions of DHA within the brain 
The fatty acid composition of biological membranes significantly influences physical 
properties of biological membranes. This results in higher or lower membrane fluidity 
and modulated activity of membrane-associated proteins, as well as vesicle formation 
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and fusion [17, 48]. DHA can also significantly alter phase behaviour, elastic 
compressibility, ion permeability and rapid flip-flop of cell membranes. The degree of 
unsaturation, makes DHA sterically incompatible with saturated sphingolipid and 
cholesterol classes and, therefore, is capable of altering lipid raft behaviour where these 
components reside [68]. DHA and AA containing phospholipids have been proposed to 
play a special role in biomembranes including neurons. This fact is due to their 
favourable biophysical properties such as high motility and motional freedom [59, 69-
71].  
 
(i) Effect on membrane bound enzyme activity and ion channels; DHA can modulate 
cyclooxygenase-2 (COX-2) activity and eicosanoid production, by replacing AA in the 
phospholipids, reducing the availability of this precursor for these metabolites. DHA can 
exhibit a neuroprotective effect. This is supported by evidence that calcium independent 
phospholipase A2 (PLA2) inhibition, increased neuronal death by reactive oxygen species 
(ROS) [72]. Through N-methyl-D-aspartate (NMDA) responses and blocking K
+
 
channels, DHA can increase the excitability of neurons; but can also stabilise neuronal 
membranes by suppressing voltage-gated Ca
2+ 
currents and Na
+
 channels [50, 65, 70, 73, 
74]. 
 
(ii) Modifications to receptors and neurotransmitters; Reduction in DHA increases 
dopamine concentrations and reduce its binding to D2-receptors, which can be reversed 
through DHA supplementation [73]. Within the brain, DHA acts as a secondary 
messenger via coupling to neuroreceptors. It is also converted, by enzymatic 
lipoxygenation, to a variety of signalling molecules known as neuroprotectins 
(dihydroxyl docosanoid) and resolvins (trihydroxyl docosanoid), which have potent anti-
inflammatory properties and are involved in the resolution of inflammation [66, 70].  
 
(iii) Signal transduction; By changing the organisation and/or composition of the lipid 
rafts, DHA can modify many signalling pathways [42, 67]. Omega-3 FAs decrease fatty 
acid synthesis via inhibition of sterol regulatory element-binding proteins (SREBP) [75], 
which are involved in cholesterol and fatty acid synthesis. They can also increase lipid 
oxidation through activation of peroxisome proliferator-activated receptor (PPAR) [48]. 
DHA is a physiological inhibitor of glutamate transport at the synapse, playing a major 
role in the regulation of synaptic efficacy. This action of DHA in glutamate synaptic 
transmission may explain, in part, the memory deficit associated with omega-3 PUFA 
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deficiency [76]. In a series of seminal findings, it was demonstrated that DHA acts as an 
inhibitor of various receptors, suppressing nuclear factor-κB (NF-κB) related cell death 
signal transduction [48, 68]. Phosphatidylethanolamine (PE) containing DHA has the 
propensity to form nonbilayer phases, which allow binding of G proteins to occur, 
suggesting a role in G protein-coupled signaling pathways [59, 69].  
(iv) Gene modification; DHA alters the transcription of the gene encoding the Aβ 
scavenger, transthyretin, which could reduce Aβ plaque formation [17, 42, 50]. 
Docosahexaenoyl-CoA is a hepatocyte nuclear factor (HNF-4α) ligand, and HNF-4α is 
involved with the transcription of DNA homodimers. Free unesterified DHA is a ligand 
for PPARs, a gene linked to lipid metabolism [66, 77]. It can also directly bind to lipid-
related transcription factors including forms of liver X receptor and retinoid X receptor 
(RxR) [15, 50]. 
(v) Promotion of nonapoptotic pathways; DHA enrichment has been shown to 
promote phosphatidylserine (PS) accumulation in membranes, which enhances Raf-1, a 
kinase involved in multiple signal transduction pathways [78], and through the 
modulation of the phosphatidylinositol (PI) 3-kinase/Akt signalling cascade. This leads 
to a suppression of caspase-3 activation and cell death. In neuronal cells DHA can be 
replaced by ω-6 DPA in omega-3 deficiency. This replacement results in lower 
promotion of  PS clustering and Akt translocation and does not aid cell survival [15, 48, 
66, 79-81]. The enrichment of membranes in DHA has thus proven crucial in 
maintaining sufficient rates of these phosphorylated/active proteins, whose associated 
survival pathways are promoted in neurons [42]. 
(vi) Neurite growth; DHA can increase both maximum neurite length and the total 
number of neurites through activating syntaxin-3, a synaptic membrane protein that 
promotes neurite outgrowth [59, 70, 81, 82], which may be associated with a determinant 
neurotrophic role of this PUFA in the maturation of the CNS [42]. 
(vii) Inflammatory processes; Omega-3 fatty acid supplementation leads to a decrease 
in lymphocyte proliferation in humans and rats, a decrease in interleukin-1 (IL-1) 
production, and a decrease in IL-2 production [67, 68]. In addition, omega-3 decreases 
proinflammatory tumour necrosis factor (TNF) alpha production in humans [67, 68]. 
Bioactive DHA products, such as neuroprotectins and resolvins, possess potent anti-
inflammatory, immunoregulatory, and neuroprotective actions by negating the pro-
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inflammatory mediators formed from omega-6 PUFAs especially AA, defined as the 
resolution of inflammation [72]. 
 
1.3 - Phospholipids 
Cell membranes are composed of a wide range of molecular species of phospholipids 
determined by the acyl composition and distribution at the sn-1 and sn-2 positions. 
Membranes vary widely in their phosphoipid composition and show an asymmetric 
distribution even within a single memebrane [48, 67, 83]. Within biological membranes 
phospholipids tend to form bilayer structures and are highly laterally mobile, while flip-
flopping i.e. movement from one side to the other is rare. The fluidity of membranes is 
dependent, in part atleast, to the acyl compositionin which highly unsaturated fatty acids 
tend to lead to increased fluidity and high levels of saturation favour rigidity due to 
closer packing of the chains. Bilayers are held together by various hydrophobic, 
coulombic, van der Waal and hydrogen bond interactions between lipids and lipid –
protein interactions. Membrane fluidity can be regulated by activation of desaturases 
which are often temperature dependent [75].   
Phospholipids are made up of several distinct classes with different polar head groups, 
including phosphatidylcholine (PC), PE, and PS. Each phospholipid class consists of a 
different combination of fatty acids, that can vary in chain length and degree of 
unsaturation at the sn-1 and sn-2 positions on the glycerol backbone, figures 7 and 8 [84]. 
In adult brain, phospholipids account for 20–25% of the dry weight and 50-60% of 
neural membranes [85-88]. The two major phospholipid components in the brain are PE 
and PC [89]. The distribution of phospholipids is normally asymmetric across the plane 
of the membrane, with PE and PS concentrated in the inner layer and PC and 
sphingomyelin concentrated in the outer layer of the bilayer. When PC, PE, and PS are 
mixed, the order parameters of sn-1 hydrocarbon chains of all three lipids are generally 
similar, indicating that the lipids mix more or less homogeneously [90]. PC tends to form 
bilayers with little curvature, while PE imposes a negative curvature on these lipid 
bilayers [60]. These bilayers are penetrated to varying degree by receptors, enzymes, and 
ion channels. These proteins can protrude differentially through the membrane or are 
localised predominantly on the intracellular or extracellular membrane surface [83, 86, 
91].  
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 Figure 7 – General depiction of a phospholipid [45] 
 
 
Figure 8 – Several different phospholipids [92] 
 
 
 
Phospholipids consist of a glycerol backbone with two fatty acids and a phosphate 
group where various headgroups can be attached. These positions are labelled sn-1, 
sn-2 and sn-3. 
These are the major phospholipids observed across biological samples. The choline 
and ethanolamine headgroups are similar in structure with the only difference being 
the three methyl groups on the nitrogen in the choline moiety. The inositol head group 
comprises a sugar unit whilst the amino acid serine is the head group in PS.  
34 
 
In phospholipids saturated fatty acids preferentially located at the sn-1 and have a role in 
neuroplasticity, while unsaturated fatty acids are located at the sn-2 are associated with 
the generation of second messengers [43, 49, 63, 89, 93]. Such sn-2 PUFAs are also 
prone to oxidation which can modify the properties of biological membranes since they 
behave more like saturated fatty acids. Removal of these oxidised fatty acids and 
replacing them with non-oxidised PUFAs is important to maintain membrane function 
and a suite of enzymes is involved in this process which includes phospholipase A2 and 
an acyltransferase. in a mechanism known as the Lands cycle. [94].  
1.3a - Synthesis of phospholipids 
Synthesis of phospholipids occurs at the ER. The newly synthesised phospholipids self-
assemble into thermodynamically stable bilayers. These layers form vesicles that detach 
from the ER and travel to other sites to resupply the membranous structures [86]. The 
pathways of phospholipid synthesis and metabolism are highly interrelated, and one 
phospholipid can be converted into another relatively simply [91]. Phospholipids can be 
made by two strategic approaches, one by CDP-diacylglycerol and the other CDP-
headgroup. The CDP-diacylglycerol mechanism involves an activated fatty acid esterfied 
glycerol backbone, which is converted to a phospholipid by reaction with a headgroup. 
The CDP-headgroup is the opposite of the previous pathway; an activated headgroup 
binds with a diacylglycerol molecule, but still yields phospholipids as products. The 
biosyntheses of phospholipids involve multiple enzymatic steps and variations in the 
levels of the substrates and the activities of the rate-limiting enzymes themselves, are 
generally the main factors controlling the rates at which phospholipids are synthesised. 
 
1.4 - Oxidation 
“While the use of more than one measurement of lipid peroxidation is important, since 
no single lipid peroxidation index is completely satisfactory, caution must be taken in 
interpreting the results [95]” 
 
Oxidative stress occurs due to an imbalance between the pro-oxidant and antioxidant 
systems. Among these targets, the breakdown of lipids is damaging because the 
formation of lipid peroxidation products leads to an uncontrollable spread of free radical 
reactions [60]. Oxidative damage to phospholipid acyl chains causes rearrangement of 
double bonds, chain shortening, and the introduction of a variety of polar group moieties 
into the hydrophobic core of the bilayer. As a consequence, structural characteristics and 
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dynamics of lipid bilayers can be affected, leading to impairment of integral enzyme 
functions [60, 96-98]. Many studies have shown that free radical damage and lipid 
peroxidation increase as a function of the degree of unsaturation of the fatty acids 
present. In this regard it has been demonstrated that the number of bis-allylic positions 
contained in the cellular lipids of intact cells, determines their susceptibility to free 
radical-mediated peroxidative events. Therefore, a high content of highly unsaturated 
fatty acid such as AA or DHA in the cell membranes, may increase the oxidative stress 
of biological systems [42, 60, 99-103]. Free radicals or ROS are defined as an atom or 
group of atoms, which have one or more unpaired electron(s), that are capable of reacting 
with lipids and initiating the peroxidation process and abstracting hydrogen from the 
PUFA [51, 84, 101, 104]. However autoxidation of PUFAs may also be triggered by low-
valent transition-metal ions such as Cu
+
 or Fe
2+
 in the presence of ascorbate or heme iron 
complexes under aerobic conditions [51, 105].  
 
1.4a – Formation of conjugated lipid hydroperoxides 
Oxidation of fatty acyl residues proceeds by a series of reactions to give phospholipid 
hydroperoxides, epoxides, and hydroxides [103]. Several species can abstract the first 
hydrogen atom and these include the radicals: hydroxyl (•OH), alkoxyl (RO•) and 
peroxyl (ROO•). The membrane lipids, mainly phospholipids containing PUFAs, are 
susceptible to peroxidation because hydrogen abstraction from a methylene (–CH2–) 
group occurs, removing one electron from the bond, leaving behind an unpaired electron 
on the carbon, –•CH–. The presence of a double bond in the fatty acid weakens the C–H 
bonds on the carbon atom and thus facilitates H• abstraction. For example, the initial 
reaction of •OH with PUFAs produces a lipid radical (L•), which in turn reacts with 
molecular oxygen to form a lipid peroxyl radical (LOO•). The LOO• can abstract 
hydrogen from an adjacent fatty acid to produce a LOOH and a second lipid radical, 
perpetuating the chain reaction. The LOOH formed can undergo reductive cleavage by 
reduced metals, such as Fe
2+
, producing lipid alkoxyl radical (LO•) [32, 60, 98, 104, 106-
108]. Lipid peroxidation is terminated by two of the peroxyl radical quenching each other 
to form a non-radical and oxygen [21]. The radicals produced in the initiation process 
undergo rearrangements from 1, 4-pentadiene (methylene-interrupted) structures into 1, 
3-pentadiene [figure 9] systems [109].  
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Rearrangement or β-scission of the generated peroxy fatty acid radical, yields a variety of 
end products such as aldehydes, short chain alkanes and hydroxylated fatty acids [110]. 
Cyclisation of the peroxyl radical gives rise to bicyclic endoperoxides that can be 
reduced to form prostanoids [84]. This results in the formation of two structurally 
different biomarkers, aldehydes that can be formed from the chain scission of fatty acids 
and cyclic rings that are created from PUFAs containing three or more double bonds 
[Isoprostanes (IsoPs) from AA, neuroprostanes (NPs) from DHA]. Therefore these two 
need to be monitored in neural tissue because of the high PUFA content, to understand 
whether ring formation of chain breakdown is occurring when the LOOHs breakdown. 
 
1.4b - Aldehydes 
Breakdown of LOOHs into smaller fragments, generates a wide variety of water-soluble 
carbonyl compounds, such as aldehydes, 2-alkenals, and 4-hydroxyalkenals via β-
scission [111]. These aldehydes show different reactivity compared with free radicals 
because of their longer half-lives, which allows diffusion of the aldehyde-based species 
to sites distant from their formation [26]. Examples of aldehydes formed from lipid 
peroxidation include 4-hydroxynonenal (HNE), 4-hydroxyhexenal (HHE) and 
malondialdehyde (MDA). HNE is one of the main aldehydes formed during lipid 
peroxidation of omega-6 PUFAs, such as LA and AA [60]. The lipophilicity of HNE, 
means that phospholipids and proteins, which are embedded in biomembranes (such as 
transporters, ion channels and receptors), become especially susceptible to attack by 
HNE [26, 112]. HNE causes degeneration and death of cultured hippocampal neurons, by 
impairing ion-motive adenosine triphosphatase activity, disrupting calcium homeostasis 
and impairing glucose and glutamate transport [101]. It can also react with PE, yielding a 
Michael adduct and a Schiff-base adduct which can be present as pyrrole derivative. 
Interestingly, PS, which has the same potential as PE, reacts weakly with HNE [111]. 
HNE is also known to make adducts with primary amine and thiol groups in proteins and 
can also inhibit NF-κB activation [113, 114].  
 
Lipid peroxidation of omega-3 PUFAs such as LNA and DHA generates a closely related 
compound, HHE [60, 115, 116]. Despite the structural similarity between HNE and 
HHE, the biological actions and efficacies of these aldehydes differ significantly. For 
example, HHE has a more pronounced effect on mitochondrial permeability transition 
than HNE. HHE modulates endothelial nitric oxide synthase through NF-κB activation 
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[114] and is a potent inducer of permeability transition in hepatic mitochondria, but not 
in mitochondria isolated from brain [116].  
 
MDA is a three-carbon, low-molecular weight aldehyde that can be produced from 
trienes via K- or L-unsaturated peroxides of PUFAs regardless if they are omega-3 or 
omega-6 [96]. MDA concentration is not a good index of lipid peroxidation. MDA is 
labile; in vivo, it is metabolised or is used in lipid cross-linking reactions and its 
concentration reflects unsaturated fatty acid composition as much as the extent of lipid 
peroxidation [109]. The assessment of TBARs provides a crude measure of aldehydes 
given the high reactivity of thiobarbituric acid with lipid peroxidation products [21, 26]. 
 
1.5 - Isoprostanes and neuroprostanes 
Conjugated lipid hydroperoxides of PUFAs containing three or more double bonds can 
undergo cyclic ring formation, instead of aldehyde formation generating another 
endpoint oxidation biomarker. The notion that IsoPs could be generated in vitro non-
enzymatically as products of autoxidation of fatty acids was actually first demonstrated 
over 20 years ago [117, 118]. IsoPs are believed to be formed via a unified free radical 
mechanism [84, 101, 119, 120], which are independent of the enzymatic COX pathway 
for PG synthesis [121-123]. IsoPs were shown to have structures similar to the PGs, but 
with cis-dialkyl stereochemistry on the cyclopentane rings as a consequence of hex-5-
enyl radical cyclisation. PGs are synthesised from free fatty acids whereas IsoPs are 
formed in situ on phospholipid moieties before being released by PLA2 activity [51], 
[124]. 
 
The NPs were later identified. They are structurally similar to the IsoPs, but are derived 
from DHA [26, 105, 110, 124-131]. Since DHA is highly concentrated in neuronal 
membranes, NPs offer a unique window into free radical damage to neuronal membranes 
in vivo [132-134]. While there are only four regioisomeric families of the IsoPs creating 
64 compounds [122, 135-138], there are eight regioisomeric families of the NPs [126]. 
NPs have eight regioisomers, each consisting of eight racemic diastereomers for a 
theoretical total of 128 different compounds [139]. The regioisomeric series of 
prostanoids are distinguished by the position of the hydroxy group in the side chain [51]. 
Quantification of NPs formed from DHA oxidation were observed to exceed the levels of 
IsoPs generated from AA, which may provide a unique marker of oxidative injury to the 
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brain [140-142]. The highly stable, chemically inert F ring IsoPs have been quantified as 
markers of oxidative damage, and have been shown to be elevated in brain tissue affected 
by numerous neurodegenerative conditions [13, 21, 140, 143, 144]. F-ring compounds 
are not the only autoxidation product, many other different ring structures can be formed, 
detailed in figure 10. Formation of these rings depends upon the reduction conditions on 
the Hx-ring intermediate; however it is widely accepted that quantification of the F-ring 
compounds is the most effective biomarker in quantification of oxidation [134, 145-147].  
 
1.5a - Formation of the cyclic prostanoids 
Non-enzymatic oxidative formation of prostanoids is a facile process which occurs very 
readily in biological tissues. The process of cyclic prostanoid formation involves free 
radical attack on fatty acids esterified to phospholipids, the creation of the cyclic ring, 
followed by subsequent phospholipase hydrolysis to release the prostanoid [125, 148].  
The formation of these cyclic compounds requires a fatty acid that has at least three 
double bonds in its structure, as the creation of the carbon ring is at the expense of two 
double bonds. For example, when AA (four double bonds) oxidises in this process it 
creates F-ring IsoPs, which lose two double bonds and the resultant IsoP is referred to as 
a F2-IsoP because there are only two double bonds left. The mechanism of formation 
shares the same initiation reaction observed in LOOH creation, instead of the peroxyl 
radical stabilising to form a hydroperoxy group, it attacks the fatty acid chain resulting in 
the formation of the cyclic ring.  
 
This pathway starts with free radicals initiating the peroxidation of PUFAs by abstracting 
a bis-allylic hydrogen to form a lipid radical. Molecular oxygen adds extremely rapidly 
to this lipid radical and then this peroxyl radical attacks an adjacent double bond to form 
an endoperoxide radical. The endoperoxide radical can undergo internal cyclisation to 
form a bicyclic endoperoxide radical which will eventually add a second molecule of 
oxygen to form a bicylic endoperoxide-peroxyl radical that can be reduced to form the 
Hx-ring isomers. Different regioisomers of Hx-ring can form, depending on which of the 
bis-allylic hydrogens is extracted by the radical of one of the methylene groups. The 
entire reaction scheme occurs via radical reactions so that each of the stereocenters in Hx-
ring is racemic [figure 10] [134, 149]. The endoperoxide unit in Hx-ring is reduced easily 
to generate F-ring IsoPs. Several sulfur species are capable of reducing Hx-ringto Fx-ring 
and antioxidants such as α-tocopherol, are also effective in reducing Hx-rings [51].  
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The mechanism of formation of the IsoPs, from AA, involves initial hydrogen abstraction 
from one of the three bisallylic methylene groups of AA at carbon atoms 7, 10, and 13 
[figure 10] [150]. Molecular oxygen adds, exactly the same as in LOOH formation, 
creating a peroxyl group at position C-11 for example, if hydrogen abstraction occurs at 
C-13. The C-11 peroxyl then attacks the C-9 double bond, forming the endoperoxide 
cyclic ring and a lipid radical at C-8. This radical at C-8 then attacks the double bond at 
C-12 creating the bicyclic endoperoxide, but also facilitates molecular oxygen addition at 
C-15 making another peroxyl group. The bicyclic endoperoxide and peroxyl groups then 
get reduced to form the F-ring IsoP, which contains two hydroxyl groups on the 
cyclopentane ring and another hydroxyl on the methyl terminus side chain. This 
particular IsoP forme is known as the 15-series, as the hydroxyl group on the methyl 
terminus chain is fifteen carbons from the carboxyl end. Removal of hydrogen through 
abstraction at C-10 gives rise to the formation of two regioisomers the 8-series and 12-
series, whereas at C-7, it leads to the formation of 5-series [120, 135].  
 
The free radical-initiated peroxidation of α-LNA and its esters generates mixtures of 
primary hydroperoxides and cyclic peroxides. Two regioisomeric series are formed from 
the oxidation of linolenate depending on the site of initial hydrogen abstraction and 
subsequent oxygen insertion and are called phytoprostanes (PPs). Hydrogen atom 
abstraction at C-14 generates type I PP whereas hydrogen abstraction at C-11 yields type 
II PP [figure 11]. Each series is composed of 16 isomers and 32 PPH1 can be formed in 
total [151]. The autoxidation of DHA derivatives proceeds very similarly to that of the 
IsoPs and leads to NPs. The higher number of bis-allylic positions results in the 
formation of eight classes of NPs by a radical peroxidation, bicyclisation, oxygenation 
and final reduction. The assignment of the individual regioisomers of NPs was based on 
the cyclisations of the individual DHA-derived hydroperoxides [figure 12].  
 
The releasing of esterified prostanoids follows a rapid de-esterification phase, which is 
regarded as one of the rate limiting steps for their release. This reaction is the first step of 
enzymatic degradation of esterified prostanoids, which later secrete effectively into the 
peripheral circulation [51, 119, 152]. One important aspect of prostanoid formation is 
that, while they result from non-enzymatic rearrangement of lipid peroxyl radicals, the 
initial source of the free radicals or the lipid peroxyl radicals is often enzymatic [134]. 
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Figure 10 – Isoprostane ring structures and their mechanism of formation 
[51, 153] 
 
  
The top two images above the line shows the amount of different ring structures that 
can be formed under oxidation and the cis-dialkyl stereochemistry of an F-ring IsoP. 
The lower picture below the line, illustrates how F-ring IsoPs are formed by 
autoxidation.IsoPs form from initial hydrogen abstraction and oxygen attack, but 
instead of the hydroperoxide forming the radical attacks the PUFA backbone 
eventually resulting in the formation of the five member ring synonymous with 
prostanoic acid. Various methylene sites create multiple positional IsoPs. Illustrated is 
the mechanism of which the four regioisomers are formed, the 5-, 8-, 12- and 15-
series IsoPs. Attack at methylene carbon 13 creates the 15-series; carbon 10 creates 8- 
and 12-series with carbon 7 resulting in 5-series IsoP. 
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Figure 11 – Phytoprostane formation from linolenic acid oxidation [154] 
 
 
 
 
Figure 12 – Neuroprostane formation from docosahexaenoic acid    
oxidation [62] 
 
 
Electron ionisation (EI-MS) (methods - [25, 127, 155-158]) are more flexible and 
specific than NICI-MS, but with reduced sensitivity because of greater fragmentation.  
The mechanism of PP formation follows the same reaction principles seen in the IsoP 
scheme. With only two sites where the hydrogen can be abstracted from LNA, only 
two different sets of PPs are formed the 9- and 16-series from carbon 11 and carbon 
14 respectively. 
Due to the amount of positions where hydrogen abstraction can occur from within the 
DHA structure, the quantity of final oxidation products, the NPs, is vast. All these 
components are formed exactly in the same manner as the previous schemes. 
Abstraction t C6 gives 4-seri s, C9 – 7- and 11-series, C12 – 10- and 14-s ries, C15 
– 13- and 17-series and finally C18 for 20-series NP. 
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1.5b – Biological properties of isoprostanes and neuroprostanes 
Due to the role of IsoPs in the pathogenesis of disease, their cellular signalling pathways 
and biological effects have been explored [159-161]. In view of their structural similarity 
with enzymatically derived PGF2α, 15-series F2-IsoPs interact with the enzymes that 
degrade PGs in vivo [47]. Such reactions include oxidation of the 15-alcohol group, 
saturation of the 13, 14-double bond, ω-oxidation, and β-oxidation. PG metabolites 
excreted in the urine are usually chain-shortened by two or four carbon atoms [152, 162, 
163]. The configuration of the hydroxyl at C-15 must be S in the equivalent IsoP, as in 
the COX-derived PG, for 15-OH dehydrogenation to occur easily. The Δ13 double bond 
of PG cannot be reduced without prior 15-OH dehydrogenation. Another reaction that is 
markedly influenced by the steric structure is the reduction of the Δ5 double bond, which 
proceeds easily for PGF2α, but is more or less impeded for the various enantiomeric pairs 
of F2-IsoPs.  
 
Peroxisomal β-oxidation is crucial for several steps of lipid catabolism, such as 
shortening of very long chain fatty acids and degrading unusual fatty acids and 
oxygenated eicosanoids, including IsoPs. In humans, peroxisomal β-oxidation of IsoP 
mainly yields 2, 3 dinor 8-IsoP [119, 144, 163, 164]. DHA oxidation products can also 
undergo the same metabolism, for example 7-F4t-NP is rapidly metabolised to 5-F3t-IsoP 
by β-oxidation in rat liver homogenates [51]. F2-IsoPs act as broncho- and 
vasoconstrictors, modulate platelet function, contract lymphatics, induce mitogenesis 
[165] and be carried by HDL in the lipoproteins of human plasma [166]. 15-F2t-IsoP and 
its 2, 3-dinor, 5, 6-dihydro metabolite bind and activate the TxB receptor to potently 
induce vasoconstriction [128, 131, 134, 140, 144, 159].  
 
1.6 - Defence against oxidation 
Oxidative stress occurs in vivo, when antioxidant defences cannot inactivate the ROS 
generated either because of free radical overproduction or insufficient degradation of 
these radicals [167]. Primary defences are mainly preventative, whereas secondary 
defences have a “back-up” protective role, which might typically involve excision/repair 
of any lesions that do develop. Primary protection relies on the scavenging and 
inactivation of ROS or redox metal ions before lipid peroxidation takes place. Enzymes 
involved in primary protection include i) the copper/zinc-dependent and manganese 
dependent superoxide dismutases; ii) cytosolic and mitochondrial glutathione peroxidase, 
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which scavenges H2O2 at relatively low concentrations; and peroxisomal catalase, which 
scavenges H2O2 at high concentrations. Chain-breaking antioxidants such as α-tocopherol 
(vitamin e) and synthetic butylated hydroxytoluene (BHT) can afford primary as well as 
secondary stage protection. They compete with initial PUFAs for peroxyl radicals, 
generating LOOHs without creating another lipid radical, which stops propogation [104, 
107]. A second line of enzymatic defence against peroxidation injury exists in most cells 
involving the removal of LOOHs at damage sites, followed by repair reactions [104]. 
 
1.7 – Lipids and Alzheimer’s disease 
Cell membrane lipid abnormalities described in AD brain contribute to Aβ deposition, 
neuronal dysfunction and are linked to the gene encoding the cholesterol transporter 
APOE [82]. As membranes comprise of phospholipids, their metabolism has been shown 
to be abnormal in AD brain cortex. Depletion of phospholipids correlates with 
accelerated membrane degeneration seen in AD brain [168]. Epidemiological and 
experimental studies have indicated that increased omega-3 fatty acid consumption 
decreases the risk of developing AD [71]. Supplementation of omega-3 fatty acids as a 
preventative measure or potential treatment of AD has been conducted in various studies, 
detailed in table 1.  
In 2005, after reviewing 12 studies on the relationship between the intake of omega-3 
fatty acids and cognitive function in the elderly, the US Department of Health and 
Human Services concluded that there was  no definitive link between low omega-3 fatty 
acid intake and loss of cognitive function during aging [37]. Despite the findings by the 
US Department of Health and Human Services, literature still associates reduced DHA 
content in this disease, based upon the findings of Söderberg et al [169, 170]. This 
particular study represents the biggest post-mortem cohort sample size indicating lower 
DHA content in AD. In vivo studies in AD mouse models, reported that reduction of 
dietary intake of omega-3 PUFAs resulted in loss of post-synaptic proteins, while a DHA 
enriched diet could prevent these effects [20, 42]. Whether DHA is protective against AD 
or is a marker for disease pathogenesis is undefined, even with the plethora of literature 
studies (table 1). However, the disparity and lack of repetition between studies represents 
significant doubt. 
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AD brain is also under extensive oxidative stress, characterised by increasing levels of 
protein and lipid oxidation. Determining the level of oxidative damage in AD brain is 
central to understanding the pathogenesis of AD and will provide the basis for a rational 
development of experimental therapeutics [19, 177]. Alterations in brain phospholipids 
and increased oxidation, results in sn-2 esterified PUFAs being suspect to free radical 
attack. The levels of these PUFAs are therefore predicted to decrease in AD brain, if lipid 
peroxidation were increased [21, 27].  
 
F2-IsoPs and NPs have been investigated in relation to AD and have been found to be 
increased in the frontal and temporal cortex of AD compared with control brains [13, 51, 
71, 123, 139, 141, 177, 178] and in post-mortem ventricular cerebrospinal fluid (CSF) 
[13, 19, 21, 26, 51, 177], obtained from autopsy-verified AD cases, as well as in 
antemortem CSF from individuals diagnosed with AD. Results have been less consistent 
in regard to peripheral F2-IsoPs, with several studies reporting increased plasma levels, 
and others reporting no significant difference in AD compared to controls. Similarly, 
urinary F2-IsoPs have been reported to be increased [13] or unchanged [136]. The 
discrepancies concerning peripheral F2-IsoPs may be due to differences in patient 
selection criteria between studies, as smoking and other conditions associated with 
oxidative stress, such as cardiovascular disease and diabetes, which can significantly 
alter IsoP levels [7]. Relationships between APOE Ɛ 4 genotype (positive [33], negative 
[19, 21, 26]), NFTs [19, 21, 26] and Aβ levels [21] have also been investigated.  
 
1.8 – Research aims and objectives 
The aim of this project was to distinguish whether there is a link between AD and higher 
lipid oxidation, as seen in the literature. This was assessed using various biomarkers in 
the oxidation mechanism, under a double-blind scenario to ensure the quality of the 
results. This project was carried out in collaborated with the Dementia Research Group, 
Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital who had 
access to South West Dementia Brain Bank, University of Bristol for brain tissue from 
both AD and age-matched controls with the project at Bristol being sponsored by the 
Alzheimer research trust (ART).  
 
As discussed earlier a dietary intervention could halve AD onset, with omega-3 PUFAs 
and antioxidants being examples of proposed solutions. Various dietary supplementation 
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and post-mortem brain studies have not confirmed whether these can help prevent or treat 
AD, instead they have only created greater disparity. This is highlighted most in post-
mortem studies, where low cohort sizes have commonly been used in conjunction with a 
couple of biomarker assays. All the assays have been explored in AD before as 
individual studies, but on different cohort sizes and brain regions which affect their 
conclusions. The advantage of this project is the use of over 70 patient samples including 
different brain regions, to elucidate any pathways or conclusions in differentiating 
between control and AD. By using this larger cohort size, multiple quantification assays 
and clinical data sets on the same tissue, we were able to investigate this, with greater 
statistical power.  
 
The levels of DHA and AA were quantified, to evaluate the relationship between these 
PUFA and AD. Various oxidation markers were also investigated to reveal the role of 
lipid oxidation in the pathogenesis of AD. These markers included LOOHs and CDs, the 
cyclic IsoPs and NPs (highly specialised biomarkers formed from oxidation of AA and 
DHA respectively) and the levels of the aldehydes, which are the final endpoint products 
of fatty acid breakdown. The quantification of the cyclic compounds required the 
development of an appropriate method using GC-EI-MS. Total antioxidant levels were 
also determined to clarify the role of protection against oxidation in AD. All samples had 
a clinical breakdown of age, Braak staging, APOE genotype, sex and post-mortem delay 
accessible for multiple lines of enquiry. Each assay was investigated independently to 
find out its specific levels in AD to observe any differences, before statistical analysis 
was performed using the clinical data and creation of pathway oxidation models using 
correlation data. 
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2  Methodological approaches 
FOREWORD 
Methods conducted within Aston University are clearly marked, A=Aston, whilst the 
ones conducted by our collaborative group, (Dementia Research Group, Institute of 
Clinical Neurosciences, University of Bristol, Frenchay Hospital) are marked B=Bristol.  
2.1 - Materials, methods and samples 
2.1a - Chemicals 
Solvents and reagents were obtained from Fisher Scientific or Sigma Aldrich and were 
HPLC grade or higher. Didocosahexaenoyl (diDHA) phospholipids were purchased from 
Avanti Lipids. The HPLC column was obtained from Wako Chemicals and the GC 
columns from Agilent. IsoP standards, deuterated and non-deuterated, were purchased 
from Cayman Chemicals. SPE cartridges were obtained from Waters and the vacuum 
manifold from Supleco. NP and PP standards were graciously provided by Dr Thierry 
Durand, Universitiés de Montepeiller I et II. 
2.1b - Tissue 
Tissue from 36 cases of neuropathologically confirmed AD (CERAD ‘probable’ or 
‘definite’ AD, Braak tangle stage IV–VI) and 35 neuropathologically-normal controls 
without AD (Braak tangle stage 0-III) were obtained from the South West Dementia 
Brain Bank, University of Bristol. The age at death, gender, post-mortem delay and 
APOE genotype were known for all cases. Samples of mid-frontal cortex (Brodmann 
area 6) and superior temporal cortex (Brodmann area 22) carefully excluding underlying 
white matter were dissected from the frozen slices of left cerebral hemisphere. The study 
had approval from the Frenchay Research Ethics Committee. The AD cases, had a mean 
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age = 78 years and post-mortem delay mean = 45.0 hours and the controls, mean age = 
81 years and post-mortem delay mean = 48.0 hours [179]. 
 
2.1c - (B) Preparation and extraction of lipids from tissue 
50 mg tissue samples were added to 350 µl of methanol at 0°C and homogenised in a 
Bertin Technologies Precellys 24 mechanical homogeniser (Stretton Scientific, Stretton, 
UK) at 6,000 rpm for 29-30 s with 15–25 2.3 mm zirconia silica beads (Stratech 
Scientific, Newmarket, UK) in a screw cap 2 ml microcentrifuge tube (Fisher Scientific, 
Loughborough, UK) that had been washed by vortexing with 1 ml of chloroform three 
times. The sample was cooled on ice after homogenisation. Chloroform (350 µl) 
containing 100 mg/l butylated hydroxytoluene (BHT; 2,6-di-tert-butyl-4-methylphenol) 
was added and the resultant solution briefly vortexed. The homogenate was transferred to 
a centrifuge tube and the beads washed with a further 150 µl of 
chloroform/BHT:methanol 2:1 (v:v). The solutions were combined and centrifuged at 
2,000g for 5 min and the supernatant was removed. The pellet was resuspended by 
vortexing in 200 µl of chloroform/BHT:methanol 1:1(v:v) and the solution was re-
centrifuged. The supernatant was removed and combined with the first supernatant and, 
after the addition of a further 400 µl of chloroform/BHT and 325 µl of 0.9% w/v 
potassium chloride, the solution was vortexed and centrifuged. The purified lipid fraction 
was obtained in the lower chloroform phase [179]. 
 
2.1d - (B) Preparation of fatty acid methyl esters 
The lower chloroform phase was removed under N2, 250 µl of 1 M ethanolic KOH added 
and the solution left overnight at room temperature in a sealed tube. 1,250 µl of distilled 
water was added along with 400 µl of hexane: diethyl ether 1:1 (v:v) containing 100 mg/l 
BHT. The biphasic solution was vortexed, centrifuged usinf the conditions above and the 
upper phase discarded. The addition of hexane:diethyl ether/BHT, vortexing, 
centrifugation and removal of the upper phase were repeated three times. The pH of the 
lower phase was adjusted to pH 3 with concentrated hydrochloric acid. 400 µl of diethyl 
ether/BHT was added, vortexing, centrifugation and removal of the upper phase repeated 
twice, and the lower phase discarded. The two upper phases (containing the free fatty 
acids derived from the lipid extract) were combined and dried under N2. Methyl esters of 
the free fatty acids were then prepared in a sealed tube with a solution of 2.5% 
concentrated H2SO4 in anhydrous methanol overnight at room temperature [179]. 
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2.2 - (B) Analysis of total fatty acid methyl esters  
FAMEs were analysed by GC and identified by co-chromatography with authenticated 
standards and by GC-MS. Heptadecanoic acid (200nmol) was used as the internal 
standard and quantified by flame ionisation detection (FID) (Bristol). All measurements 
were made in duplicate and the mean value calculated for each fatty acid as a molar 
percentage of the total fatty acid content [71, 179]. 
2.2a - (A) Thin layer chromatography and GC-EI-MS phospholipid 
composition analysis 
Lipids were initially purified by TLC on Merck Kieselgel 60; separation of phospholipid 
classes and neutral lipid classes was achieved using a chloroform/methanol solvent 
system. PE and PC were major components together with PS and PI. Phospholipids were 
transmethylated using sulphuric acid-methanol and the corresponding fatty acid methyl 
esters were extracted into hexane and analysed by GC-MS (Agilent 6890 GC with 5973 
MSD) on a 30m DB23 column using helium as a carrier gas. Lipids were quantified 
using heptadecanoic acid as an internal standard.    
 
2.3 – (A + B) Conjugated diene and lipid hydroperoxide determination  
PUFAs undergo free radical attack on their methylene interrupted carbon, resulting in the 
formation of the 1, 3 pentadiene motif. This motif is synonymous with lipid oxidation 
and is regarded as the first step in the oxidative breakdown of PUFAs. Formation of the 
conjugated system allows for UV detection at a separate wavelength to the methylene 
interrupted non-conjugated diene system. In conjunction with HPLC, lipid moieties can 
be separated out and then, UV spectroscopy can be used to show differences between 
conjugated and non-conjugated systems for individual phospholipids.   
2.3a (A) - LC-UV-ESI-MS analysis 
Separation of extracted lipids was achieved on an Agilent 1100 LC linked with a UV 
diode array detector and subsequent analysis carried out using an electrospray ion trap 
mass spectrometer using the method by Mawatari and Murakami [180]. Lipid samples 
were dissolved in isohexane/isopropanol (3:1, v/v) and injected onto a Wakosil 5 NH2 
column (150mm x 4.6mm) held at 40°C at a flow rate of 1ml min
-1
. Spectral information 
was obtained at wavelengths of 210 and 234nm for each of the eluting phospholipids. 
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The 234nm absorbance value is a measure of CD formation produced during the 
oxidation of PUFAs having the 1, 3 pentadiene motif and 210nm absorbance related to 
non-oxidised fatty acids.  
2.3b (A) - UV spectrometer analysis 
Lipids were dissolved in ethanol:water (9:1, v/v) and the ultraviolet absorption at 210 and 
234 nm were measured (with a complementary blank), using a Jenway 6505 UV/vis 
spectrophotometer. The percentage difference between the maximum absorbance at 
234nm of the peroxidised phospholipid and 210nm of the corresponding non-peroxidised 
phospholipid was also calculated. A molar extinction coefficient of 27,000 M
-1
cm
-l
 [181] 
was used for calculation of the CDs concentration [95, 182-185]. 
 
2.3c (B) - Lipid hydroperoxide assay (FOX) 
The ferrous orange xylenoyl (FOX) assay kit was used to measure the amount of 
LOOHs.  Briefly, brain homogenates (c. 50 mg frontal, temporal cortex) were prepared 
in 100% cold (5°C) HPLC grade methanol before being homogenised with 450 µl of 
buffer solution (1:9 w/v tissue).  Into a 96-well plate the following was pipetted; 90 µl of 
0.25 mM FeSO4 (ferrous sulphate, prepared fresh for each assay), 35 µl of 25 mM H2SO4 
(sulphuric acid), 35 µl of 0.1 mM xylenol orange and 160 µl of distilled water. Blanks 
were prepared by replacing the tissue extract with methanol.  A volume of tissue extract 
was chosen that gave an absorbance at 580 nm of 0.7-0.8. Samples were incubated at 
room temperature until the reaction was complete, and absorbance at 580 nm was then 
measured. With tissue samples, a further addition was then made of 7 µL of 0.25 mM 
cumene hydroperoxide (CHP, 1.66 nmol), then incubation at room temperature for 30-60 
minutes until the reaction had reached a stable end point, and the absorbance at 580 nm 
was re-measured.  Levels of LOOHs are expressed as CHP equivalents [186]. 
2.4 - (B) Antioxidant assay 
This spectrophotometric method involves the generation of the ABTS [2,2’-azinobis-(3-
ethylbenzothiazoline-6-sulphonic acid)] radical cation in a decolourisation technique in 
which the radical is generated directly in a stable form prior to reaction with putatative 
antioxidants. Trolox (6-hydroxy-2, 5, 7, 8-tetramethychroman-2-carboxylic acid) is used 
as a standard. 
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Figure 13 – Chromophore used for conjugated diene determination [187]  
 
 
 
Figure 14 – Chromophore used for lipid hydroperoxide determination 
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From initial hydrogen abstraction from methylene carbons under oxidation, the 
unconjugated diene bonds rearrange to form a CD system, denoted in the red boxes 
above. These bonds can be monitored by UV at 234nm. Non-conjugated bonds can be 
observed at 203-210nm wavelengths as discussed in the introduction. 
The FOX assay is a very specific determination of LOOH levels. The products from 
lipid peroxidation react upon addition of iron sulphate (Fe
2+
) to produce a propagating 
lipid radical and oxidised iron (Fe
3+
). Xylenoyl orange, depicted at the bottom, can 
trap metal ions and the xylenoyl-metal complex produces a blue solution which is 
observed spectrophotometrically. 
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The percentage inhibition of absorbance at 734 nm is calculated and plotted as a function 
of the concentration of antioxidants and of Trolox for the standard reference data. 
Briefly, the ABTS reagent (7mM in water) was reacted with potassium persulphate 
(2.45mM) and then diluted with phosphate buffered saline (ph7.4) to produce a solution 
with an absorbance of (±0.02) at 734 nm. The mixture was then allowed to equilibrate at 
30 °C. Brain tissue samples (100mg) were homogenised in buffer solution before being 
applied, along with Trolox standards and blanks, into a 96-well plate. The diluted ABTS 
solution was added to each well (250µl) and the plate incubated at 30 °C for 6 minutes 
before reading the absorbance at 734 nm. The % inhibition of absorbance at 734 nm was 
calculated and plotted as a function of concentration of antioxidants and of Trolox for the 
standard reference data [188].  
2.5 - (B) Aldehyde determination using TBARs assay 
Measuring the end products of lipid peroxidation is one of the most widely accepted 
assays for oxidative damage.  These aldehydic products of lipid peroxidation are 
generally accepted markers of oxidative stress. MDA forms a 1:2 adduct with 
thiobarbituric acid.  The adduct formed from the reaction of MDA in samples with 
thiobarbituric acid (TBA) can be measured colorimetrically. TBARs levels are 
determined against a  MDA standard calibration curve. A series of MDA standards were 
prepared by dilution from a starting concentration of 250µM down to 0µM for creation 
of a correlation curve. The TBA reagent was made by diluting the TBA acid with sodium 
hydroxide. Into a microcentrifuge tube the sample (50µl, in 1.15% KCl), MDA standard 
(50µl), SDS Lysis solution (50µl, mixed thoroughly and left for 5 minutes) and 125 µL 
of the TBA reagent were pipetted. Tubes were then incubated at 95°C for 45-60 minutes, 
cooled in an ice bath for 5 minutes before centrifuging at 3000rpm for 15 minutes. The 
supernatant (200µl) was taken and placed into a 96-well plate and the absorbance 
measured at 532nm [189]. The concentration of TBARs was assatained by using the 
MDA standard calibration curve. 
2.6 (A) - Total (free and esterified) F2-isoprostanes and F4-neuroprostanes 
Two extraction procedures for these compounds were utilised, however, the method of 
Morrow et al [190, 191], did not perform as well as the one detailed below by Nourooz-
Zadeh et al [192]. To verify whether the extraction had worked, TLC was performed as 
described in Morrow et al [190, 191] and was unsuccessful. 
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Figure 15 – Loss of chromophore formed from antioxidant reaction [193] 
 
 
 
Figure 16 – Chromogen formed for aldehydes quantification 
The antioxidant assay utilises the ABTS cation radical to quantify total levels. In this 
figure, the radical is formed by prior reaction with potassium persulphate in 
conjunction with Trolox, is used to form a calibration curve for later sample 
determination. Any antioxidants present react with the cation turning the coloured 
ABTS solution to a clear solution with no absorbance at 734nm wavelength. 
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Quantification of aldehydes in this project was conducted using the classical TBA 
reaction with aldehydes which proceeds smoothly regardless of which aldehydes is 
present. Specifically in this scheme, MDA forms a 1:2 adduct with TBA. The MDA-
TBA adduct formed from the reaction of MDA in samples with TBA can be measured 
colorimetrically or fluorometrically. The wavelength at 532nm was utilised for 
determination. 
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Hence the method by Nourooz-Zadeh et al [192], which had also been checked by the 
same TLC method was chosen. Samples were incubated with 1ml of an aqueous solution 
of potassium hydroxide (1.0M) at 45°C for 30 minutes, then acidified using 2ml of water 
adjusted to pH 2.0 with HCl and allowed to equilibrate at 4°C for 15 minutes. The 
sample was applied on a C18 cartridge (500mg) preconditioned with methanol and water 
pH 2.0. The cartridge was sequentially washed with 10ml of water (pH 2.0) and 
acetonitrile: water (15:85 v/v). Lipids were eluted by washing the cartridge with 5ml of 
hexane: ethyl acetate: iso-propanol (30:65:5 v/v). This eluate was then applied to an NH2 
cartridge (500mg) pre-conditioned with hexane (5ml). The NH2 cartridge was 
sequentially washed with 10ml of hexane: ethyl acetate (30:70 v/v), acetonitrile: water 
(9:1v/v) and acetonitrile. Prostanoids were eluted from the NH2 cartridge with 5ml of 
ethyl acetate: methanol: acetic acid (10:85:5 v/v). Addition of 30µl PP (3µg in ethanol) 
was used as internal standard. The sample was immediately transferred into a screw cap 
vial and the solvent was evaporated under nitrogen at room temperature [110, 121, 127, 
140, 192, 194, 195].  
The pentafluorobenzyl (PFB) ester was prepared by adding 40µl of PFB-Br (10% in 
acetonitrile) and 20µl of DIPEA (10% in acetonitrile) to the dried sample following 
solid-phase extraction. The vial was sealed with a PTFE-lined cap and kept at 45°C for 
forty five minutes. The solvent was removed under a stream of nitrogen. BSTFA 
containing 1% TMCS (30µl) was added; the vial was sealed and incubated at 70° for 
thirty minutes. The solvent was removed under nitrogen and the residue was 
reconstituted in iso-hexane (20µl). All the samples were stored at -20° until GC-MS 
analysis [110, 156, 190, 191].  
The GC column was a fused-silica capillary column (HP-5MS, 5% phenyl methyl 
siloxane, 30m x 0.25mm ID 0.25µm film thickness). The initial oven temperature of 
160ºC was increased at a rate of 20ºC/min to reach a maximum temperature of 310ºC, 
which was held for 2 mins. The injector system mode was splitless; carrier gas was 
helium at a constant flow-rate of 1ml/min. GC-MS temperatures were as follows: injector 
300ºC, interface 250ºC, source 220ºC, and quadrupole 100ºC. The elution order in the 
GC chromatography went, PP first followed by IsoP then NP, this was confirmed using 
the commercially available IsoP and the synthesised PP and NP. The ion for 
quantification was the m/z 191 ion from the fragmentation of the F-ring of these 
prostanoids, along with the known mass of the internal standard. 
56 
 
3  Independent study analysis 
FOREWORD 
This chapter will discuss sets of results obtained by ourselves; separate from the larger 
cohort multiple assay study, detailed in the research aims and objectives. The larger 
study can be found in chapter 5, after the pathway models of lipid oxidation. These 
results are being utilised within this thesis to understand any relationships between AD 
and control in phospholipid compositions, post-mortem effect on CD levels and will also 
detail the discussion on the HPLC and prostanoid method development.  
3.1 – Fatty acid analysis 
SUMMARY 
DHA is an important fatty acid within the CNS and has a plethora of roles as described in 
chapter 1, the depletion of which has been highlighted in AD. DHA is associated with 
phospholipids, so loss of this particular fatty acid may reduce phospholipid content as 
well.  The loss of PUFA and phospholipid content will have effects on the properties of 
membranes, where they reside, which literature links to the effects of AD. Therefore, 
phospholipid fatty acid compositions were determined to find any differences, which 
may be specific for AD. 
3.1a – Phospholipid composition 
An aliquot of a brain lipid extract run on TLC allowed separation of phospholipids as 
stated in the methods section and enabled us to gain compositional data of phospholipids 
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In order from the bottom of the TLC plate, the retention of the phospholipids went PI, 
PS, PC, and PE with a non-polar band, comprising of triacylglycerols, cholesterols etc, 
running close to the solvent front. Use of an internal standard of known mass allowed for 
mass determination of each collected fraction via GC. Comparison between AD and 
control in the frontal lobe (table 2) showed a decrease in PC and PE with an increased 
level of PS. The decrease in PC and PE can be attributed to the theory of AD 
pathogenesis, either through metabolism deficits or through oxidation of specific 
membranes or membrane constituents. Fatty acid compositional analysis of the 
phospholipids clearly showed percentage differences in DHA between the three 
phospholipids postulated upon above. DHA appeared to be lower in PC, PE and PS; 
however this loss was greatest in PC. Justification for this loss, according to literature is 
down to AD pathogenesis and oxidation; however attention must be drawn to dietary 
intake and synthesis.  
3.2 – Conjugated diene and phospholipid hydroperoxides 
SUMMARY 
LOOHs and CDs are the initial products of oxidation which can be readily quantified as 
described in the methods section for the specific products. The methylene carbon 
between the double bonds is susceptible to hydrogen abstraction by free radicals, before 
addition of molecular oxygen to form the peroxide radical which can stabilise to form the 
hydroperoxide. This mechanism also causes the double bond to rearrange and create the 
conjugated double bond system. Therefore increased oxidation will be correlated to 
higher primary oxidation products. AD and the role of lipid peroxidation were 
investigated to elucidate the role of primary products in differentiating between the 
disease and control samples. 
3.2a – Separation and oxidation of single substrate phospholipids  
Initial trials for the separation of phospholipids were investigated using the commercial 
samples of PC and PE, monitoring their elution at 210nm, as PUFAs absorb within the 
UV range 200-210nm. The phospholipids were well separated with relatively strong 
absorbance due to the high PUFA content in the samples. The LOOHs co-elute with the 
parent molecule for the phospholipid species. Since oxidation of mixed biological lipids 
is complex, we decided to investigate the oxidation of commercially obtained single 
substrates diDHA PC.  
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Table 2 – Mass and composition of each phospholipid class detected by   
thin layer chromatography in frontal control and AD samples 
Control (n=4)  Alzheimer (n=4) 
Phospholipid Mass (nmol) % composition  Phospholipid Mass (nmol) % composition 
PI 27.6 ± 1.2 3.8  PI 17.2 ± 4.3 2.3 
PS 356.7 ± 23.6 49.4  PS 426.0 ± 36.7 57.1 
PC 51.5 ± 8.7 7.1  PC 34.0 ± 12.1 4.6 
PE 286.8 ± 35.1 39.7  PE 269.1 ± 41.8 36.0 
 
 Control samples phospholipid fatty acid composition (%)  
 12:0 14:0 16:0 16:1 18:0 18:1 AA EPA DHA U* 
PI     80.0±23.9     20.0±10.9 
PS  0.9±0.5 43.9±12.5  20.6±7.8 28.0±7.7   5.5±1.6 1.1±0.6 
PC 4.9±1.4  23.9±15.6  23.0±11.2 16.9±5.6 15.9±7.9  9.8±4.2 5.6±2.7 
PE   4.4±3.6  22.4±9.3 3.8±2.3 12.2±5.7 13.1±4.3 22.7±7.8 21.4±9.4 
 
Alzheimer samples phospholipid fatty acid composition (%) 
 12:0 14:0 16:0 16:1 18:0 18:1 AA EPA DHA U* 
PI     82.0±35.6     18.0±7.6 
PS  0.8±0.3 39.2±7.8 1.0±0.3 21.3±11.7 32.5±13.6   3.5±2.1 1.6±1.1 
PC 5.8±2.7  27.8±19.6  26.6±9.5 13.0±7.4 17.1±8.6   9.7±6.7 
PE   5.8±3.7  18.8±7.4 7.9±4.6 14.2±9.9 9.9±5.4 19.7±9.3 23.7±11.2 
 
 
 
 
From TLC, isolated phospholipid classes were analysed by GC-FID with 
heptadecanoic acid standard. The small sample size highlighted variation across the 
phospholipids and fatty acids, with AD samples having lower PC and PE content, but 
had increased PS content. Percentage composition of each phospholipid class 
indicated that the aminophospholipids were the highest in the brain, namely PS and 
PE. Additionally, across the fatty acids, DHA was seen to be lower in AD across 
these phospholipids and AA appeared to be higher in AD. 
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Rationalisation for this oxidation test was to justify whether DHA oxidises rapidly in 
phospholipids, with the view of evaluating the safest way of handling brain lipid extracts. 
Air oxidised samples from time course studies revealed that a 234nm absorbance 
increased with time. After 48h approximately 3.0% of the substrate had been oxidised. 
Exposure to air (up to 168h) resulted in increased CD formation which was detected at 
234nm (data not shown). The four chromatograms in figure 17 showed the progressive 
formation of CD formation with time. It was observed that oxidation of this DHA 
phospholipid substrate, did not breakdown as quick as anticipated. Literature indicates 
that DHA oxidises quickly, but our results indicate a proportionatly substrate loss of 3% 
by LC-UV using 210nm and 234nm wavelengths. Attempts to increase oxidation of the 
phospholipids, by addition of hemin chloride and CHP or by the use of Fenton reagent 
(iron-ascorbic acid complex), were unsuccessful.  
3.2b – HPLC phospholipid separation of biological samples 
Lipid extracts from frontal AD brain samples and their age matched controls were 
dissolved in isohexane/isopropanol (3:1, v/v) containing 0.01% BHT and separated by 
HPLC. The elution order of the phospholipids given in the method was PC, PE, PI and 
PS, which was verified using standards and MS fragmentation. Using both the MS and 
UV, phospholipid hydroperoxides in these samples were determined using the CD 
measurement at 234nm wavelength. Figure 18 shows an example of the chromatograms 
for both AD and control samples, with figure 19 detailing the corresponding levels of 
phospholipid hydroperoxides. 
As stated previously, the peaks in the chromatogram relate to PUFA intensity not 
necessarily meaning they are of highest mass. PC and PE were observed to be the only 
two phospholipids which formed their respective hydroperoxides in the chromatograms. 
The highest 234nm absorbance found, was for PCOOH in the AD brain samples 
compared with the control samples. Also notably, 234nm absorbance for PE was visible 
in the AD cases and very little was observed in the control samples, indicating a 
difference in phospholipid oxidation between control and AD. This suggests that 
preferential oxidation appears to be happening to PC and PE in AD samples, which 
correlates with the earlier reduction in PC and PE DHA content observed in the 
phospholipid fatty acid compositional analysis. 
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Figure 17 – LC-UV chromatograms of a time course oxidation experiment 
on diDHA PC. 
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Table 3 - 210nm absorbance versus 234nm absorbance over a given time 
course at rtp (22ºC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time (hr) 210nm abs (mAU) 234nm abs (mAU) % oxidation 
0 1637.4 ± 142.6 16.9 ± 2.4 1.0 ± 0.2 
0.5 1627.0 ± 175.8 17.0 ± 1.6 1.0 ± 0.1 
1 1610.6 ± 156.4 18.3 ± 3.1 1.1 ± 0.2 
2 1594.5 ± 236.3 19.5 ± 2.7 1.2 ± 0.1  
4 1536.8 ± 163.2 20.2 ± 1.9 1.3 ± 0.4 
6 1578.1 ± 189.2 21.5 ± 2.7 1.3 ± 0.2 
24 1468.2 ± 135.1 25.7 ± 4.6 1.7 ± 0.5 
48 1487.3 ± 126.9 47.6 ± 18.6 3.1 ± 0.8 
The above figures and table are results obtained from oxidation of diDHA PC under 
RTP. Intensity of the unoxidised DHA PC appears to reduce proportionatly over the 
given time frame reaching around 3.1% oxidation after 48 hours. The increase in 
234nm absorbance can be clearly seen in figure 17. In the chromatogram, the elution 
order went injection solvent followed by the phospholipid. In image A there is only 
one peak for the phospholipid at 210nm and then as you follow the time course a 
secondary peak appears behind the 210nm wavelength. This can be observed in image 
D, where you can see another peak absorbing at 234nm indicating the presence of 
conjugated lipid hydroperoxides. 
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Figure 18 - LC-UV chromatograms of Alzheimer and control samples 
 
 
 
 
 
 
 
 
 
Figure 19 - Bar graphs showing levels of phospholipid hydroperoxides in 
AD and control 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The elution order of samples in the chromatogram went injection solvent and 
antioxidant first, followed by SM second, PC third, PE fourth, PI fifth and then PS the 
last peak. The hydroperoxides elute at the same time but have a different wavelength 
to their non-peroxidised equivalents (210nm versus 234nm). This HPLC technique 
works differently to GC. In GC the largest abundance has the largest peak; here the 
largest peak refers to the strongest absorption. PS was higher in GC-MS 
determination, whereas PE is larger by this analysis due to its increased unsaturated 
content. 
PC and PE hydroperoxides were observed to be lower in the AD samples compared 
with the control ones, PS and PI were detected but no oxidised derivative was found 
in the chromatograms hence their omission. This may indicate preferential oxidation 
in the AD state of PC over the other detectable phospholipids. 
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3.2c – Post-mortem delay and phospholipid hydroperoxide levels  
Our collaborators provided us with the samples used in [71], where they confirmed that 
post-mortem  tissue with time and temperature [RT (23ºC) and 4°C] as controllable 
variables, showed no detrimental reduction on the fatty acid levels. Additional to their 
study, phospholipid hydroperoxides were quantified to verify the levels of oxidation by 
HPLC-UV. On performing the analysis we were also able to confirm that there was no 
significant difference in CD levels, as observed in the figures overleaf. Each graph 
(figure 20) shows all the lipid classes in the chromatogram by percentage area of the 
designated peak. Across all the graphs there appear to be small changes in percentages of 
all detected lipids, whether nonperoxidised or peroxidised. This clearly supplements the 
conclusion that under these specific extraction and handling parameters, no sample 
deterioration is observed. 
3.3 – Discussion of independent study 
Phospholipid compositional analysis highlighted a percentage drop in PE, PC and PI with 
a corresponding reduction in PUFAs, which is in agreement with the general consensus 
of AD. DHA levels were lower in the AD samples compared with the controls across all 
the phospholipids. Of more importance is the increase in PS, with a reduced DHA 
content. PS, as previously stated, is the main phospholipid involved in apoptosis. Upon 
insult PS moves towards the cell surface, where the major PE and PC membranes exist, 
and acts as marker for damage. This damaged cell can then be removed by macrophages 
reducing potential damage. The change in composition of the affected membrane(s) 
would affect integrity, transmission and diffusion leading to cellular death. PI reduction 
indicates lowering synaptic transmission, affecting neural cells and their signalling 
pathways. PE and PC are core membrane based phospholipids and the reduction of these 
demonstrates further, the link between AD progression and the loss of membrane 
integrity.  
The reduced level of DHA in the phospholipids of AD samples also agrees with the 
literature in table 1, whether this is due to breakdown or a dietary issue is undefined. 
Lower intake of DHA in AD may emphasise this loss or reduced metabolism of the DHA 
precursor, α-LNA. As we age the activity of desaturases, enzymes that introduce double 
bonds in the Sprecker pathway, begin to slow reducing production of key intermediates 
in fatty acid synthesis.  
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 Figure 20 – HPLC-UV analysis of phospholipids and their respective 
hydroperoxides 
 
 
  
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
←A 
 B→ 
←C 
 D→ 
These four images show the affect of temperature and post-mortem delay on brain 
tissue samples (n=3) at six different times on phospholipid and phospholipid 
hydroperoxide levels. These charts represent the proportionality of each component 
in terms of their specific absorbance at the chosen wavelengths. At RTP over a 72 
hour time frame (A), brain samples suffered no reduction in non-peroxidised 
components with the same conclusion at 4°C (B). The two lower graphs in the figure, 
show that the percentage levels of phospholipid hydroperoxides did not increase 
proportionately over the same time frame at RTP (C) and at 4°C (D). 
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DHA is critical to brain function, the brain can survive without it by replacing with DPA 
but this reduces the capabilities and will increase abnormalities [54]. Therefore 
supplementation of DHA in AD may be of therapeutic value. 
 
The oxidation studies on diDHA phospholipids indicated no clear increase in conjugated 
lipid hydroperoxide over the time period. This clearly shows that DHA is not as 
susceptible to oxidation as is commonly believed [99, 196]. The large number of 
conformations and constant fluid motion of the PUFA chain makes hydrogen abstraction 
difficult. However once intiated the rate of oxidation would be elevated. The 
phospholipid, by which the PUFA is esterified onto, plays an extremely important role in 
defending the PUFA. The phospholipid headgroup can interact with oxidative aldehydes, 
through addition reactions, so reducing the potential oxidative damage [112]. 
Antioxidants present in the biological environment, would offer protection for the 
vulnerable PUFAs by either quenching lipid peroxidation or by providing an alternative 
substrate for hydrogen abstraction, therefore preventing further lipid membrane damage 
[104, 107].  
 
Analysis of the samples used in [71], indicated that the post-mortem delay had no effect 
on phospholipid levels or their respectivehydroperoxides. Combining the outcomes of the 
diDHA time course and the post-mortem samples indicates that the breakdown of 
phospholipids and PUFAs in vitro is not detrimental. There was a specific increase in 
PCOOH in the AD state using a small cohort compared to the controls, which may again 
relate to exclusive oxidation of the membrane bound PC over the other major 
phospholipids. The reduction in DHA content within the PC pool as well as the increased 
PCOOH and PS levels, demonstrates that breakdown of PC and elevation of PS are 
unique to AD using this cohort.  
 
3.4 – Discussion of method development 
Analytically, we did not possess the GC-NICI-MS system and only had a GC-EI-MS 
system in which to employ a method for the quantification of the NPs. A number of  EI-
MS and CI-MS methods were thus evaluated to assess their performance and potential 
extension to NP quantification using the available instrumentation. Normally, a 
deuterated standard of a known mass would be used in IsoP and NP quantification, but 
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using EI-MS conditions they produce exactly the same retention times and fragments as 
the quantifiable material.  
 
Using the same principal, seen in FAME quantification, a smaller chain prostanoid was 
implemented in union with a GC column which sorted fatty acids by chain length rather 
than degree of unsaturation. The smaller chain prostanoid in question was a PP. This 
nonenzymatic oxidation product of α-LNA, commonly found in plants, was generously 
given to us by Dr Thierry Durand along with the 4 series NP. In conjunction with the 
commercially available IsoP and acquired PP and NP, it allowed for simple 
chromatography to be obtained for method development, before quantification of these 
biomarkers in the biological samples was completed.  
 
From thorough analysis of literature mass spectra, it was found that all the F-ring based 
prostanoids share two keys ions indicative of their structure. These ions were m/z 191 
and 217 which are fragments of the cyclopentane ring where the two derivatised 
hydroxyls reside. The m/z 191 ion (Me3SiO+=CH-OSiMe3) is a rearrangement ion that is 
frequently a base ion of many F-ring compounds, and the m/z 217 ion (Me3SiO-CH
+
-
CH2-CH
+
-OSiMe3) [Figure 29] is usually a prominent ion in compounds with an F-ring 
[118, 157, 158, 163, 165]. From building the chromatographic library, it was discovered 
that the m/z 191 rearrangement fragment was increasingly more stable than the m/z 217 
ion, therefore one SIM could be used for the quantification of all the F-ring IsoPs and 
NPs.  
 
Using eleven carefully selected methods, only two methods were viable on the chosen 
system using the selected m/z 191 fragmentation ion. The nine methods which were not 
feasible included the following, Milatovic et al [132], Musiek et al [139], Imbusch et al 
[165], Wiswidel et al [194], Morrow et al [118, 148], Kyung Mee Kim et al [25, 155], 
Favreau et al [156], Praticó et al [157] and Waugh et al [158]. These methods either had 
issues with GC column thermal stability or quantification by EI-MS. This left only two 
methods with the potential to extend for NP quantification, Bessard et al [127] and 
Chiabrando et al [164]. Bessard et al [127] is a specific method for the quantification of 
IsoPs by EI-MS, in particular the 15 series IsoP. By monitoring the m/z 481 ion from 15-
series IsoP fragmentation and quantification using a deuterated 15-series IsoP, it allows 
for definitive analysis on one series of IsoP.  
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Figure 21 – Prostanoid mass spectra and chromatography (A= IsoP [158], 
B= PP [154], C= NP [47] and D= Actual EI-MS spectra and 
chromatography) 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C 
D 
These four mass spectra are; (A) 5, 8, 12, 15 series IsoP, (B) 16-series PP, (C) all 
series of NPs and (D) actual NP spectra by EI-MS system and m/z 191 chromatograph 
of PP, IsoP and NP. The red boxes in the figures highlight the presence of the ions 
m/z 191 and 217 from several publications and (D) the actual fragments from PP 
using our system, along with SIM at m/z 191 showing PP, IsoP and NP. In the 
majority of spectra these two ions dominate within EI-MS chromatograms, which 
makes justification for there use in this new method important. Since PPs contain the 
same ions as the other classes, two ions can be monitored with carbon length changing 
the retention time, similar to FAMEs in GC. 
PP 
IsoP 
NP 
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However drawbacks for Bessard et al [127] included; specific quantification of one series 
rather than all F-rings, the chosen ions were not observed in the same intensity seen in 
paper when used and selective ion monitoring (SIM) chromatography signals were 
matched by noise. The other viable method was Chiabrando et al [164]. This utilised a 
short acquisition chromatographic runtime with a quick temperature ramp, best suited 
with the chosen column. Originally the method was used for IsoP quantification, but the 
chromatography allowed for the potential to extend towards NP quantification. 
Modification of the runtime, temperature ramp and using the target ions provided the 
means for NP quantification and more importantly a consistent platform for their analysis 
not performed using GC-EI-MS.  
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4  Pathway models of lipid oxidation 
4.1 – Defining the pathway 
A causal pathway model can be used to visualise the pattern of correlation between a set 
of variables to map the alternative pathway(s) of lipid oxidation in both AD and control 
states for both fatty acids, in terms of their specific endpoint markers. From either AA or 
DHA, initial CDs and LOOHs (denoted FOX in the pathway) can be formed in a 
combined conjugated LOOH component synonymous with classical oxidation 
mechanisms. The final endpoint biomarkers the aldehydes and IsoPs or NPs, can be 
created either from the peroxyl radical breaking the fatty acid in either a chain scission 
mechanism, or through endoperoxide formation which creates prostanoids.  
 
The degree of unsaturation of both AA and DHA means that even the initial formation of 
the primary lipid oxidation product does not stop other methylene carbons from 
undergoing hydrogen abstraction, creating aldehydes or prostanoids from these sites. The 
putative links between all the markers used in this project are illustrated in the classical 
pathway model in figure 22. Not accounted for in this pathway are the roles of 
antioxidants, which can quench certain sections of the oxidation mechanism. These were 
independently correlated with each marker in the pathways to determine the roles 
antioxidants are having in defence or agonist in AD or control. Correlation data for each 
brain region was first acquired as a starting point for the pathway model to identify any 
initial relationships between all the assays utilised. Tables 4-7 show the correlation 
values (r) alongside the p values for each assay in the pathway. Following the pathway 
there appears to be a difference between the CD and LOOH in both brain regions, which 
was investigated prior to completing the pathway. 
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In the frontal region, CDs were negatively correlated with LOOH (p = 0.034) and the 
temporal region showed no correlation between them (p = 0.822). There should be no 
difference between these two markers as they are formed in situ following the classical 
mechanism. However this disparity appearing in this analysis between these two products 
in the means of the two tests and the correlation results, supplements their removal from 
the pathway model. 
 
These initial markers (CD and LOOH) of oxidation are transient intermediates in the 
mechanism and while the performing of the assays is standard, the results show a 
difference between these two. The chromophore for CD determination at 234nm can 
suffer from other components absorbing at this wavelength [197]. The FOX assay also 
has drawbacks, revolving around low linear range and low reproducibility [198]. 
Therefore FOX and CD results were combined to create a new variable known as 
FOXCD, rather than discard the pathway model and question the classical oxidation 
mechanism without any supplementary experiments. This new variable along with the 
initial fatty acids precursors was used to determine correlation values to see whether 
aldehydes or ring formation was favoured. Detailed analysis of each pathway for both 
fatty acids is discussed in the next two sections. 
 
4.2 – Pathway model for DHA breakdown 
 
When DHA is oxidised it can produce the primary oxidation product, the combined 
classical conjugated lipid hydroperoxide which can then follow independent pathways to 
final biomarkers (NPs and TBARs) as previously discussed. The tables below show the 
correlation data between each assay for each brain region and tissue state. In the control 
frontal lobe the FOXCD variable in the DHA mechanism appeared to show that 
aldehydes were being favoured in formation compared to the NPs. Specifically as the 
levels of FOXCD decreased the levels of aldehydes increased, however when correlating 
the initial fatty acid against the endpoint markers it was observed that correlation 
(positive) was greater with NPs than the aldehydes. The results obtained from the 
temporal region in the control cohort agreed with the previous frontal results, with the 
favoured endpoint being the aldehydes, but in this instance the initial fatty acid correlated 
greater with the aldehydes rather than the NPs.  
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Table 4 – Correlation analysis of total data sets for DHA oxidation within 
the frontal lobe 
Correlations 
  FRdha FRnp FRcd FRfox FRtbars 
FRdha 
Pearson Correlation (r)  .172 .223 -.168 -.124 
Sig. (2-tailed) (p)  .192 .081 .196 .342 
FRnp 
Pearson Correlation (r) .172  .067 .035 .206 
Sig. (2-tailed) (p) .192  .595 .783 .102 
FRcd 
Pearson Correlation (r) .223 .067  -.257
*
 -.061 
Sig. (2-tailed) (p) .081 .595  .034 .620 
FRfox 
Pearson Correlation (r) -.168 .035 -.257
*
  .219 
Sig. (2-tailed) (p) .196 .783 .034  .072 
FRtbars 
Pearson Correlation (r) -.124 .206 -.061 .219  
Sig. (2-tailed) (p) .342 .102 .620 .072  
*. Correlation is significant at the 0.05 level (2-tailed).   
Table 5 – Correlation analysis of total data sets for AA oxidation within    
the frontal lobe  
 Correlations 
  FRaa FRip FRcd FRfox FRtbars 
FRaa Pearson Correlation (r)  .347
**
 .128 -.181 -.386
**
 
Sig. (2-tailed) (p)  .006 .300 .145 .001 
FRip Pearson Correlation (r) .347
**
  -.053 -.165 -.179 
Sig. (2-tailed) (p) .006  .682 .205 .167 
FRcd Pearson Correlation (r) .128 -.053  -.257
*
 -.061 
Sig. (2-tailed) (p) .300 .682  .034 .620 
FRfox Pearson Correlation (r) -.181 -.165 -.257
*
  .219 
Sig. (2-tailed) (p) .145 .205 .034  .072 
FRtbars Pearson Correlation (r) -.386
**
 -.179 -.061 .219  
Sig. (2-tailed) (p) .001 .167 .620 .072  
**. Correlation is significant at the 0.01 level (2-tailed).   
*. Correlation is significant at the 0.05 level (2-tailed).   
 
 
 
As observed in the classical oxidation pathway, both CDs and LOOHs are being 
regarded as the same component, addition of molecular oxygen to the pentadienyl 
radical causes the double bonds to flip into a conjugated system. In the frontal DHA 
correlation we see that DHA oxidises to form CDs (first yellow box), a positive 
association (r = 0.223, p = 0.081), over LOOHs (adjacent yellow box) which was a 
negative association (r = -0.168, p = 0.196). The opposite was observed with AA, a 
more significant negative correlation with LOOHs (r = -0.181, p = 0.145) over the 
CD (r = 0.128, p = 0.300). However in both tables, there is a clear dissociation 
between CD and FOX. Interpretation of this indicates that as CD decrease LOOHs 
increase or as LOOHs decrease the CD are increasing and is a significant negative 
correlation (green boxes; r = -0.257, p = 0.034). 
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Table 6 – Correlation analysis of total data sets for DHA oxidation within 
the temporal lobe  
Correlations 
  TPdha TPnp TPcd TPfox TPtbars 
TPdha Pearson Correlation (r)  .103 .099 .224 -.010 
Sig. (2-tailed) (p)  .420 .432 .075 .938 
TPnp Pearson Correlation (r) .103  .044 -.075 -.048 
Sig. (2-tailed) (p) .420  .723 .561 .711 
TPcd Pearson Correlation (r) .099 .044  -.028 .269
*
 
Sig. (2-tailed) (p) .432 .723  .822 .030 
TPfox Pearson Correlation (r) .224 -.075 -.028  .171 
Sig. (2-tailed) (p) .075 .561 .822  .164 
TPtbars Pearson Correlation (r) -.010 -.048 .269
*
 .171  
Sig. (2-tailed) (p) .938 .711 .030 .164  
*. Correlation is significant at the 0.05 level (2-tailed).   
Table 7 – Correlation analysis of total data sets for AA oxidation within    
the temporal lobe 
Correlations 
  TPaa TPip TPcd TPfox TPtbars 
TPaa Pearson Correlation (r)  -.099 -.039 .219 -.271
*
 
Sig. (2-tailed) (p)  .716 .758 .082 .030 
TPip Pearson Correlation (r) -.099  -.249 -.152 .001 
Sig. (2-tailed) (p) .716  .336 .574 .996 
TPcd Pearson Correlation (r) -.039 -.249  -.028 .269
*
 
Sig. (2-tailed) (p) .758 .336  .822 .030 
TPfox Pearson Correlation (r) .219 -.152 -.028  .171 
Sig. (2-tailed) (p) .082 .574 .822  .164 
TPtbars Pearson Correlation (r) -.271
*
 .001 .269
*
 .171  
Sig. (2-tailed) (p) .030 .996 .030 .164  
*. Correlation is significant at the 0.05 level (2-tailed).   
 
 
 
  
 
 
 
 
In the temporal DHA correlation we see that DHA oxidises to form LOOHs (first 
yellow box), a positive association (r = 0.224, p = 0.075), over CD (adjacent yellow 
box) which was also a positive association (r = 0.099, p = 0.432). The same was 
observed with AA, a more significant positive correlation with LOOHs (r = 0.219, p 
= 0.082) over the CD (r = -0.039, p = 0.758). However in both tables, there is a clear 
dissociation between CD and FOX. Interpretation of this indicates that CD and 
LOOHs have no significant correlation in either brain regions. In the classical 
pathway both CDs and LOOHs are formed in union, but this early correlation analysis 
appears to show that in the temporal region (green box) no correlation between the 
two (r = -0.028, p = 0.822), implying that one of these can be increasing or decreasing 
with no direct affect on the other. 
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Figure 23 – Pathway model for correlations between markers 
 
 
 
 
 
 
 
 
Table 8 – Correlation values for DHA oxidation (blue arrow) 
Pathway Control samples AD samples 
Frontal lobe Temporal lobe Frontal lobe Temporal lobe 
A -0.370* 0.041 0.088 0.102 
B -0.050 0.015 0.122 0.159 
C -0.089 0.362* -0.138 -0.205 
D 0.336 -0.127 0.037 0.263 
* = Correlation is significant at the 0.05 level (2-tailed) 
MODERATE relationship (± 0.6 - ± 0.4) = Blue, WEAK relationship (± 0.3 - ± 0.1) = Green 
Table 9 – Correlation values for AA oxidation (red arrow)  
Pathway Control samples AD samples 
Frontal lobe Temporal lobe Frontal lobe Temporal lobe 
A -0.370* 0.041 0.088 0.102 
B 0.145 -0.035 -0.013 0.621 
C -0.489** -0.391* -0.227 -0.244 
D 0.470* -0.172 -0.048 0.833 
* = Correlation is significant at the 0.05 level (2-tailed) 
** = Correlation is significant at the 0.01 level (2-tailed) 
STRONG relationship (± 0.9 - ± 0.7) = Red, MODERATE relationship (± 0.6 - ± 0.4) = Blue, WEAK 
relationship (± 0.3 - ± 0.1) = Green 
 
DHA / AA 
TBARs 
NP / IsoP 
FOXCD 
C 
D 
A 
B 
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With the AD results, the frontal region showed that the FOXCD variable had a stronger 
positive correlation with the NPs, once again DHA was observed to show a weak 
negative correlation to aldehydes rather then the NPs. The temporal lobe correlation 
results showed that both the FOXCD and DHA variables positively correlated with the 
NPs. Initial findings indicate that in the frontal and temporal regions DHA oxidised to 
yield aldehydes in the control samples, where as the AD favours the ring formation 
pathway creating NPs suggesting a specific oxidation pathway seen earlier in the 
elevated PCOOH assay.   
4.3 – Pathway model for AA breakdown 
The same pathway illustrated above can be performed on AA and its specific oxidation 
products for both regions and disease states. IsoPs are only created from AA oxidation, 
so their results are independent of the DHA derived NPs. In the frontal control lobe 
FOXCD was negatively correlated with the aldehydes over the IsoPs and this was also 
observed with the correlation between AA and TBARs. Of note in the frontal lobe was 
the positive correlation between AA and IsoPs which is in complete contrast to the 
aldehydes. The control temporal lobe samples appeared to show that FOXCD broke 
down to form aldehydes, with the AA variable negatively correlated to aldehydes. With 
the AD frontal samples, FOXCD and AA levels correlated better with the aldehydes than 
the IsoPs. In the AD temporal region, the strongest positive correlation values observed 
were between both FOXCD and AA with IsoPs. These outcomes differ from the previous 
DHA pathway model. In AD DHA oxidised to form the cyclic prostanoids in both brain 
regions, AA oxidation appears to depend upon the brain region. Frontal lobe results 
suggest that chain scission was occurring forming aldehydes, but in the temporal region 
ring formation is favoured. 
4.4 – Antioxidant interactions in the pathway model  
In the control cohort no significant findings were found between antioxidant assay and 
any of the markers, table 16. Of interest was the positive association with both IsoP and 
NP, as antioxidants increased these two appear to increase indicating the role of these 
protective compounds in the final reduction stage in the formation of prostanoids. This 
same characteristic seems to also apply to the aldehydes as they increase with elevating 
levels of antioxidants.  
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Figure 24 – Interaction between antioxidants and the assays used in the 
pathway models 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10 – Correlation values between antioxidant levels and the assays 
used in the pathway model 
Assay Control samples AD samples 
Frontal lobe Temporal lobe Frontal lobe Temporal lobe 
AA -0.065 -0.160 -0.065 -0.148 
DHA -0.005 -0.197 -0.212 -0.287 
IsoP 0.283 -0.345 -0.094 -0.342 
NP 0.188 0.245 0.301 -0.165 
CD -0.025 -0.062 -0.136 -0.137 
FOX 0.035 -0.474** 0.264 0.396* 
TBARs 0.222 -0.103 0.386* 0.282 
* = Correlation is significant at the 0.05 level (2-tailed) 
** = Correlation is significant at the 0.01 level (2-tailed) 
MODERATE relationship (± 0.6 - ± 0.4) = Blue, WEAK relationship (± 0.3 - ± 0.1) = Green 
The coloured arrows represent the diversity of roles in which antioxidants can affect 
the respective marker. AA and DHA can be actively defended by antioxidants in 
reducing hydrogen abstraction by sacrificing themselves. CD and FOX can be 
quenched by antioxidants stopping propagation or by stopping the initial abstraction 
required for the formation of these two products. IsoP and NP are different, as 
antioxidants can perform two separate roles. They can stop the formation of these 
compounds initially, but they can also reduce the endoperoxide to form these 
components therefore actually increasing the amount of F-rings. Aldehydes can 
promote further oxidation which the antioxidants can suppress. 
AA 
TBARs 
Antioxidants 
IsoP 
CD 
DHA 
NP 
FOX 
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The temporal region highlights a strong significant affect on the LOOH levels. As 
antioxidants are reduced in the control samples, this is causing the LOOHs to increase 
because of the lower defence mechanisms preventing the initial hydrogen abstraction and 
oxygen insertion.  Within the frontal lobe of AD samples the aldehyde assay was the 
most significantly correlated, with the increasing antioxidants elevating the TBARs 
response. This contradicts the role antioxidants have in protecting vulnerable components 
from oxidation. Unless antioxidants are stabilising the lipid peroxyl radicals, yielding 
LOOHs which would then appear to be breaking down to aldehydes through chain 
scission. 
Over the other assays it appears that the oxidation pathway is being ushered in favouring 
aldehyde formation. FOX and NP are also positively correlated with antioxidants, 
suggesting that the reduction processes are converting any unstable endoperoxides or 
peroxides to either F-ring prostanoids or LOOHs by supplying the hydrogen required for 
this process. In the temporal lobe the most significant correlated assay was the FOX, 
demonstrating that as the antioxidant levels increased the concentration of LOOHs raised 
with them.  
4.5 – Significance of pathways for both DHA and AA breakdown 
From the AA and DHA breakdown models the following pathways can be predicted to 
be significant biochemically. Damaged fatty acids appear to be breaking down into 
reactive aldehydes more than the cyclic prostanoids in both control brain regions. This 
suggests that the oxidised fatty acids are fragmenting into shorter chain products by chain 
scission. The frontal region highlighted negative correlations between FOXCD and 
TBARs, suggesting that conjugated lipid hydroperoxides are being broken down to 
aldehydes. In the temporal lobe a steady state of formation between FOXCD and TBARs 
variables appears to be happening. One difficulty faced with the TBARs assay is that the 
products of enzymatic and non-enzymatic formation of aldehydes cannot be 
differentiated so we cannot determine whether this is a true representation of non-
enzymatic oxidation.  
In AD samples, FOXCD followed NP formation instead of TBARs in a steady state 
formation cycle. From both lobes you can clearly see different processing in the DHA 
oxidation pathway with the control samples preferring aldehyde formation and the AD 
samples favouring NPs when analysing the correlational data. Following the same 
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principles governed in the DHA pathway, it is now possible to investigate if there were 
any differences in the AA oxidation process between lobes and disease state. For both 
brain regions in the control cohort it can clearly be observed that aldehydes are favoured 
in formation compared with the IsoPs. Frontal region analysis shows that both FOXCD 
and AA levels are reduced with increasing formation of aldehydes. The AD cohort in the 
frontal region highlights a different preferred endpoint biomarker to the temporal region. 
Within the frontal lobe greater correlation was observed with the aldehydes and in the 
temporal lobe the IsoPs. This suggests that damaged fatty acids undergo chain 
fragmentation in the frontal lobe and ring formation in the temporal of AD samples. 
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5  Large cohort statistical analysis 
FOREWORD 
The following chapters will discuss both sets of results obtained by us and from our 
collaborative group, (Dementia Research Group, Institute of Clinical Neurosciences, 
University of Bristol, Frenchay Hospital) highlighted at the beginning of the relevant 
sections similar to the system stated at the start of chapter 2. These results are being 
utilised within this thesis to understand relationships between multiple factors involving 
the disorder. The following assays were completed by our collaborators, DHA and AA 
composition, LOOHs, antioxidant status and aldehyde content while at Aston we 
completed CD and prostanoid quantification. Individual sample results can be found in 
appendix A and B. 
5.1 – Cohort only statistical analysis 
The advantages of this project are the copious variables available to investigate the 
involvement of lipid peroxidation and eventual breakdown in AD pathogenesis, through 
analytical assays and classification data. Independent variables (fatty acids, antioxidants, 
or other biomarkers) have been investigated in separate literature studies, often with 
fluctuating cohort sizes. An example of which is the PUFA data, Skinner et al [175] 
which used 25 post-mortem samples [largest quoted compiled of 10 control, 15 AD], we 
analysed 71 post-mortem samples [35 control, 36 AD] which is part of a larger 172 
cohort [58 control, 114 AD [179]]. As discussed previously, Braak staging [section 1.1b], 
APOE gene [section 1.1d(ii)], along with post-mortem delay and age at death were 
introduced into the statistical analysis alongside the assays. These extra variables utilised 
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herein allow for a more in-depth examination into AD, with greater statistical power 
primarily from a larger cohort size and secondarily with the variables presented. In order 
to perform statistical analysis, the software SPSS, (SPSS Inc) was used to conduct 
analysis of variance and correlation coefficients.  
Each assay was plotted against post-mortem delay and age at death to observe whether 
any detrimental effects occurred from these two time dependent factors (graphs can be 
found in the appendix C) either from breakdown under sample preparation or from 
normal ageing processes which would reduce the association with AD pathogenesis. The 
IsoP assay highlighted a slight dependence with post-mortem delay and age but this was 
attributed to outliers in the results. Agreeing with our collaborators [71] post-mortem 
delay was found to have no effect on any other assay for the entire cohort size, with no 
additional trends witnessed with age at death. On this basis both PM delay and age were 
removed from further statistical analyses. 
The table overleaf denotes sample number, APOE genotype, Braak staging (0-VI), post-
mortem delay (hours) and finally the age (years) at which the patient died. Statistical 
analysis will be performed on individual brain regions in the software; this is due to 
missing data from certain assays in specific regions which will reduce the inherent 
statistical power, this lowers the amount of samples viable for the determination. This is 
fundamental in analysis of the Braak staging and temporal lobe, where the IsoP assay had 
to be removed from the analysis. 
alysis of the effects within each brain region was performed using a multivariate analysis 
of variance (MANOVA) with cohort as the lone independent variable. In this context, 
MANOVA provides an analysis technique to examine multiple dependent variables 
simultaneously without inflating the type one error rate as would results from multiple 
independent tests.  The data for the frontal lobe were analysed with a single factor 
(control vs AD) MANOVA with AA, DHA, IsoP, NP, CD, ABTS, FOX and TBARs as 
dependent variables. The analysis revealed overall significant effect of cohort (F(8, 45) = 
2.627, p = 0.019; Wilks λ = 0.682). Wilks’ lambda is the most commonly used F-value as 
advised by Tabachnick and Fidell (1997) [199].  
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 Table 11 – Clinical data on Alzheimer and control samples  
 
Control Alzheimer 
Sample 1=no 
2=yes 
O-6 
Braak 
stage 
Post  
mortem 
delay 
(hours) 
Age 
 at 
death 
Sample 1=no 
2=yes 
0-6 
Braak 
stage 
Post  
mortem 
delay 
(hours) 
Age  
at 
death 
16 1 0 46.00 95 190 1 5 71.00 89 
36 1 2 24.00 78 196 2 6 77.00 78 
57 1 3 35.00 82 203 1 2 88.00 79 
79 1 2 103.00 81 205 2 5 9.00 78 
98 1 2 62.00 88 211 1 1 44.00 83 
103 1 2 106.00 76 213 2 6 42.00 81 
106 1 0 72.00 88 219 2 4 43.00 77 
110 1 2 18.00 93 224 1 4 53.00 96 
112 1 0 92.00 80 228 2 5 72.00 87 
120 1 2 28.00 88 241 2 5 67.00 87 
122 1 2 30.00 82 242 1 3 70.00 79 
127 1 3 48.00 84 243 1 6 79.00 88 
130 1 2 48.00 75 284 2 6 24.00 82 
147 1 1 33.00 73 287 2 4 58.00 85 
150 1 2 66.00 69 288 2 5 43.00 83 
206 1 1 59.00 73 289 1 3 43.00 91 
254 1 3 40.00 90 290 1 5 82.00 89 
269 1 2 24.00 83 302 2 6 25.00 70 
295 1 2 3.00 82 318 2 2 42.00 71 
321 1 . 24.00 79 326 2 5 48.00 69 
333 1 1 17.00 84 330 2 5 50.00 74 
336 2 2 37.00 82 341 1 3 48.00 95 
352 1 0 24.00 72 508 2 5 5.00 80 
355 1 1 48.00 78 538 1 6 43.00 63 
390 1 2 56.00 82 558 2 6 9.00 64 
402 1 2 23.00 76 561 2 5 24.00 74 
407 2 2 60.00 91 568 2 6 21.00 78 
412 2 3 96.00 82 573 2 5 39.00 89 
461 2 3 10.00 77 580 1 6 90.00 65 
467 2 3 6.00 75 592 1 6 22.00 65 
563 2 4 79.00 48 601 1 6 61.00 68 
678 2 2 216.00 84 683 1 5 48.00 83 
714 2 3 35.00 73 685 1 5 48.00 74 
721 2 2 5.50 90 687 . 6 5.00 60 
733 2 3 37.75 93 713 2 6 24.50 62 
     725 2 5 12.00 69 
          
          
          
          
          
          
          
Additional data on the samples, this includes APOE genotype (1= 0 alleles, 2= 1 or more 
alleles denoted no and yes), Braak staging (0-6), post-mortem delay in hours and finally 
age at which the patient died. This data was released after the experiments were finished, 
under the double-blind study requirements to improve the validity of the work conducted. 
81 
 
Post-hoc analysis of the between group effects revealed that ABTS levels (antioxidant 
assay) were significantly different between groups. Evaluating the means of the ABTS 
results in the frontal lobe clearly showed an elevated level in the AD state, whether this is 
a host response to oxidation or overproduction is questionable and requires further 
investigation. The data acquired from the temporal lobe were also analysed with a single 
factor (control vs AD, table 12) MANOVA with AA, DHA, IsoP, NP, CD, ABTS, FOX 
and TBARs as dependent variables. The analysis revealed that there was no overall 
significant effect in the cohort (F(8, 4) = 0.576, p = 0.765; Wilks λ = 0.465). This 
outcome defers any post-hoc analysis in the temporal lobe because of the insignificance 
in this analysis. Contrary to the findings in the frontal analysis, no significant overall 
effect of cohort was found for any of the assays in the temporal lobe. The results suggest 
that pathogenesis of AD preferentially effects the frontal region under this cohort 
MANOVA analysis, with the frontal antioxidants being the most significant assay in 
differentiating between AD and control.  
Table 13 shows the descriptive analysis of the cohort MANOVA, with the means and 
deviation for each assay. For the two fatty acids, across both brain regions, there was a 
reduction DHA and AA in the AD state from a mean-based analysis. This difference 
agrees with the common theory of lower fatty acids in AD compared to control samples 
however subjectively, these findings are not significant due to the variation in the 
standard deviation. DHA and AA levels appear to have no relevance in the determination 
or differentiation between AD and control samples which agress with Skinner et al [175].  
 
CDs and LOOHs are closely correlated; formation of the hydroperoxide is accompanied 
by bonds migrating to form conjugated bonds. Initial analysis of the CD and LOOH 
levels shows that the control samples, regardless of brain region were higher than the AD 
samples. With the consensus on enhanced oxidation in AD, these primary products of 
lipid breakdown should be elevated in this disease. Nevertheless, CD and LOOH 
determination does not show how far the process of oxidation has progressed. If these 
compounds have broken down to further downstream biomarkers then a reduction in CD 
will occur unless you have a steady state of formation and conversion. Sample variation 
appears to also negate any conclusions, especially when the frontal samples have a larger 
deviation than the mean.  
 
 
82 
 
Table 12 – Cohort statistical analysis including variables significant in the 
MANOVA in both frontal and temporal regions 
Frontal Multivariate Tests
b
 
Effect Value F Hypothesis df Error df Sig. 
cohort 
Pillai's Trace .318 2.627
a
 8.000 45.000 .019 
Wilks' Lambda .682 2.627
a
 8.000 45.000 .019 
Hotelling's Trace .467 2.627
a
 8.000 45.000 .019 
Roy's Largest Root .467 2.627
a
 8.000 45.000 .019 
Tests of Between-Subjects Effects in the Frontal region 
Source 
Dependent 
Variable 
Type III Sum of 
Squares df Mean Square F Sig. 
Cohort FRdha 7.569 1 7.569 2.069 .156 
FRaa .355 1 .355 .748 .391 
FRIsoP 259.283 1 259.283 1.294 .261 
FRnp .263 1 .263 .008 .930 
FRcd .568 1 .568 .205 .652 
FRabts 73.222 1 73.222 11.606 .001 
FRfox 1.202E8 1 1.202E8 2.838 .098 
FRtbars .267 1 .267 .014 .906 
 
Temporal Multivariate Tests
b
 
Effect Value F Hypothesis df Error df Sig. 
cohort 
Pillai's Trace .535 .576
a
 8.000 4.000 .765 
Wilks' Lambda .465 .576
a
 8.000 4.000 .765 
Hotelling's Trace 1.151 .576
a
 8.000 4.000 .765 
Roy's Largest Root 1.151 .576
a
 8.000 4.000 .765 
Tests of Between-Subjects Effects in the Temporal region 
Source 
Dependent 
Variable 
Type III Sum of 
Squares df Mean Square F Sig. 
Cohort TPdha 4.617 1 4.617 1.971 .188 
TPaa .124 1 .124 .338 .573 
TPIsoP 2.160 1 2.160 1.256 .286 
TPnp 32.611 1 32.611 .465 .509 
TPcd .307 1 .307 .797 .391 
TPabts 5.005 1 5.005 .613 .450 
TPfox 4.561E7 1 4.561E7 1.573 .236 
TPtbars 12.939 1 12.939 1.084 .320 
 
 
 
 
 
The data for the frontal lobe were analysed with a single factor (control vs AD) 
MANOVA with AA, DHA, IsoP, NP, CD, ABTS, FOX and TBARs as dependent 
variables. The analysis revealed overall significant effect of cohort (F(8, 43) = 2.627, 
p = 0.019; Wilks λ = 0.682). Post-hoc analysis of the between group effects revealed 
that ABTS levels (antioxidant assay) were significantly different between groups. In 
the temporal region there was no significant difference the variables between AD and 
control, making post-hoc analysis difficult unlike the frontal lobe. 
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Table 13 – Descriptive analysis of the cohort MANOVA analysis 
 
1=Control 
2=Alzheimer 
FRdha 
(% of fatty 
acids)  
FRaa 
(% of fatty 
acids) 
FRip 
(µg/g tissue) 
 
FRnp 
(µg/g tissue) 
 
FRcd 
(mmol dm
-
3
/g) 
FRabts 
TEAC per g  
(µmol/g) 
FRfox 
(CHPE/g wet 
weight) 
FRtbars 
(nmol MDA/g 
tissue) 
1 N 33 33 27 29 33 33 33 33 
Mean 15.52 8.63 8.34 7.76 1.53 11.09 6859.68 12.01 
Std. Deviation 1.36 0.80 23.83 7.07 1.85 2.13 6814.09 4.80 
2 N 31 36 35 36 36 35 35 35 
Mean 14.49 8.31 1.55 6.27 1.17 13.01 4210.37 12.63 
Std. Deviation 2.32 0.63 3.91 5.70 1.59 2.91 5249.77 3.89 
 
 
 
1=Control 
2=Alzheimer 
TPdha 
(% of fatty 
acids) 
TPaa 
(% of fatty 
acids) 
TPip 
(µg/g tissue) 
 
TPnp 
(µg/g tissue) 
 
TPcd 
(mmol dm
-
3
/g) 
TPabts 
TEAC per g  
(µmol/g) 
TPfox 
(CHPE/g wet 
weight) 
TPtbars 
(nmol MDA/g 
tissue) 
1 N 34 34 12 31 33 30 33 33 
Mean 15.01 8.96 5.76 4.15 1.08 10.64 5091.60 13.00 
Std. Deviation 1.54 0.98 15.77 5.85 0.68 2.28 5316.74 2.77 
2 N 33 33 5 35 35 30 35 35 
Mean 14.62 8.45 0.10 6.52 0.84 12.98 1920.63 12.68 
Std. Deviation 2.06 0.67 0.05 7.14 0.50 2.50 2980.72 3.99 
 
Data from all the assays are summarised in the above two tables for both brain 
regions for control and AD. There were no differences between DHA and AA 
content, prostanoid quantification, CD levels and TBARs. LOOHs were lower in AD 
compared to the control, but there was also a large amount of variation making any 
conclusions difficult.  Post-hoc analysis of the between group effects of the cohort 
MANOVA revealed that ABTS levels (antioxidant assay) were significantly different 
between groups. In the temporal region there was no significant difference the 
variables between AD and control. The data in the tables indicate that levels of 
antioxidants in the frontal region were higher in AD (p = 0.001), highlighted yellow 
in the first table.  
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With the newly developed method, the levels of the F-ring prostanoids were quantified in 
both frontal and temporal lobes in both disease tissue states. In the frontal and temporal 
lobes, control samples had higher IsoP averages compared to AD. NP levels were higher 
in the temporal region for AD samples, with little comparative difference observed in the 
frontal region. This demonstrates that in the temporal region, higher DHA oxidation is 
occurring, which may be of consequence of AD pathogenesis. However, interpretation of 
the results is difficult because of the standard deviations, which again nullify any 
conclusions.  
Across the brain regions and individual sample groups, it was observed that there is no 
difference between AD and control in terms of the shorter chain aldehydes. The 
difference between the two is the lowest seen compared with the other assay averages. 
This can be concluded because the standard deviation is lower than the previous tests, 
which was so influencial in commenting on previous results. In previous oxidation tests 
(except CD) the mean and standard deviation varied by a large amount. FOX and 
prostanoid markers suffered from high variation in mean and the deviation was greater 
than the average, precluding the ability to draw conclusions. It would appear that the 
aldehydes are being regulated in terms of their formation in both circumstances as the 
difference between control and AD samples is minuscule. 
In the frontal lobe, AD samples had slightly higher levels of antioxidants than the 
respective control cohort. Under the oxidation theory these protective compounds should 
be lower, because of the increased initiation and propagation stages of lipid peroxidation, 
but this is not the case. This same finding is also observed in the temporal region, where 
AD samples had higher levels of antioxidants than the control samples. Under 
progressive interpretation of all the results, the elevated levels of antioxidants support the 
notion that the AD cohort does not exhibit enhanced oxidation. The next statistical 
analysis that was performed involved the introduction of the genetic variable, to 
investigate the link between the clinical data and all the assays performed. Both regions 
were analysed even though the temporal region demonstrated no significant statistical 
findings thus far. 
5.2 – MANOVA frontal and temporal analysis (Cohort and APOE) 
Tissue was classified into two groups based on the number of APOE Ɛ 4 alleles present 
in the specimen’s sample: the first group has no APOE Ɛ 4 alleles; the second group had 
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at least one allele of this risk gene. Once more the samples were processed in terms of the 
eight dependent variables but with addition of the APOE grouping (Control and AD with 
APOE1 vs APOE2 as the independent variables MANOVA with AA, DHA, IsoP, NP, 
CD, ABTS, FOX and TBARs as dependent variables). Evaluating the APOE genotype 
individually from cohort, appears to show no significant variation across the eight assays, 
demonstrating that the presence of more alleles does not correlate with any increased 
lipid breakdown or production of measurable metabolites.  
The analysis revealed a strong interaction effect between cohort and risk (F(8, 43) = 
5.026, p < 0.001; Wilks λ = 0.517), with post-hoc tests indicating that LOOHs (FRfox, p 
= 0.001) was the most robust assay with IsoPs (p = 0.053), NPs (p = 0.075), CD (p = 
0.072) and antioxidant (p = 0.056) being over p = 0.05 but being referred to as being 
trend-level significant. Introduction of the genetic parameter appears to be a very 
significant outcome detailing the difference between AD and control. Table 15 depicts 
that in both genotype groups that IsoP levels were considerably higher in the control state 
compared to the AD, but this is not clearly seen in figure 25. 
Next, the temporal region samples using the same conditions were examined for any 
correlations. From the tables overleaf it was discovered that no assays were significant in 
the temporal region under the same parameters which contrasts with the findings reported 
above for the frontal lobe. The temporal data was analysed with a two factor (control vs 
AD, APOE1 vs APOE2) MANOVA with AA, DHA, IsoP, NP, CD, ABTS, FOX and 
TBARs as dependent variables. As seen with the earlier MANOVA, the temporal region 
had no significant results with introduction of the APOE genotype. This then implies that 
the frontal lobe seems to be the most affected by the variables. 
As discussed earlier the early discovery of higher levels of antioxidants in the AD state 
accounts for the reduction in oxidation and in particular this biomarker. Due to the 
emphasis attached with IsoPs in oxidation, there is lower AA oxidation in the frontal lobe 
in AD. Interestingly, when the control cohort have one or more alleles, the levels of IsoP 
increase dramatically which may authenticate the role in which the genetic parameters 
and oxidation share. NP levels were also of interest, being similar biomarkers to the 
IsoPs, within this analysis even with their respective p values.  Discussing the two 
sample groups separately, it can be implied that the increased allele content correlates 
itself with higher levels of oxidation in terms of NPs. Therefore relating genetic variation 
to the precise non-enzymatic oxidation of DHA in the brain tissue.  
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Table 14 – Cohort and APOE statistical analysis, including post-hoc tests   
in both frontal and temporal lobes 
 
Frontal Multivariate Tests
b
 
Effect Value F Hypothesis df Error df Sig. 
Apoe Wilks' Lambda .833 1.080
a
 8.000 43.000 .395 
cohort * apoe Wilks' Lambda .517 5.026
a
 8.000 43.000 .000 
Tests of Between-Subjects Effects in the Frontal region 
Source 
Dependent 
Variable 
Type III Sum of 
Squares df Mean Square F Sig. 
cohort * apoe FRdha .064 1 .064 .017 .897 
FRaa .881 1 .881 1.852 .180 
FRIsoP 737.360 1 737.360 3.940 .053 
FRnp 103.144 1 103.144 3.316 .075 
FRcd 9.125 1 9.125 3.389 .072 
FRabts 22.406 1 22.406 3.838 .056 
FRfox 4.264E8 1 4.264E8 12.106 .001 
FRtbars 54.275 1 54.275 2.963 .091 
Temporal Multivariate Tests
b
 
Effect Value F Hypothesis df Error df Sig. 
Apoe Wilks' Lambda .086 1.335
a
 8.000 1.000 .588 
cohort * apoe Wilks' Lambda .010 12.041
a
 8.000 1.000 .219 
Tests of Between-Subjects Effects in the Temporal region 
Source 
Dependen
t Variable 
Type III Sum of 
Squares df Mean Square F Sig. 
cohort * apoe TPdha .468 1 .468 .194 .671 
TPaa .054 1 .054 .115 .743 
TPIsoP .449 1 .449 .207 .661 
TPnp 56.280 1 56.280 .696 .428 
TPcd .002 1 .002 .004 .951 
TPabts 4.689 1 4.689 1.218 .302 
TPfox 1.640E7 1 1.640E7 .525 .489 
TPtbars 26.721 1 26.721 2.382 .161 
 
 
 
 
Once more the samples were processed in terms of the eight dependent variables but 
with addition of the APOE grouping. In both brain lobes there was no significant 
difference in the possession of increased alleles. APOE1 vs APOE2 MANOVA with 
AA, DHA, IsoP, NP, CD, ABTS, FOX and TBARs as dependent variables revealed a 
strong interaction effect between cohort and risk (F(8, 43) = 5.026, p < 0.001; Wilks λ 
= 0.517), with post-hoc tests indicating that IsoP, ABTS and FOX were significant 
(p<0.05), with trend significance seen in the NP and CD. Duplicate analysis in the 
temporal region with the same variables indicated no difference. 
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Table 15 – Descriptive analysis of the APOE and cohort MANOVA analysis 
1=Control 
2=Alzheimer 1= 0 alleles present 
2= 1 or 2 alleles 
FRIsoP 
 
(µg/g) 
FRnp 
 
(µg/g) 
FRcd 
(mmol dm
-
3
/g) 
FRabts 
TEAC per g 
(µmol/g) 
FRfox 
CHPE/g wet 
weight 
1 1 Mean 5.72 7.65 1.79 11.26 8718.71 
Std. Deviation 16.51 7.03 2.04 2.40 6857.67 
N 21 22 25 25 25 
2 Mean 17.53 8.12 0.71 10.55 1050.20 
Std. Deviation 41.61 7.77 0.63 0.78 328.73 
N 6 7 8 8 8 
2 1 Mean 1.81 4.23 0.86 11.71 2341.94 
Std. Deviation 5.61 3.19 1.05 2.11 2118.35 
N 15 15 15 14 14 
2 Mean 1.04 8.11 1.43 14.05 5694.23 
Std. Deviation 1.52 6.60 1.91 3.05 6380.12 
N 19 20 20 20 20 
 
 
 
 
Figure 25 – Frontal isoprostane levels between cohort and the APOE 
variable  
 
 
 
Frontal IsoPs were observed to be higher in the control cohort regardless of the 
amount of alleles present in the APOE gene. This observation was over p = 0.05, but 
can be considered as being trend-level significant.  
Once the MANOVA was conducted, descriptive analysis allowed for determination 
of the means and standard deviation of the significant assays in the post-hoc output. 
The genetic variable was grouped into two separate classes; group 1 consisted of 
samples, in both AD and control, which had no alleles in the APOE with group 2 
having the samples which possessed 1 or 2 alleles.  
   Control     Alzheimer    Control     Alzheimer 
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The higher antioxidant status in AD tissue and the higher NP levels in this tissue when 
one or more alleles are present, demonstrates a link between the two. Any oxidised DHA 
in the prostanoid formation pathway will be reduced to form non-destructive components 
with antioxidant intervention, which will amplify stable biomarkers. The genotype itself 
may play a determining affect on the NP levels, increased alleles equates to higher risk of 
AD and with the consensus on oxidation in AD, this assay agrees with the notion of 
higher oxidation. Yet this differs from the previous IsoP determination. AD samples had 
lower levels of IsoP compared with controls and this then highlights the role of 
preferential DHA oxidation. Against this theory is the lack of statistical significance in 
both DHA and AA fatty acid levels for these samples, where no reduction was 
determined.  Oxidation of DHA should lower that particular PUFA content regardless of 
disease state. However, a small percentage decrease in fatty acid levels (mg) will be 
magnified at the prostanoid level (μg) due to the mass variation.  
CD levels were also statistically significant in the cohort and APOE genotypes 
MANOVA. Frontal CD levels were evaluated to be higher in the control state when no 
alleles are present on the APOE, but addition of one or more alleles shifts this result to 
being higher in the AD state. CDs are the primary products of PUFA oxidation and their 
reduction in the zero allele state can be attributed to the higher levels of antioxidants 
reduced hydrogen abstraction by free radicals therefore preventing PUFA oxidation. On 
the other hand, the introduction of the alleles appears to favour the negative role of 
antioxidants, where the biomarker levels such as CD and NPs are higher.  
This supports the theory that oxidation appears to be of significance with increasing 
alleles in AD with two independent assays. Conversely when the control samples have 
one or more alleles the CD levels reduce dramatically along with IsoP and NPs indicating 
differences between them in oxidation. This implicates the link between genetic content 
and oxidation once again as previously stated in the link between DHA and Aβ pathway. 
LOOHs, shared with the CDs, are primary products of free radical hydrogen abstraction 
and oxidation and their findings should closely relate to the findings of the CD 
determination. Once more the same outcomes are observed with zero allele states having 
higher LOOH levels in the control group compared to the AD set. Introduction of the 
alleles shifts the results into favouring higher oxidation in AD, which is completely 
different to the means-based analysis that indicated higher antioxidant status in AD. 
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Figure 26 – Frontal neuroprostane levels between cohort and the APOE 
variable  
 
 
 
 
Figure 27 – Frontal conjugated diene levels controlling for APOE and 
cohort  
 
 
 
 
CDs, trend-level significant (p = 0.072), in the zero allele state had control samples 
with higher levels than the respective AD, interpretation of the second allele class 
indicates that AD had a higher amount of CD than the control samples. The second 
APOE allele group both the NPs and CDs have shown a higher level of oxidation, 
which is different to the previous means based analysis, standard deviation is also 
high. 
NPs were also trend-level significant (p = 0.075), but were higher in the samples 
which had 1 or 2 alleles present in the APOE gene, regardless of whether it was AD 
or control in comparison to having no alleles. This indicates that DHA oxidation, 
forming NPs, are affected by the genetic variable. 
   Control     Alzheimer    Control     Alzheimer 
   Control       Alzheimer     Control        Alzheimer 
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Figure 28 – Frontal lipid hydroperoxide levels controlling for APOE and 
cohort  
 
 
 
Figure 29 – Frontal antioxidant levels controlling for APOE and cohort  
 
 
 
 
TEAC (p = 0.056), was not as significant as the earlier MANOVA without APOE in 
the frontal region. AD samples were observed to have higher levels of antioxidants 
than the control groups no matter how many alleles were present. Errors are greatly 
reduced unlike the previous assays from the post-hoc analysis. 
LOOHs (p = 0.001), were the most significant assay from the post-hoc analysis in the 
APOE and cohort MANOVA. When the sample has 1 or 2 alleles present, the levels 
of LOOHs are increased in AD, the opposite is observed in the 0 allele group with the 
control cohort having higher LOOH levels to the respective AD. 
   Control       Alzheimer    Control    Alzheimer 
 Control       Alzheimer  Control    Alzheimer 
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5.3 – Refinement of MANOVA frontal analysis (Cohort and APOE) 
In the previous section the MANOVA analysis was detailed, but in the majority of the 
graphs outliers were generated from the significant assays in the post-hoc breakdown. 
Therefore the samples denoted in each of the affected graphs, were removed to elucidate 
whether there is a significant difference under these variables, or to verify that the 
outliers in the boxplots were causing the variation in this analysis. APOE1 vs APOE2 
MANOVA with IsoP, NP, CD, ABTS and FOX as dependent variables, these tests were 
the only ones significant in the previous cohort APOE post-hoc analysis hence the 
admission of the other tests.  
The analysis revealed a strong interaction effect between cohort and risk (F (5, 33) = 
3.367, p = 0.014; Wilks λ = 0.662), with post-hoc tests indicating that only FOX was 
significant (p = 0.010), table 16.  This modified MANOVA verifies that the significance 
of certain assays seen in the first APOƐ  frontal analysis, in the post-hoc, was attributed 
to the influence of outliers. Essentially the conclusions discussed for the LOOH (FOX) in 
the first APOE MANOVA are applicable to the findings of this second MANOVA. 
When no alleles are present, the control samples have a higher level of LOOHs than the 
matched AD cohort. This reverses when 1 or more alleles are present in the sample. 
LOOHs were observed to be higher in the AD cohort with the increased allele presence, 
figure 30.   
5.4 – MANOVA frontal and temporal analysis (Cohort and Braak staging) 
From the genetic implications a clear observation was found. Specifically,possessing 
extra alleles promotes differences between IsoP, NP, CD, ABTS and LOOH assays. In 
section 1.1b, Braak staging was discussed in post-mortem tissue classification. Stages 0-
VI has been regrouped into two definite groups because of the limitations with the 
MANOVA. Stages 0-III, defined as group one and stages IV-VI classed as group 2 as 
this evenly splits the data. Once again each region was dealt with separately. Frontal and 
temporal samples were independently processed in terms of the eight dependent variables 
but with addition of the Braak stages grouping. Frontal control and AD samples with 
Braak grouping, as independent variables, MANOVA with AA, DHA, IsoP, NP, CD, 
ABTS, FOX and TBARs as dependent variables.  
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Table 16 – Cohort and APOE statistical analysis of the variables significant 
in the post-hoc analysis in the frontal region, removal of outliers in previous 
MANOVA 
Frontal Multivariate Tests
b
 
Effect Value F Hypothesis df Error df Sig. 
Apoe Wilks' Lambda .841 1.248
a
 5.000 33.000 .310 
cohort * apoe Wilks' Lambda .662 3.367
a
 5.000 33.000 .014 
Tests of Between-Subjects Effects in the Frontal region 
Source 
Dependent 
Variable 
Type III Sum of 
Squares df Mean Square F Sig. 
cohort * apoe FRIsoP 4.053 1 4.053 1.074 .307 
FRnp 27.136 1 27.136 .868 .357 
FRcd 2.698 1 2.698 1.605 .213 
FRabts 8.966 1 8.966 2.050 .161 
FRfox 2.793E8 1 2.793E8 7.351 .010 
 
Figure 30 – Lipid hydroperoxide levels controlling for APOE and cohort 
with removal of outliers 
 
 
 
 
 
The removal of the outliers found in the previous MANOVA found that APOE1 vs 
APOE2 MANOVA with IsoP, NP, CD, ABTS and FOX as dependent variables. The 
analysis revealed a strong interaction effect between cohort and risk (F (5, 33) = 
3.367, p = 0.014; Wilks λ = 0.662), with post-hoc tests indicating that only FOX was 
significant (p=0.010). This then implies that the findings in the first APOE 
MANOVA were down to the outliers affecting the mean of that sample size. In terms 
of FOX, control samples with no alleles had higher levels of LOOH compared to the 
AD equivalent. This was then reversed in the 1 or more allele state where AD 
samples had increased levels of FOX compared to the control. 
   Control       Alzheimer    Control    Alzheimer 
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Table 17 – Cohort and Braak staging statistical analysis including variables 
significant in the MANOVA in both frontal and temporal regions 
 Frontal Multivariate Tests
b
 
Effect Value F Hypothesis df Error df Sig. 
cohort * Braak 
stages 
Pillai's Trace .174 1.106
a
 8.000 42.000 .379 
Wilks' Lambda .826 1.106
a
 8.000 42.000 .379 
Hotelling's Trace .211 1.106
a
 8.000 42.000 .379 
Roy's Largest Root .211 1.106
a
 8.000 42.000 .379 
Tests of Between-Subjects Effects in the Frontal region 
Source 
Dependent 
Variable 
Type III Sum 
of Squares Df Mean Square F Sig. 
cohort * Braak 
stages 
FRdha 4.490 1 4.490 1.199 .279 
FRaa 1.308 1 1.308 2.785 .102 
FRIsoP 40.094 1 40.094 .189 .665 
FRnp 1.061 1 1.061 .030 .862 
FRcd 2.145 1 2.145 .875 .354 
FRabts 7.547E-6 1 7.547E-6 .000 .999 
FRfox 4.744E7 1 4.744E7 1.102 .299 
FRtbars 9.398 1 9.398 .473 .495 
 
Temporal Multivariate Tests
b
 
Effect Value F Hypothesis df Error df Sig. 
cohort * Braak 
stages 
Pillai's Trace .085 .557
a
 7.000 42.000 .786 
Wilks' Lambda .915 .557
a
 7.000 42.000 .786 
Hotelling's Trace .093 .557
a
 7.000 42.000 .786 
Roy's Largest Root .093 .557
a
 7.000 42.000 .786 
Tests of Between-Subjects Effects in the Temporal region 
Source 
Dependent 
Variable 
Type III Sum of 
Squares Df Mean Square F Sig. 
cohort * Braak 
 stages 
TPdha .002 1 .002 .000 .984 
TPaa .002 1 .002 .002 .962 
TPnp 12.197 1 12.197 .258 .614 
TPcd .027 1 .027 .070 .793 
TPabts 8.059 1 8.059 1.468 .232 
TPfox 2.036E7 1 2.036E7 .981 .327 
TPtbars 12.768 1 12.768 .954 .334 
 
 
 
 
 
Braak staging is divided into six different groups, each group having different sample 
sizes making MANOVA analysis difficult. To reduce such problems the Braak stages 
will be put into two groups of equal size to improve statistical analysis. Stages 0-III 
are defined as group 1 with the remaining IV-VI being in group 2. Addition of the 
Braak staging to the analysis had no relevance in differentiating between AD and 
control; IsoPs had to be removed from the temporal results due to missing data. 
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The analysis revealed no effect between cohort and Braak grading (F(8, 42) = 1.106, p = 
0.379; Wilks λ = 0.826), with post-hoc analysis being excluded because of the p value. 
Introduction of Braak staging appears to have no statistical affect on differentiating 
between the tissues. MANOVA processing of the temporal data controlling for cohort 
and Braak staging had to be modified due to lack of sample numbers in the IsoP assay. 
Thus only seven out of the eight dependent variables were used alongside the two 
independent factors. Control and AD with Braak staging in the temporal lobe was 
analysed as the two independent factors with the remaining AA, DHA, NP, CD, ABTS, 
FOX and TBARs as the dependent factors in the MANOVA. The analysis revealed that 
there was no interaction between cohort and Braak staging (F(7, 42) = 0.557, p = 0.786; 
Wilks λ = 0.915). Both the frontal and temporal lobes, under cohort analysis, appear to 
show that Braak staging has no statistical and therefore no influence in the determination 
of AD for these assays. 
 
5.5 – Discussion of statistical analysis 
DHA and AA levels appear to have no relevance in the determination or differentiation 
between AD and control samples which agress with Skinner et al [175]. Our 
collaborators concluded from a larger cohort study that only the saturated stearic acid 
(18:0) and palmitic acid (16:0) had a statistical significance between the two states, with 
AD tissue having more of these two fatty acids the impact of which is more significant 
than both DHA and AA [179]. Palmitic and stearic acid were reported to induce 
hyperphosphorylation of tau [179] and paired with the associated increase in PS, where 
these fatty acids have been observed in large percentages, promote the externalisation of 
PS. Increasing saturated fatty acid phospholipid content, can be attributed to the high fat 
diets commonly observed within modern western diets [37, 58, 80]. Therefore these 
saturated fatty acids may be an influential component of AD pathogenesis, more than 
DHA and AA. 
 
CD and LOOHs indicated no difference or at least no increase in the AD state, but of 
more interest was the standard deviation. In the FOX assay the variation was greater than 
the mean precluding any conclusion.  Primary products, determined herein, only provide 
a snap shot of the state of oxidation, if the pathway has progressed past these compounds 
then these will appear reduced unless a steady state of formation and conversion is 
happening. Deviation between the samples may be attributed to the state of oxidation at 
that time point. Previous literature [71] confirmed that the extraction method used on 
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these same samples in collaboration with temperature and time delay suffered from no 
detrimental reduction in fatty acid and CD levels. This further augments the concept that 
the variation in LOOH is down to the progression of the oxidation pathway.  
 
Analysis of the two independent end point markers confirmed that oxidation was not 
elevated in AD, except for temporal NP levels which were increased in the AD cohort. 
IsoPs and NPs had a large standard deviation similar to the LOOHs nullifying any 
potential conclusions. Levels of chain scission aldehydic products showed no difference 
between AD and control groups, but the results obtained had a reduced standard 
deviation than both the prostanoids and LOOHs. TEAC determination indicated that AD 
samples had higher antioxidant levels compared to the control. The suppression of all the 
oxidation markers in the AD samples is assumed to be linked to increased antioxidant 
protection. The means-based analysis implies that in the sample cohort, oxidation is not 
significant in AD using these biomarkers except for the levels of antioxidants. Following 
the general consensus in literature regarding increased oxidation in AD, it makes sense 
that up-regulated oxidation in turn promotes antioxidant levels to counteract the 
imbalance in situ as a host response. However, too many antioxidants can increase 
oxidation biomarkers as discussed previously. Formation of the prostanoids requires 
reduction which antioxidants can easily perform, therefore increasing levels of this 
particular biomarker. Either way the apparent variation in antioxidant levels can be 
argued in both theories with the results acquired.  
Levels of TEAC were higher in AD regardless of the number of alleles present in the 
APOE genotype and more significantly the higher allele content in AD increased the 
level of antioxidants. Control samples had lower antioxidant levels when more than one 
allele was present on the APOE synonymous with the other statistically significant 
assays. This clear association between APOE and antioxidants in AD seems to enhance 
their role regardless of perception (positive or negative). Positively, these compounds 
reduce oxidation by competing with radicals and supplying themselves as hydrogen atom 
donors instead of the methylene carbon for example, hence protecting the vulnerable 
PUFAs. This would then lead to a marked reduction in oxidation markers. Negatively, 
when quenching the oxidation process any propagation reactions already occurring will 
be driven to their respective stable markers, therefore increasing the oxidation markers. 
Either way increased antioxidant levels are in contrast to the oxidation theory perceived 
in the literature regarding AD pathogenesis.  
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The increased levels of antioxidants were further investigated with correlations against 
Aβ, phospho-tau, post synaptic and dendritic spine proteins, neprilysin and three 
enzymes (insulin-degrading, angiotensin-converting and β-secretase) by our collaborators 
[200]. They found that antioxidant levels and insoluble Aβ were the only statistically 
significant variables, comparing APOE ε4 positive to APOE ε4 negative. The pathways 
illustrated in figure - 31 shows how both sAPPα and Aβ are made and their links to 
APOE and DHA.  
 
The formation of sAPPα, through the non-amyloidogenic pathway, promotes cell 
survival and anti-inflammatory activities [17, 29, 49, 81]. Where as the formation of Aβ 
from the same starting compound, in the amyloidgenic pathway, causes more damage by 
elevating cell death and oxidative stress [201]. One of the determining factors on whether 
sAPPα or Aβ forms depends on which secretase enzyme cleaves the βAPP from the 
membrane. In the non-amyloidgenic pathway α-secretase splits βAPP to form a 83-
residue protein known as sAPPα, however in the amyloidgenic pathway β-secretase 
breaks βAPP into a 99-residue protein which is then converted to Aβ by γ-secretase 
activity [202]. According to our collaborators there was no increase in β-secretase 
activity in AD, which starts the process of Aβ formation.  
 
The formation of Aβ causes oxidative stress levels to increase, however our results differ 
from this. All the lipid oxidation biomarkers quantified in this study, show no elevation 
in AD where Aβ production is greater. The pathway shown in figure 31 shows that free 
DHA is converted to NPs under high Aβ synthesis and should increase in the 
amyloidgenic process. The results obtained herein show no increase in NPs or IsoPs in 
AD for both brain regions. This suggests that either Aβ is increasing oxidative stress and 
the host is responding by upregulated antioxidant levels, or the increase in oxidation is 
not breaking down the fatty acids. However, the reason behind the elevated Aβ and 
antioxidants in Tayler et al [200] and our study are unclear. Whether the elevated 
oxidation associated with Aβ is affecting other components like cholesterol and APOE, 
as seen in figure 31, requires further investigation.  
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    Figure 31 – Nonamyloidgenic and amyloidgenic pathways [203] 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
The diagram above shows two separate pathways denoted A and B. Pathway A 
describes the non-amyloidogenic pathway. SORL1, the βAPP membrane-integral 
sorting receptor sortilin-1, when near βAPP (in the presence of APOE) allows for 
processing of the precursor protein into secretory APPα under α-secretase. DHA 
actively supports this mechanism after enzymatic release by PLA2. LOX derived 
neuroprotectin D1 supports sAPPα in general cell survival, reducing inflammatory 
processes and pro-apoptotic proteins. Pathway B denotes the amyloidogenic pathway 
where the formation of Aβ is formed instead of APP. When SORL-1 is not proximal 
to βAPP, the α-secretase pathway is replaced by β-secretase and presenlin-1 
(PS1)/BACE activity that produce Aβ peptides. These peptides increase oxidation, 
leading to neuroprostane formation from DHA and neurotoxic sterols from 
cholesterol carrying APOE. Under these conditions oxidative stress, dysfunction and 
finally apoptosis are promoted. 
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The other variable which was linked to the elevated antioxidant levels was the APOE 
genotype, which is also linked to reducing fibril Aβ formation [204]. APOE is a carrier 
for lipids, cholesterol and antioxidants [205], but is also shown to have antioxidant 
activity [206] and may be responsible for the elevated levels of these defence 
compounds. The protein binding site of APOE that is associated with its antioxidant 
capacity lies between residues 141 and 155 of the protein [207]. However, there are 
many variants of APOE and each type has its own antioxidant activity and it has been 
shown that APOE2>APOE3>APOE4 in terms of oxidative defence [204, 208]. The 
reduced capacity of APOE4 as a antioxidant is down to the different proteins at 112 and 
158 residues compared to both APOE2 and APOE3 [207]. Therefore more antioxidants 
would be recruited to sites where APOE4 was present. Such antioxidants as glutathione, 
glutathione peroxidase [209], superoxide dismutases [206] and catalase [205] have all 
been shown to be elevated in APOE4 samples. 
 
5.6 – Future directions 
The results and discussion in the previous sections have suggested that the role of lipid 
oxidation in AD pathogenesis is not justified. Various oxidation assays indicated no 
increase in AD, but questions remain over the variability in the results. Quantification of 
the transient intermediates involved in the initial stages of oxidation, the CD and LOOH 
assays, suggest that the results from these assays are independent of one another. This 
could be attributable to other compounds absorbing at the CD wavelength, 
reproducibility of both of these spectrophotometric methods or even the heterogeneity of 
the human brain tissue. The newly derived GC-EI-MS method requires further evaluation 
using other biological fluids (e.g. plasma and urine) to fully validate the method. 
 
Antioxidant levels are higher in AD samples in both brain regions. Determination of 
water soluble antioxidant composition is required to find the reason for the increased 
levels in AD, preferably using LC. Candidate antioxidants likely to be involved in the 
brain include α-tocopherol, ascorbic acid or glutathione. The antioxidant capacity of 
APOE requires further investigation in AD. The ABTS assay works on radical 
scavengers such as gluthathione and vitamin e [210], where as APOE works by inhibiting 
metal induced oxidation [207]. Therefore the use of the Cu
2+
 reduction assay may 
demonstrate the antioxidant activity of APOE [211].  Genomic approaches such as DNA 
microarray could be used to evaluate whether genes encoding the biosynthesis pathways 
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of these molecules are the reason for elevated antioxidant levels in AD. Analysis of 
sterols being transported by APOE, in particular the neurotoxic sterols (24S- and 7β-
hydroxycholesterol) formed upon interaction with the Aβ protein under the 
amyloidogenic pathway, may differentiate between AD and control as higher Aβ levels 
increase the presence of these modified cholesterol markers.  
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6   Conclusions 
            This project forms part of a large multiple variable analysis into the role of lipid 
oxidation in the pathogenesis of AD with clinical data sets. The causal pathway models 
for DHA oxidation indicate that control samples followed chain breakdown mechanisms 
to form aldehydes while the AD samples, went through ring formation to create the 
cyclic NPs. AA pathway models in the AD temporal region produced IsoPs with the 
frontal lobe forming aldehydes, similar to the control samples for both brain regions. 
This demonstrated that different lipid oxidation mechanisms in AD and control were 
occurring in both frontal and temporal lobes. Determination of the lipid oxidation marker 
levels showed that there was no significant difference between AD and control. The 
antioxidants, however, were higher in both brain regions of the AD samples which could 
indicate low lipid peroxidation and their lack of consumption in catabolism. Statistically, 
only frontal antioxidant levels were significant in differentiating between AD and control 
without any clinical variables.  
 
Introduction of the APOE variable suggested that LOOHs were higher in the control 
when 1 or 2 alleles are present, which could be attributable to the lower antioxidant 
levels. Analysis of post-mortem, age at death and Braak staging did not show any 
differences between AD and control. Antioxidants were higher in AD and that may 
explain why the lipid oxidation markers were lower compared to the controls across the 
brain regions. Since elevated lipid peroxidation has been linked to AD pathogenesis (1.1d 
i Oxidation), the results obtained here appear to be counter intuitive with multiple 
oxidative biomarkers being reduced in AD. 
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Clinically, increased supplementation of omega-3 PUFAs and antioxidants has been a 
common suggestion as a dietary intervention for lowering the risk of AD in many large 
epidemiological studies, table 1. This study suggests that such an intervention would 
most likely be ineffective against AD per se although it may support improvement in 
other areas of general health. It can be argued that the elevated levels of antioxidants 
could be a negative consequence of AD and that the supplementation of such compounds 
could aggravate the condition further. In terms of lipid peroxidation, no definitive 
markers or target site for intervention have been revealed. Perhaps other non-lipid targets 
such as APOE hold the key to unravelling this condition. 
 
102 
 
7    References 
1. J. Hardy, The amyloid hypothesis for Alzheimer's disease: A critical reappraisal. Journal of 
Neurochemistry, 2009. 110: p. 1129-1134. 
2. P. M.Kidd, Alzheimer's Disease, Amnestic Mild Cognitive Impairment, and Age-Associated 
Memory Impairment: Current Understanding and Progress Toward Integrative Prevention. 
Alternative Medicine Review, 2008. 13(2): p. 85-115. 
3. Cleusa P Ferri, Martin Prince, Carol Brayne, Henry Brodaty, Laura Fratiglioni, Mary Ganguli, 
Kathleen Hall, Kazuo Hasegawa, Hugh Hendrie, Yueqin Huang, Anthony Jorm, Colin Mathers, 
Paulo R Menezes, Elizabeth Rimmer, and M. Scazufca, Global prevalence of dementia: a Delphi 
consensus study. The Lancet, 2005. 366: p. 2112-2117. 
4. Carlijn R. Hooijmans and A.J. Kiliaan, Fatty acids, lipid metabolism and Alzheimer pathology. 
European Journal of Pharmacology, 2008. 585: p. 176–196. 
5. E. WIlkinson. Alzheimer's drug 'halts' decline.  2008  [cited 2010 13th September 2010]; 
Available from: http://news.bbc.co.uk/1/hi/7525115.stm. 
6. J. Hughes. Vitamin B 'puts off Alzheimer's'.  2010  [cited 2010 13th September 2010]; Available 
from: http://www.bbc.co.uk/news/health-11232356. 
7. Rebecca Craig-Schapiro, Anne M. Fagan, and D. M.Holtzman, Biomarkers of Alzheimer's 
disease. Neurobiology of Aging, 2009. 35: p. 128-140. 
8. Michael T. Heneka and M.K. O'Banion, Inflammatory processes in Alzheimer's disease. Journal 
of Neuroimmunology, 2007. 184(1): p. 69-91. 
9. Yvonne Freund-Levi, Hans Basun, Tommy Cederholm, Gerd Faxe´n-Irving, Anita Garlind, 
Mikaela Grut, Inger Vedin, Jan Palmblad, Lars-Olof Wahlund, and M. Eriksdotter-Jo¨nhagen, 
Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric 
symptoms. International Journal of Geriatric Psychiatry, 2007. 23(2): p. 161-169. 
10. Jignesh D Pandya, Kunjan R Dave, and S.S. Katyare, Effect of long-term aluminum feeding on 
lipid/phospholipid profiles of rat brain myelin. Lipids in Health and Disease, 2004. 3(1): p. 13. 
11. Cynthia Boudrault, Richard P. Bazinet, and D.W.L. Ma, Experimental models and mechanisms 
underlying the protective effects of n-3 polyunsaturated fatty acids in Alzheimer's disease. Journal 
of Nutritional Biochemistry, 2009. 20: p. 1-10. 
12. Ron Brookmeyer, Elizabeth Johnson, Kathryn Ziegler-Graham, and H.M. Arrighi, Forecasting 
the global burden of Alzheimer's disease. Alzheimer's & Dementia, 2007. 3: p. 186-191. 
13. E. E. Tuppo, L. J. Forman, B. W. Spur, R. E. Chan-Ting, A. Chopra, and T.A. Cavalieri, Sign of 
lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain 
Research Bulletin, 2001. 54(5): p. 565-568. 
14. Adelina Comas-Herrera, Raphael Wittenberg, Linda Pickard, and M. Knapp, Cognitive 
impairment in older people: future demand for long-term care serives and the associated costs. 
International Journal of Geriatric Psychiatry, 2007. 22: p. 1037-1045. 
103 
 
15. Greg M. Cole, Qiu-Lan Ma, and S.A. Frautschy, Omega-3 fatty acids and dementia. 
Prostaglandins, Leukotrienes and Essential Fatty Acids. 81(2): p. 213-221. 
16. H. Braak and E. Braak, Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathologica, 1991. 82: p. 239-259. 
17. Sabrina Florent-Be´chard, Ce´ dric Desbe`ne, Pierre Garcia, Ahmad Allouche, Ihsen Youssef, 
Marie-Christine Escanye´, Violette Koziel, Marine Hanse, Catherine Malaplate-Armand, 
Christophe Stenger, Badreddine Kriem, Frances T. Yen-Potin, Jean Luc Olivier, Thierry Pillot, 
and T. Oster, The essential role of lipids in Alzheimer’s disease. Biochimie, 2009: p. 1-6. 
18. David L. Marcus, Christopher Thomas, Charles Rodriguez, Katherine Simberkoff, Jir S. Tsai, 
James A. Strafaci, and M.L. Freedman, Increased Peroxidation and Reduced Antioxidant Enzyme 
Activity in Alzheimer’s Disease. Experimental Neurology, 1998. 150: p. 40-44. 
19. Thomas J. Montine, William R. Markesbery, William Zackert, Stephanie C. Sanchez, L. Jackson 
Roberts II, and J.D. Morrow, The Magnitude of Brain Lipid Peroxidation Correlates with the 
Extent of Degeneration but Not with Density of Neuritic Plaques or Neurofibrillary Tangles or 
with APOE Genotype in Alzheimer’s Disease Patients. American Journal of Pathology, 1999. 
155(3): p. 863-868. 
20. P.K. Mukherjee, A. Chawla, M.S. Loayza, and N.G. Bazan, Docosanoids are multifunctional 
regulators of neural cell integrity and fate: Significance in aging and disease. Prostaglandins, 
Leukotrienes and Essential Fatty Acids 2007. 77: p. 233-238. 
21. D. Allan Butterfield, Alessandra Castegna, Christopher M. Lauderback, and J. Drake, Evidence 
that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease 
brain contribute to neuronal death. Neurobiology of Aging, 2002. 23: p. 655-664. 
22. H. Kretzschmar, Brain banking: opportunities, challenges and meaning for the future. Nature 
Reviews, Neuroscience, 2009. 10: p. 70-77. 
23. H. Braak, U. Rub, C. Schultz, and K. Del Tredici, Vulnerability of cortical neurons to 
Alzheimer's and Parkinson's diseases, in Alzheimer's Disease: A Century of Scientific 
and Clinical Research, George Perry, Jesus Avila, June Kinoshita, and M.A. Smith, 
Editors. 2006, IOS Press. p. 35-44. 
24. Danielle G. Smith, Roberto Cappai, and K.J. Barnham, The redox chemistry of the Alzheimer's 
disease amyloid β peptide. Biochimica et Biophysica Acta, 2007. 1768(8): p. 1976-1990. 
25. Kyung Mee Kim, Byung Hwa Jung, Ki-Jung Paeng, Inseong Kim, and B.C. Chung, Increased 
urinary F2-isoprostanes levels in the patients with Alzheimer’s disease. Brain Research Bulletin, 
2004. 64: p. 47-51. 
26. D. Allan Butterfield, Jennifer Drake, Chava Pocemich, and A. Castegna, Evidence of oxidative 
damage in Alzheimer's disease brain: Central role for amyloid b-peptide. TRENDS in Molecular 
Medicine, 2001. 7(12): p. 548-554. 
27. William E Connor and S.L. Connor, The importance of fish and docosahexaenoic acid in 
Alzheimer disease. The American Journal of Clinical Nutrition, 2007. 85: p. 929-930. 
28. P.H. Reddy, Amyloid precursor protein-mediated free radicals and oxidative damage: 
Implications for the development and progression of Alzheimer’s disease. Journal of 
Neurochemistry, 2006. 96: p. 1-13. 
29. Kim N. Green, Hilda Martinez-Coria, Hasan Khashwji, Eileen B. Hall, Karin A. Yurko-Mauro, 
Lorie Ellis, and F.M. LaFerla, Dietary Docosahexaenoic Acid and Docosapentaenoic Acid 
Ameliorate Amyloid-b and Tau Pathology via a Mechanism Involving Presenilin 1 Levels. The 
Journal of Neuroscience, 2007. 27(16): p. 4385-4395. 
30. Qiu-Lan Ma, Fusheng Yang, Emily R. Rosario, Oliver J. Ubeda, Walter Beech, Dana J. Gant, 
Ping Ping Chen, Beverly Hudspeth, Cory Chen, Yongle Zhao, Harry V. Vinters, Sally A. 
Frautschy, and G.M. Cole, -Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation 
of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 
Fatty Acids and Curcumin. Neurobiology of Disease, 2009. 29(28): p. 9078-9089. 
31. Hossain Shahdat, Michio Hashimoto, Masanori Katakura, Koji Miwa, Toshio Shimada, and O. 
Shido, Mechanism of Docosahexaenoic acid-induced inhibition of in vitro A1-42 fibrillation and 
A1-42-induced toxicity in SH-S5Y5 cells. Journal of Neurochemistry, 2009. 111(2): p. 568-579. 
32. G. Spiteller, Peroxyl radicals: Inductors of neurodegenerative and other inflammatory diseases. 
Their origin and how they transform cholesterol, phospholipids, plasmalogens, polyunsaturated 
fatty acids, sugars, and proteins into deleterious products. Free Radical Biology & Medicine, 
2006. 41: p. 362-387. 
104 
 
33. Lidia Glodzik-Sobanska, Elizabeth Pirraglia, Miroslaw Brys, Susan de Santi, Lisa Mosconi, 
Kenneth E. Rich, Remigiusz Switalski, Leslie Saint Louis, Martin J. Sadowski, Frank Martiniuk, 
Pankaj Mehta, Domenico Pratico, Raymond P. Zinkowski, Kaj Blennow, and M.J.d. Leon, The 
effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer’s 
disease. Neurobiology of Aging, 2009. 30: p. 672-681. 
34. M.C. Morris, The role of nutrition in Alzheimer's disease: epidemiological evidence. European 
Journal of Neurology, 2009. 16 (Supplement 1): p. 1-7. 
35. L. Terrisse, J. Poirier, P. Bertrand, A. Merched, S. Visvikis, G. Siest, R. Milne, and E. Rassart, 
Increased Levels of Apolipoprotein D in Cerebrospinal Fluid and Hippocampus of Alzheimer's 
Patients. Journal of Neurochemistry, 1998. 71: p. 1643-1650. 
36. Stephen Salloway and S. Correia, Alzheimer disease: Time to improve its diagnosis and 
treatment. Cleveland Clinic Journal Of Medicine, 2009. 76(1): p. 49-58. 
37. José A Luchsinger and R. Mayeux, Dietary factors and Alzheimer's disease. The Lancet 
Neurology, 2004. 3: p. 579-587. 
38. Nikolaos Scarmeas, Yaakov Stern, Ming-Xin Tang, Richard Mayeux, and Jose A. Luchsinger, 
Mediterranean Diet and Risk for Alzheimer's Disease. Annuals of Neurology, 2006. 59: p. 912-
921. 
39. J.M. Ellison, A 60-Year-Old Woman With Mild Memory Impairment. Journal of the American 
Medical Association, 2008. 300(13): p. 1566-1574. 
40. Emiliano Albanese, Alan D. Dangour, Ricardo Uauy, Daisy Acosta, Mariella Guerra, Sara S. 
Gallardo Guerra, Yueqin Huang, KS Jacob, Juan Llibre de Rodriguez, Lisseth Hernandex 
Noriega, Aquiles Salas, Ana Luisa Sosa, Renata M. Sousa, Joseph Williams, Cleusa P Ferri, and 
M.J. Prince, Dietary fish and meat intake and dementia in Latin America, China, and India: a 
10/66 Dementia Research Group population-based study. The American Journal of Clinical 
Nutrition, 2009. 90: p. 392-400. 
41. Martha Clare Morris, Denis A. Evans, Julia L. Bienias, Christine C. Tangney, David A. Bennett, 
Robert S. Wilson, Neelum Aggarwal, and J. Schneider, Consumption of Fish and n-3 Fatty Acids 
and Risk of Incident Alzheimer Disease. Archives of Neurology, 2003. 60: p. 940-946. 
42. Sabrina Florent-Béchard, Catherine Malaplate-Armand, Violette Koziel, Badreddine Kriem, Jean-
Luc Olivier, Thierry Pillot, and T. Oster, Towards a nutritional approach for prevention of 
Alzheimer's disease: Biochemical and cellular aspects. Journal of the Neurological Sciences, 
2007. 262: p. 27-36. 
43. Clive Bate, Mourad Tayebi, Luisa Diomede, Mario Salmona, and A. Williams, Docosahexaenoic 
and eicosapentaenoic acids increase prion formation in neuronal cells. BMC Biology, 2008. 
6(1): p. 39. 
44. Kathleen M.Gustafson, John Colombo, and S. E.Carlson, Docosahexaenoic acid and cognitive 
function: Is the link mediated by the autonomic nervous system? . Prostaglandins, Leukotrienes 
and Essential Fatty Acids. 79(3): p. 135-140. 
45. David L. Nelson and M.M. Cox, Lehninger Principles of Biochemistry. Fourth edition ed. 2005, 
New York: W. H. Freeman and Company. 
46. Howard Sprecher, Devanand L. Luthria, B. S. Mohammed, and S.P. Baykousheva, Reevaluation 
of the pathways for the biosynthesis of polyunsaturated fatty acids. Journal of Lipid Research, 
1995. 36: p. 2471-2477. 
47. L. Jackson Roberts, Thomas J. Montine, William R. Markesbery, Andrew R. Tapper, Pierre 
Hardy, Sylvain Chemtob, Wolff D. Dettbarn, and J.D. Morrow, Formation of Isoprostane-like 
Compounds (Neuroprostanes) in Vivo from Docosahexaenoic Acid. The Journal of Biological 
Chemistry, 1998. 273(22): p. 13605-13612. 
48. Gerd Schmitz and J. Ecker, The opposing effects of n-3 and n-6 fatty acids. Progress in Lipid 
Research, 2008. 47: p. 147-155. 
49. Clive Bate, Victoria Marshall, Laura Colombo, Luisa Diomede, Mario Salmona, and A. 
Williams, Docosahexaenoic and eicosapentaenoic acids increase neuronal death in response to 
HuPrP82-146 and Ab1-42. Neuropharmacology, 2008. 54: p. 934-943. 
50. Miguel A. Contreras, Rebecca Sheaff Greiner, Michael C. J. Chang, Carol S. Myers, J. Norman 
Salem, and S.I. Rapoport, Nutritional Deprivation of a-Linolenic Acid Decreases but Does Not 
Abolish Turnover and Availability of Unacylated Docosahexaenoic Acid and Docosahexaenoyl-
CoA in Rat Brain. Journal of Neurochemistry, 2000. 75: p. 2392-2400. 
105 
 
51. Ullrich Jahn, Jean-Marie Galano, and T. Durand, Beyond Prostaglandins—Chemistry and 
Biology of Cyclic Oxygenated Metabolites Formed by Free-Radical Pathways from 
Polyunsaturated Fatty Acids. Angewandte Chemie International Edition, 2008. 47: p. 5894-5955. 
52. Gerard Bannenberg, Makoto Arita, and C.N. Serhan, Endogenous Receptor Agonists: Resolving 
Inflammation. The Scientific World Journal, 2007. 7: p. 1440-1462. 
53. P.C. Calder, Polyunsaturated fatty acids and inflammation. Prostaglandins, Leukotrienes and 
Essential Fatty Acids, 2006. 75: p. 197-202. 
54. Kuresh A. Youdim, Antonio Martin, and J.A. Joseph, Essential fatty acids and the brain: 
possible health implications. International Journal of Developmental Neuroscience, 2000. 18: p. 
383-399. 
55. M.T. Nakamura and T.Y. Nara, Essential fatty acid synthesis and its regulation in mammals. 
Prostaglandins, Leukotrienes and Essential Fatty Acids, 2003. 68: p. 145-150. 
56. H. Breivik, Long-Chain Omega-3 Speciality Oils. Vol. 21. 2007, Bridgwater: The Oily Press. 
57. H.-Y. Kim, Novel Metabolism of Docosahexaenoic Acid in Neural Cells. The Journal of 
Biological Chemistry, 2007. 282(26): p. 18661-18665. 
58. S.M. Innis, Dietary omega 3 fatty acids and the developing brain. Brain Research, 2008. 1237: p. 
35-43. 
59. Inna Kan, Eldad Melamed, Daniel Offen, and P. Green, Docosahexaenoic acid and arachidonic 
acid are fundamental supplements for the induction of neuronal differentiation. Journal of Lipid 
Research, 2007. 48: p. 513-517. 
60. A. Catala, Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and 
oxidizied phospholipids active in physiological and/or pathological conditions. Chemistry and 
Physics of Lipids, 2009. 157: p. 1-11. 
61. N.M. Attar-Bashi, R.S. Weisinger, D.P. Begg, D. Li, and A.J. Sinclair, Failure of conjugated 
linoleic acid supplementation to enhance biosynthesis of docosahexaenoic acid from alpha-
linolenic acid in healthy human volunteers. Prostaglandins, Leukotrienes and Essential Fatty 
Acids, 2007. 76: p. 121-130. 
62. S.E. Feller, Acyl chain conformations in phospholipid bilayers: a comparative study of 
docosahexaenoic acid and saturated fatty acids. Chemistry and Physics of Lipids, 2008. 153(1): 
p. 76-80. 
63. Stephen R. Wassall and W. Stillwell, Docosahexaenoic acid domains: the ultimate non-raft 
membrane domain. Chemistry and Physics of Lipids, 2008. 153: p. 57-63. 
64. Fre´de´ ric Calon and G. Cole, Neuroprotective action of omega-3 polyunsaturated fatty acids 
against neurodegenerative diseases: Evidence from animal studies. Prostaglandins, Leukotrienes 
and Essential Fatty Acids, 2007. 77: p. 287-293. 
65. Su Chen and P.V. Subbaiah, Phospholipid and fatty acid specificity of endothelial lipase: 
Potential role of the enzyme in the delivery of docosahexaenoic acid (DHA) to tissues. 
Biochemica et Biophysica Acta, 2007. 1771: p. 1319-1328. 
66. Joshua T Green, Sarah K Orrand, and R.P. Bazinet, The emerging role of group VI calcium-
independent phospholipase A2 in releasing docosahexaenoic acid from brain phospholipids. 
Journal of Lipid Research. 49(May 2008): p. 939-944. 
67. Shlomo Yehuda, Sharon Rabinovitz, Ralph L. Carasso, and D.I. Mostofsky, The role of 
polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiology of Aging, 
2002. 23: p. 843-853. 
68. Robert S. Chapkin, Wooki Kim, Joanne R. Lupton, and D.N. McMurray, Dietary 
docosahexaenoic and eicosapentaenoic acid: Emerging mediators of inflammation. 
Prostaglandins, Leukotrienes and Essential Fatty Acids, 2009. 81(2): p. 187-191. 
69. Gwendolyn Barcelo-Coblijn, Endre Hogyes, Klara Kitajka, Laszlo G. Puskas, Agnes Zvara, 
Laszlo Hackler Jr, Csaba Nyakas, Zsuzsa Penke, and T. Farkas, Modification by 
docosahexaenoic acid of age-induced alterations in gene expression and molecular composition 
of rat brain phospholipids. Proceedings of the National Academy of Sciences of the United States 
of America, 2003. 100(20): p. 11321-11326. 
70. R.J. Wurtman, Synapse formation and cognitive brain development: effect of docosahexaenoic 
acid and other dietary constituents. Metabolism Clinical and Experimental, 2008. 57(Supplement 
2): p. S6-S10. 
106 
 
71. Thomas Fraser, Hannah Tayler, and S. Love, Low-temperature improved-throughput method for 
analysis of brain fatty acids and assessment of their post-mortem stability. Journal of 
Neuroscience Methods, 2008. 169: p. 135-140. 
72. Angelo O. Rosa and S.I. Rapoport, Intracellular- and extracellular-derived Ca2+ influence 
phospholipase A2-mediated fatty acid release from brain phospholipids. Biochimica et Biophysica 
Acta, 2009. 1791: p. 697-705. 
73. Lloyd A. Horrocks and A.A. Farooqui, Docosahexaenoic acid in the diet: its importance in 
maintenance and restoration of neural membrane function. Prostaglandins, Leukotrienes and 
Essential Fatty Acids, 2004. 70: p. 361-372. 
74. J. Norman Salem, Burton Litman, Hee-Yong Kim, and Klaus Gawrisch, Mechanisms of Action of 
Docosahexaenoic Acid in the Nervous System. Lipids, 2001. 36: p. 945-959. 
75. Takashi Matsuzaka, Hitoshi Shimano, Naoya Yahagi, Michiyo Amemiya-Kudo, Tomohiro 
Yoshikawa, Alyssa H. Hasty, Yoshiaki Tamura, Jun-ichi Osuga, Hiroaki Okazaki, Yoko Iizuka, 
Akimitsu Takahashi, Hirohito Sone, Takanari Gotoda, Shun Ishibashi, and N. Yamada, Dual 
regulation of mouse D5- and D6-desaturase gene expression by SREBP-1 and PPAR. Journal of 
Lipid Research, 2002. 43: p. 107-114. 
76. Barbara Grintal, Gaelle Champiel-Potokar, Monique Lavialle, Sylvie Vancassel, Sylvie Breton, 
and I. Denis, Inhibition of astroglial glutamate transport by polyunsaturated fatty acids: 
Evidence for a signalling role of docosahexaenoic acid. Neurochemistry International, 2009. 54: 
p. 535-543. 
77. Quy N. Diep, Rhian M. Touyz, and E.L. Schiffrin, Docosahexaenoic Acid, a Peroxisome 
Proliferator–Activated Receptor-a Ligand, Induces Apoptosis in Vascular Smooth Muscle Cells by 
Stimulation of p38 Mitogen-Activated Protein Kinase. Hypertension, 2000. 36: p. 851-855. 
78. Sujoy Ghosh, Jay C. Strum, Vicki A. Sciorra, Larry Daniel, and R.M. Bell, Raf-1 Kinase 
Possesses Distinct Binding Domains for Phosphatidylserine and Phosphatidic Acid. The Journal 
of Biological Chemistry, 1996. 271(14): p. 8472-8480. 
79. Hee-Yong Kim, Mohammed Akbar, Audrey Lau, and L. Edsall, Inhibition of Neuronal Apoptosis 
by Docosahexaenoic Acid (22:6n-3). The Journal of Biological Chemistry, 2000. 275(10): p. 
35215-35223. 
80. Huang-Chuan Pan, Tsung-Kuei Kao, Yen-Chuan Ou, Dar-Yu Yang, Yu-Ju Yen, Chun-Chiang 
Wang, Yu-Han Chuang, Su-Lan Liao, Shue-Ling Raung, Ching-Wen Wu, An-Na Chiang, and 
C.-J. Chen, Protective effect of docosahexaenoic acid against brain injury in ischemic rats. 
Journal of Nutritional Biochemistry, 2008: p. ARTICLE IN PRESS. 
81. Pao-Yuan Wang, Jen-Jui Chen, and H.-M. Su, Docosahexaenoic acid supplementation of 
primary rat hippocampal neurons attenuates the neurotoxicity induced by aggregated amyloid 
beta protein42 and up-regulates cytoskeletal protein expression. Journal of Nutritional 
Biochemistry, 2010. 21(4): p. 345-350. 
82. A.T. Michael-Titus, Omega-3 fatty acids and neurological injury. Prostaglandins, Leukotrienes 
and Essential Fatty Acids, . 77: p. 295-300. 
83. A.D. Postle, Phospholipid lipidomics in health and disease. European Journal of Lipid Science 
and Technology, 2009. 111: p. 2-13. 
84. Huiyong Yin, Brian E. Cox, Wei Liu, Ned A. Porter, Jason D. Morrow, and G.L. Milne, 
Identification of intact oxidation products of glycerophospholipids in vitro and in vivo using 
negative ion electrospray iontrap mass spectrometry. Journal of Mass Spectrometry, 2009. 44(5): 
p. 672-680. 
85. Akhlaq A. Farooqui, Lloyd A. Horrocks, and T. Farooqui, Interactions Between Neural 
Membrane Glycerophospholipid and Sphingolipid Mediators: A Recipe for Neural Cell Survival 
or Suicide. Journal of Neuroscience Research, 2007. 85: p. 1834-1850. 
86. Akhlaq A. Farooqui, Lloyd A. Horrocks, and T. Farooqui, Glycerophospholipids in brain: their 
metabolism, incorporation into membranes, functions, and involvement in neurological disorders. 
Chemistry and Physics of Lipids, 2000. 106: p. 1-29. 
87. J.E. Vance, Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two 
metabolically related aminophospholipids. Journal of Lipid Research, 2008. 49: p. 1377-1387. 
88. F. M. Corrigan, D. F. Horrobin, E. R. Skinner, J. A. O. Besson, and M.B. Cooper, Abnormal 
content of n-6 and n-3 long-chain unsaturated fatty acids in the phosphoglycerides and 
cholesterol esters of parahippocampal cortex from Alzheimer's disease patients and its 
107 
 
relationship to acetyl CoA content. The International Journal of Biochemistry & Cell Biology, 
1998. 30: p. 197-207. 
89. M. Soderberg, C. Edlund, K. Kristensson, and G. Dallner, Lipid Compositions of Different 
Regions of the Human Brain During Aging. Journal of Neurochemistry, 1990. 54: p. 415-423. 
90. Daniel Huster, Klaus Arnold, and K. Gawrisch, Influence of Docosahexaenoic Acid and 
Cholesterol on Lateral Lipid Organization in Phospholipid Mixtures. Biochemistry, 1998. 37: p. 
17299-17308. 
91. Wataru Araki and R. J.Wurtman, How Is Membrane Phospholipid Biosynthesis Controlled in 
Neural Tissues? Journal of Neuroscience Research, 1998. 51: p. 667-674. 
92. Jeremy M. Berg, John L. Tymoczko, and L. Stryer, Biochemistry. 5th ed. 2002, New York: W.H 
Freeman and Company. 
93. Tibor Farkas, Klara Kitajka, Elfrieda Fodor, Istva´n Csengeri, Eila Lahdes, Young K. Yeo, 
Zolta´n Krasznai, and J.E. Halver, Docosahexaenoic acid-containing phospholipid molecular 
species in brains of vertebrates. Proceedings of the National Academy of Sciences of the United 
States of America, 2000. 97(2): p. 6362–6366. 
94. Siddhartha Das, Cynthia Castillo, and T. Stevens, Phospholipid remodeling/generation in 
Giardia: the role of the Lands cycle. Trends in Parasitology, 2001. 17(7): p. 316-319. 
95. Miao-Lin Hu, Edwin N. Frankel, Brian E. Leibovitz, and A.L. Tappel, Effect of Dietary Lipids 
and Vitamin E on In Vitro Lipid Peroxidation in Rat Liver and Kidney Homogenates. The Journal 
of Nutrition, 1989. 119: p. 1574-1582. 
96. Denise Grotto, Lucas Santa Maria, Juliana Valentini, Clóvis Paniz, Gabriela Schmitt e Solange, 
Cristina Garcia, Valdeci Juarez Pomblum, João Batista T. Rocha, and M. Farina, Importance of 
the lipid peroxidation biomarkers and methodological aspects for malondialdehyde 
quantification. Química Nova, 2009. 32(1): p. 169-174. 
97. Paolo Montuschi, Peter J. Barnes, and L.J.R. II, Isoprostanes: markers and mediators of 
oxidative stress. The FASEB Journal, 2004. 18: p. 1791-1800. 
98. Francesco M. Megli and L. Russo, Different oxidized phospholipid molecules unequally affect 
bilayer packing. Biochemica et Biophysica Acta, 2008. 1778: p. 143-152. 
99. Mina Araseki, Kanako Yamamoto, and K. Miyashita, Oxidative Stability of Polyunsaturated 
Fatty Acid in Phosphatidylcholine Liposomes. Journal of Bioscience, Biotechnology and 
Biochemistry, 2002. 66(12): p. 2573-2577. 
100. A Negre-Salvayre, C Coatrieux, C Ingueneau, and R. Salvayre, Advanced lipid peroxidation end 
products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for 
the inhibitors. British Journal of Pharmacology, 2007. 2007: p. 1-15. 
101. W.R. Markesbery, The Role of Oxidative Stress in Alzheimer's Disease. Archives of Neurology, 
1999. 56: p. 1449-1452. 
102. Stig Rehncrona, David S. Smith, Bjorn Akesson, Eva Westerberg, and B.K. Siesjo, Peroxidative 
Changes in Brain Cortical Fatty Acids and Phospholipids, as Characterized During Fe
2+
- and 
Ascorbic acid-Stimulated  Lipid Peroxidation In Vitro. Journal of Neurochemistry, 1980. 34(6): 
p. 1630-1638. 
103. Thomas M. McIntyre, Guy A. Zimmerman, and S.M. Prescott, Biologically Active Oxidized 
Phospholipids. The Journal of Biological Chemistry, 1999. 274 (36)(September 3): p. 25189-
25192. 
104. A.W. Girotti, Lipid hydroperoxide generation, turnover, and effector action in biological systems. 
Journal of Lipid Research, 1998. 39: p. 1529-1542. 
105. Cinzia Signorini, Serafina Perrone, Cristiana Sgherri, Lucia Ciccoli, Giuseppe Buonocore, Silvia 
Leoncini, Viviana Rossi, Daniela Vecchio, and M. Comporti, Plasma Esterified F2-Isoprostanes 
and Oxidative Stress in Newborns: Role of Nonprotein-Bound Iron. Pediatric Research, 2008. 
63(3): p. 287-291. 
106. Francesco M. Megli, Luciana Russo, and K. Sabatini, Oxidized phospholipids induce phase 
separation in lipid vesicles. FEBS Letters, 2005. 579: p. 4577-4584. 
107. A E Holley and K.H. Cheeseman, Measuring free radical reactions in vivo. British Medical 
Bulletin, 1993. 49(3): p. 494-505. 
108. Yoshichika Kawai, Sayaka Takeda, and J. Terao, Lipidomic Analysis for Lipid 
Peroxidation-Derived Aldehydes Using Gas Chromatography-Mass Spectrometry. 
Chemical Research in Toxicology, 2007. 20: p. 99-107. 
108 
 
109. R.A. Wheatley, Some recent trends in the analytical chemistry of lipid peroixdation. Trends in 
Analytical Chemistry, 2000. 19(10): p. 617-628. 
110. J. Nourooz-Zadeh, N.K. Gopaul, S. Barrow, A.I. Mallet, and E.E. Anggard, Analysis of F2-
isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-
mass spectrometry: development of a solid-phase extraction procedure. Journal of 
Chromatography B, 1995. 667: p. 199-208. 
111. Michel Guichardant, Pascale Taibi-Tronchie, Laurent B. Fay, and M. Lagarde, Covalent 
modifications of aminophospholipids by 4-hydroxynonenal. Free Radical Biology & Medicine, 
1998. 25(9): p. 1049-1056. 
112. R.J. Schaur, Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Molecular Aspects 
of Medicine, 2003. 24: p. 149-159. 
113. M. Guichardant, N. Bernoud-Hubac, B. Chantegrel, C. Deshayes, and M. Lagarde, Aldehydes 
from n-6 fatty acid peroxidation. Effects on aminophospholipids. Prostaglandins, Leukotrienes 
and Essential Fatty Acids, 2002. 67(2-3): p. 147-149. 
114. A.A. Farooqui, Lipid Mediators in the Neural Cell Nucleus: Their Metabolism, Signaling, and 
Association with Neurological Disorders. The Neuroscientist, 2009. 15(4): p. 392-407. 
115. M. Guichardant, B. Chantegrel, C. Deshayes, A. Doutheau, P. Moliere, and M. Lagarde, Specific 
markers of lipid peroxidation issued from n−3 and n−6 fatty acids. Biochemical Society 
Transactions, 2004. 32, Part 1: p. 139-140. 
116. Eric K. Long, Tonya C. Murphy, Laura J. Leiphon, John Watt, Jason D. Morrow, Ginger L. 
Milne, Jocelyn R. H. Howard, and M.J.P. Sr, Trans-4-hydroxy-2-hexenal is a neurotoxic product 
of docosahexaenoic (22:6; n-3) acid oxidation. Journal of Neurochemistry, 2008. 105: p. 714-
724. 
117. L. Jackson Roberts II and J.D. Morrow, The generation and actions of isoprostanes. Biochemica 
et Biophysica Acta, 1997. 1345: p. 121-135. 
118. Jason D. Morrow, Kristina E. Hill, Raymond F. Burk, Tarek M. Nammour, Kamal F. Badr, and 
L.J.R. II, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-
cyclooxygenase, free radical-catalyzed mechanism. Proceedings of the National Academy of 
Sciences of the United States of America, 1990. 87: p. 9383-9387. 
119. Anna Iannone, Anna Petroni, Elisabetta Murru, Lina Cordeddu, Gianfranca Carta, Maria Paola 
Melis, Stefania Bergamini, Lara Della Casa, Laura Cappiello, Romina Carissimi, Marianne 
O’Shea, Doris Bell, Enrico De Santis, and S. Banni, Impairment of 8-iso-PGF2 isoprostane 
metabolism by dietary conjugated linoleic acid (CLA) Prostaglandins, Leukotrienes and Essential 
Fatty Acids, 2009. 80: p. 279-287. 
120. J. Nourooz-Zadeh, Key issues in F2-isoprostane analysis. Biochemical Society Transactions, 
2008. 36(5): p. 1060-1065. 
121. Jaffar Nourooz-Zadeh, Barry Halliwell, and E.E. Anggard, Evidence for the Formation of F3-
Isoprostanes during Peroxidation of Eicosapentaenoic Acid. Biochemical and Biophysical 
Research Communications, 1997. 236: p. 467-472. 
122. Domenico Pratico, Orla P. Barry, John A. Lawson, Mustafa Adiyaman, Seong-Woo Hwang, 
Subhash P. Khanapure, Luigi Iuliano, Joshua Rokach, and G.A. Fitzgerald, IPF2a-I: An index of 
lipid peroxidation in humans. Proceedings of the National Academy of Sciences of the United 
States of America, 1998. 95: p. 3449-3454. 
123. Sarah L. Cuddihy, Sameh S. Ali, Erik S. Musiek, Jacinta Lucero, Sarah J. Kopp, Jason D. 
Morrow, and L.L. Dugan, Prolonged a-Tocopherol Deficiency Decreases Oxidative Stress and 
Unmasks a-Tocopherol-dependent Regulation of Mitochondrial Function in the Brain. The 
Journal of Biological Chemistry, 2008. 283(11): p. 6915-6924. 
124. Akhlaq A. Farooqui, Lloyd A. Horrocks, and T. Farooqui, Modulation of inflammation in brain: 
a matter of fat. Journal of Neurochemistry, 2007. 101(3): p. 577-599. 
125. Kai On Chu, Chi Chiu Wang, Michael Scott Rogers, and C.P. Pang, Quantifying F2-isoprostanes 
in umbilical cord blood of newborn by gas chromatography-mass spectrometry. Analytical 
Biochemistry, 2003. 316: p. 111-117. 
126. Douglass F. Taber, P. Ganapati Reddy, and K.O. Arneson, A Potential Route to Neuroprostanes 
and Isoprostanes: Preparation of the Four Enantiomerically Pure Diastereomers of 13-F4t-
NeuroP. Journal of Organic Chemistry, 2008. 73(9): p. 3467-3474. 
127. Janine Bessard, Jean-Luc Cracowski, Franc¸oise Stanke-Labesque, and G. Bessard, 
Determination of isoprostaglandin F2a type III in human urine by gas chromatography–electronic 
109 
 
impact mass spectrometry. Comparison with enzyme immunoassay. Journal of Chromatography 
B, 2001. 754: p. 333-343. 
128. S. Basu, Metabolism of 8-iso-prostaglandin F2a. FEBS Letters, 1998. 428: p. 32-36. 
129. Daniel F. Wendelborn, Karen Seibert, and L.J.R. II, Isomeric prostaglandin F2 compounds 
arising from prostaglandin  D2: A family of icosanoids produced in vivo in humans. Proceedings 
of the National Academy of Sciences of the United States of America, . 85: p. 304-308. 
130. X. Hou, L.J. Roberts II, D.F. Taber, J.D. Morrow, K. Kanai, F. Gobeil Jr, M.H. Beauchamp, S.G. 
Bernier, G. Lepage, D.R. Varma, and S. Chemtob, 2, 3-Dinor-5, 6-dihydro-15-F2t-isoprostane: A 
bioactive prostanoid metabolite. American Journal of Physiology - Regulatory, Integrative and 
Comparative Physiology, 2001. 281: p. R391-R400. 
131. S.W. Hoffman, B.A. Rzigalinski, K.A. Willoughby, and E.F. Ellis, Astrocytes Generate 
Isoprostanes in Response to Trauma or Oxygen Radicals. Journal of Neurotrauma, 2000. 17(5): 
p. 415-420. 
132. Dejan Milatovic, Mike VanRollins, Ke Li, Kathleen S. Montine, and T.J. Montine, Suppression 
of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate 
immune response in vivo by alpha or gamma - tocopherol. Journal of Chromatography B, 2005. 
827: p. 88-93. 
133. Giuseppe Zanoni, Enrico M. Brunoldi, Alessio Porta, and G. Vidari, Asymmetric Synthesis of 14-
A4t-Neuroprostane: Hunting for a Suitable Biomarker for Neurodegenerative Diseases. Journal 
of Organic Chemistry, 2007. 72: p. 9698-9703. 
134. S.S. Davies, Lipidomic approaches to measuring isoprostanes and other markers of oxidative 
stress. European Journal of Lipid Science and Technology, 2009. 111: p. 64-74. 
135. Chiara Chiabrando, Claudia Rivalta, Renzo Bagnati, Anna Valagussa, Thierry Durand, Alexandre 
Guy, Pia Villa, Jean-Claude Rossi, and R. Fanelli, Identification of metabolites from Type III F2-
isoprostane diastereoisomers by mass spectrometry. Journal of Lipid Research, 2002. 43: p. 495-
509. 
136. Kristina Claeson Bohnstedt, Bo Karlberg, Lars-Olof Wahlund, Maria Eriksdotter Jonhagen, Hans 
Basun, and S. Schimdt, Determination of isoprostanes in urine samples from Alzheimer patients 
using porous graphitic carbon liquid chromatography-tandem mass spectrometry. Journal of 
Chromatography B, 2003. 796: p. 11-19. 
137. Horst Schweer, Bernhard Watzer, Hannsjorg W. Seyberth, and R.M. Nusing, Improved 
Quantification of 8-epi-Prostaglandin F2a and F2-isoprostanes by Gas Chromatography/Triple 
Stage Quadrupole Mass Spectrometry: Partial Cyclooxygenase-dependent Formation of 8-epi-
Prostaglandin F2a in Humans. Journal of Mass Spectrometry, 1997. 32. 
138. J. Nourooz-Zadeh, M. B. Cooper, D. Ziegler, and D.J. Betteridge, Urinary 8-epi-PGF2a and its 
endogenous b-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total 
body oxidative stress. Biochemical and Biophysical Research Communications, 2005. 330: p. 
731-736. 
139. Erik S. Musiek, Jin K. Cha, Huiyong Yin, William E. Zackert, Erin S. Terry, Ned A. Porter, 
Thomas J. Montine, and J.D. Morrow, Quantification of F-ring isoprostane-like compounds (F4-
neuroprostanes) derived from docosahexaenoic acid in vivo in humans by a stable isotope dilution 
mass spectrometric assay. Journal of Chromatography B, 2004. 799: p. 95-102. 
140. Cinzia Signorini, Lucia Ciccoli, Silvia Leoncini, Silvia Carloni, Serafina Perrone, Mario 
Comporti, Walter Balduini, and G. Buonocore, Free iron, total F2-isoprostanes and total F4-
neuroprostanes in a model of neonatal hypoxic-ischemic encephalopathy: neuroprotective effect 
of melatonin. Journal of Pineal Research, 2009. 46: p. 148-154. 
141. Gemma Casadesus, Mark A Smith, Samar Basu, Jing Hua, Dae E Capobianco, Sandra L Siedlak, 
X. Zhu, and G. Perry, Increased isoprostane and prostaglandin are prominent in neurons in 
Alzheimer disease. Molecular Neurodegeneration, 2007. 2: p. 2. 
142. Long Guo Quan and J.K. Cha, Recent advances in the stereoselective synthesis of isoprostanes 
and neuroprostanes. Chemistry and Physics of Lipids, 2004. 128: p. 3-14. 
143. Erik S. Musiek, Rebecca S. Breeding, Ginger L. Milne, Giuseppe Zanoni, Jason D. Morrow, and 
B.A. McLaughlin, Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation 
which enhance neurodegeneration. Journal of Neurochemistry, 2006. 97: p. 1301-1313. 
144. Caiqiong Liu, Tracy Tazzeo, Alexandre Guy, Thierry Durand, and L.J. Janssen, 
Pharmacological actions of isoprostane metabolites and phytoprostanes in human and bovine 
110 
 
pulmonary smooth muscles. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2007. 76: p. 
57-64. 
145. Gemma Calamandrei, Aldina P. Venerosi, Angela Valanzano, Maria Anna De Berardinis, Anita 
Greco, Maria Puopolo, and L. Minghetti, Increased Brain Levels of F2-Isoprostane Are an Early 
Marker of Behavioral Sequels in a Rat Model of Global Perinatal Asphyxia. Pediatric Research, 
2004. 55(1): p. 85-92. 
146. Etsuo Niki, Yasukazu Yoshida, Yoshiro Saito, and N. Noguchi, Lipid peroxidation: Mechanisms, 
inhibition, and biological effects. Biochemical and Biophysical Research Communications, 2005. 
338: p. 668-676. 
147. Huiyong Yin, Wei Liu, Kasia Goleniewsk, Ned A. Porter, Jason D. Morrow, and R.S.P. Jr, 
Dietary supplementation of -3 fatty acid-containing fish oil suppresses F2-isoprostanes but 
enhances inflammatory cytokine response in a mouse model of ovalbumin-induced allergic lung 
inflammation. Free Radical Biology & Medicine, 2009. 47(5): p. 622-628. 
148. Jason D. Morrow, Thomas M. Harris, and L.J.R. II, Noncyclooxygenase Oxidative Formation of 
a Series of Novel Prostaglandins: Analytical Ramifications for Measurement of Eicosanoids. 
Analytical Biochemistry, 1990. 184: p. 1-10. 
149. Jason D. Morrow, Tanya A. Minton, Chetan R. Mukundan, Michelle D. Campbell, William E. Zackert, 
Vincent C. Daniel, Kamal F. Badrll, Ian A. Blair, and L.J. Roberts, Free Radical-induced Generation 
of Isoprostanes in Vivo. The Journal of Biological Chemistry, 1994. 269(11): p. 4317-4326. 
150. Russell J. Waugh, Jason D. Morrow, L. Jackson Roberts II, and R.C. Murphy, Identification and 
Relative Quantitation of F2-Isoprostane Regioisomers Formed In Vivo in the Rat. Free Radical 
Biology & Medicine, 1997. 23(6): p. 943-954. 
151. Thierry Durand, Vale´rie Bultel-Ponce´, Alexandre Guy, Susanne Berger, Martin J. Mueller, and 
J.-M. Galano, New Bioactive Oxylipins Formed by Non-Enzymatic Free-Radical-Catalyzed 
Pathways: the Phytoprostanes. Lipids, 2009. 44: p. 875-888. 
152. S. Basu, Isoprostanes: Novel Bioactive Products of Lipid Peroxidation. Free Radical Research, 
2004. 38(2): p. 105-122. 
153. Joshua Rokach, Seongjin Kim, Sophie Bellone, John A. Lawson, Domenico Praticò, William S. 
Powell, and G.A. FitzGerald, Total synthesis of isoprostanes: discovery and quantitation in 
biological systems. Chemistry and Physics of Lipids, 2004. 128: p. 35-56. 
154. Ruth Imbusch and M.J. Mueller, Formation of isoprostane F2-like compounds (Phytoprostanes 
F1) from -linolenic acid in plants. Free Radical Biology & Medicine, 2000. 28(5): p. 720-726. 
155. Kyung Mee Kim, Byung Hwa Jung, Ki-Jung Paeng, Sang Wook Kim, and B.C. Chung, 
Alteration of plasma total F2-isoprostanes before and after hemodialysis in end-stage renal 
disease patients. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2004. 70: p. 475-478. 
156. Frederic Favreau, Isabelle Petit-Paris, Thierry Hauet, Delphine Dutheil, Yves Papet, Gerard 
Mauco, and C. Tallineau, Cyclooxygenase 1-dependent production of F2-isoprostane and 
changes in redox status during warm renal ischemia-reperfusion. Free Radical Biology & 
Medicine, 2004. 36(8): p. 1034-1042. 
157. Domenico Praticò, John A. Lawson, and G.A. FitzGerald, Cylooxygenase-dependent Formation 
of the Isoprostane, 8-Epi Prostaglanidn F2. The Journal of Biological Chemistry, 1995. 270(17): 
p. 9800-9808. 
158. Russell J. Waugh and R.C. Murphy, Mass Spectrometric Analysis of Four Regioisomers of F2-
Isoprostanes Formed by Free Radical Oxidation of Arachidonic Acid. Journal of American 
Society for Mass Spectrometry, 1996. 7: p. 490-499. 
159. Fadi T. Khasawneh, Jin-Sheng Huang, Fozia Mir, Subhashini Srinivasan, Chinnaswamy 
Tiruppathi, and G.C.L. Breton, Characterization of isoprostane signaling: Evidence for a unique 
coordination profile of 8-iso-PGF2a with the thromboxane A2 receptor, and activation of a 
separate cAMP-dependent inhibitory pathway in human platelets. Biochemical Pharmacology, 
2008. 75: p. 2301-2315. 
160. Anna Nicolaou and G. Kokotos, Bioactive Lipids. Vol. 17. 2004, Bridgwater: The Oily Press. 
161. The Eicosanoids, ed. P. Curtis-Prior. 2004: John Wiley & Sons, Ltd. 
162. Ulf Diczfalusy and S.E.H. Alexson, Peroxisomal chain-shortening of prostaglandin F2a. Journal 
of Lipid Research, 1988. 29: p. 1629-1636. 
163. Ulf Diczfalusy and S.E.H. Alexson, ldentification of metabolites from peroxisomal b-oxidation of 
prostagIandins. Journal of Lipid Research, 1990. 31: p. 301-314. 
111 
 
164. Chiara Chiabrando, Anna Valagussa, Claudia Rivalta, Thierry Durand, Alexandre Guy, Ettore 
Zuccato, Pia Villa, Jean-Claude Rossi, and R. Fanelli, Identification and Measurement of 
Endogenous beta-Oxidation Metabolites of 8-epi-Prostaglandin F2a. The Journal of Biological 
Chemistry, 1999. 274(3): p. 1313-1319. 
165. Ruth Imbusch and M.J. Mueller, Analysis of Oxidative Stress and Wound-Inducible Dinor 
Isoprostanes F1 (Phytoprostanes F1) in Plants. Plant Physiology, 2000. 124: p. 1293-1303. 
166. Julie M Proudfoot, Anne E Barden, Wai Mun Loke, Kevin D Croft, Ian B Puddey, and T.A. 
Mori, High Density Lipoprotein is the Major Lipoprotein Carrier of Plasma F2-Isoprostanes 
Journal of Lipid Research, 2009. 50: p. 716-722. 
167. Michel Guichardant and M. Lagarde, Analysis of biomarkers from lipid peroxidation: A 
comparative study. European Journal of Lipid Science and Technology, 2009. 111: p. 75-82. 
168. Roger M. Nitsch, Jan K. Blusztajn, Anastassios G. Pittas, Barbara E. Slack, John H. Growdon, 
and a.R.J. Wurtman, Evidence for a membrane defect in Alzheimer disease brain. Proceedings of 
the National Academy of Sciences of the United States of America, 1992. 89: p. 1671-1675. 
169. Me´lanie Plourde, Me´lanie Fortier, Mile`ne Vandal, Jennifer Tremblay-Mercier, Erika 
Freemantle, Michel Be´gin, Fabien Pifferi, and S.C. Cunnane, Unresolved issues in the link 
between docosahexaenoic acid and Alzheimer’s disease. Prostaglandins, Leukotrienes and 
Essential Fatty Acids, 2007. 77: p. 301-308. 
170. M. Soderberg, C. Edlund, I. Alafuzoff, K. Kristensson, and G. Dallner, Lipid Composition in 
Different Regions of the Brain in Alzheimer's Disease/Senile Dementia of Alzheimer's Type. 
Journal of Neurochemistry, 1992. 59: p. 1646-1653. 
171. Ernst J. Schaefer, Vanina Bongard, Alexa S. Beiser, Stefania Lamon-Fava, Sander J. Robins, 
Rhoda Au, Katherine L. Tucker, David J. Kyle, Peter W. F. Wilson, and P.A. Wolf, Plasma 
Phosphatidylcholine Docosahexaenoic Acid Content and Risk of Dementia and Alzheimer 
Disease. The Framingham Heart Study. Archives of Neurology, 2006. 63: p. 1545-1550. 
172. Pascale Barberger-Gateau, Luc Letenneur, Valérie Deschamps, Karine Pérès, Jean-François 
Dartigues, and S. Renaud, Fish, meat, and risk of dementia: Cohort study. British Medical 
Journal 2002. 325: p. 932-933. 
173. Walter J. Lukiw, Jian-Guo Cui, Victor L. Marcheselli, Merete Bodker, Anja Botkjaer, Katherine 
Gotlinger, Charles N. Serhan, and N.G. Bazan, A role for docosahexaenoic acid–derived 
neuroprotectin D1 in neural cell survival and Alzheimer disease. The Journal of Clinical 
Investigation, 2005. 115(10): p. 2774-2783. 
174. Erin E. Reich, William R. Markesbery, L. Jackson Roberts II, Larry L. Swift, Jason D. Morrow, 
and T.J. Montine, Brain Regional Quantification of F-ring and D-/E-RIng Isoprostanes and 
Neuroprostanes in Alzheimer's Disease. American Journal of Pathology, 2001. 158(1): p. 293-
297. 
175. E. R. Skinner, C. Watt, J. A. O. Besson, and P.V. Best, Differences in the fatty acid composition 
of the grey and white matter of different regions of the brains of patients with Alzheimer's disease 
and control subjects. Brain, 1993. 116: p. 717-725. 
176. Yvonne Freund-Levi, Maria Eriksdotter-Jo¨nhagen, Tommy Cederholm, Hans Basun, Gerd 
Faxe´n-Irving, Anita Garlind, Inger Vedin, Bengt Vessby, Lars-Olof Wahlund, and J. Palmblad, 
-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD 
Study. Archives of Neurology, 2006. 63: p. 1402-1408. 
177. Domenico Pratico` , Virginia M.-Y.Lee, John Q. Trojanowski, Joshua Rokach, and G.A. 
Fitzgerald, Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid 
peroxidation in vivo. FASEB, 1998. 12: p. 1777-1783. 
178. Mike VanRollins, Randall L. Woltjer, Huiyong Yin, Jason D. Morrow, and T.J. Montine, F2-
Dihomo-isoprostanes arise from free radical attack on adrenic acid. Journal of Lipid Research, 
2008. 49: p. 995-1005. 
179. Thomas Fraser, Hannah Tayler, and S. Love, Fatty Acid Composition of Frontal, Temporal and 
Parietal Neocortex in the Normal Human Brain and in Alzheimer’s Disease. Neurochemical 
Research 2009. 35(3): p. 503-513. 
180. Shiro Mawatari and K. Murakami, Analysis of Membrane Phospholipid Peroxidation by Isocratic 
High-Performance Liquid Chromatography with Ultraviolet Detection. Analytical Biochemistry, 
1998. 264: p. 118–123. 
112 
 
181. Gottfried Haase and W.L. Dunkley, Ascorbic acid and copper in linoleate oxidation. I. 
Measurement of oxidation by ultraviolet spectrophotometry and the thiobarbituric acid test. 
Journal of Lipid Research, 1969. 10: p. 555-560. 
182. Firoze B. Jungalwala, James E. Evans, and R.H. McCluer, High-Performance Liquid 
Chromatography of Phosphatidylcholine and Sphingomyelin with Detection in the Region of 
200nm. Biochemistry Journal, 1976. 145: p. 517-526. 
183. Kazuhiro Kubo, Morio Saito, Tadahiro Tadokoro, and A. Maekawa, Preferential Incorporation 
of Docosahexaenoic Acid into Nonphosphorus Lipids and Phosphatidylethanolamine Protects 
Rats from Dietary DHA-Stimulated Lipid Peroxidation. The Journal of Nutrition, 2000. 130: p. 
1749-1759. 
184. Elisabetta Angioni, Giovanni Lercker, Natale G. Frega, Gianfranca Carta, Maria Paola Melis, 
Elisabetta Murru, Simona Spada, and S. Banni, UV spectral properties of lipids as a tool for their 
identification. European Journal of Lipid Science and Technology, 2002. 104: p. 59-64. 
185. Ryungsoon Song Kim and F.S. LaBella, Comparison of analytical methods for monitoring 
autoxidation profiles of authentic lipids. Journal of Lipid Research, 1987. 28: p. 1110-1117. 
186. M. Hermes-Lima, W.G. Willmore, and K.B. Storey, Quantification of lipid peroxidation in tissue 
extracts based on Fe(III)xylenol orange complex formation. Free Radical Biology & Medicine, 
1995. 19(3): p. 271-80. 
187. C. Schneider, An update on products and mechanisms of lipid peroxidation. Molecular Nutritional 
Food Research, 2009. 53: p. 315-321. 
188. R. Re, N. Pellegrini, A. Proteggente, A. Pannala, M. Yang, and C. Rice-Evans, Antioxidant 
activity applying an improved ABTS radical cation decolorization assay. Free Radical Biology & 
Medicine, 1999. 26(9-10): p. 1231-7. 
189. H. Ohkawa, N. Ohishi, and K. Yagi, Assay for lipid peroxides in animal tissues by thiobarbituric 
acid reaction. Analytical Biochemistry, 1979. 95(2): p. 351-8. 
190. Manisha Patel, Li-Ping Liang, Huagong Hou, Benjamin B. Williams, Maciej Kmiec, Harold M. 
Swartz, Joshua P. Fessel, and L.J.R. II, Seizure-induced formation of isofurans: novel products of 
lipid peroxidation whose formation is positively modulated by oxygen tension. Journal of 
Neurochemistry, 2008. 104: p. 264-270. 
191. Ginger L. Milne, Stephanie C. Sanchez, Erik S. Musiek, and J.D. Morrow, Quantification of F2-
isoprostanes as a biomarker of oxidative stress. Nature Protocols, 2007. 2(1): p. 221-226. 
192. Jaffar Nourooz-Zadeh, Edwin H. C. Liu, Erik. E. Anggard, and B. Halliwell, F4-Isoprostanes: A 
Novel Class of Prostanoids Formed during Peroxidation of Docosahexaenoic Acid (DHA). 
Biochemical and Biophysical Research Communications, 1998. 242: p. 338-344. 
193. Dejian Huang, Boxin Ou, and R.L. Prior, The Chemistry behind Antioxidant Capacity Assays. 
Journal of Agricultural and Food Chemistry, 2005. 53: p. 1841-1856. 
194. Ingrid Wiswedel, Daniela Hirsch, Siegfried Kropf, Martin Gruening, Eberhard Pfister, Tankred 
Schewe, and H. Sies, Flavanol-rich Cocoa Drink Lowers Plasma F2-Isoprostane Concentrations 
in Humans. Free Radical Biology & Medicine, 2004. 37(3): p. 411-421. 
195. Emilie Mas, Francoise Michel, Alexandre Guy, Valerie Bultel, Yoan Falquet, Patrick Chardon, 
Jean-Claude Rossi, Jean Paul Cristol, and T. Durand, Quantification of urinary F2-isoprostanes 
with 4(RS)-F4t-neuroprostane as an internal standard using gas chromatography-mass 
spectrometry. Application to polytraumatized patients. Journal of Chromatography B, 2008. 872: 
p. 133-140. 
196. Libin Xu, Todd A. Davis, and N.A. Porter, Rate Constants for Peroxidation of Polyunsaturated 
Fatty Acids and Sterols in Solution and in Liposomes. Journal of American Chemical Society, 
2009. 131(36): p. 13037-13044. 
197. Kevin Moore and L.J.R. II, Measurement of Lipid Peroxidation. Free Radical Research, 1998. 
28: p. 659-671. 
198. Ricard Bou, Rafael Codony, Alba Tres, Eric A. Decker, and F. Guardiola, Determination of 
hydroperoxides in foods and biological samples by the ferrous oxidation–xylenol orange method: 
A review of the factors that influence the method’s performance. Analytical Biochemistry, 2008. 
377: p. 1-15. 
199. Christine P. Dancey and J. Reidy, Statistics Without Maths for Psychology. Third edition ed. 
2004, London: Pearson Prentice Hall. 
113 
 
200. Hannah Tayler, Thomas Fraser, J Scott Miners, Patrick G. Kehoe, and S. Love, Oxidative 
balance in Alzheimer's disease: Relationship to APOE, Braak tangle stage and the concentrations 
of soluble and insoluble A. Journal of Alzheimer's disease, 2010. 22(4): p. 1363-1373. 
201. Charlotte Sahlin, Frida Ekholm Pettersson, Lars N. G. Nilsson, Lars Lannfelt, and A.-S. 
Johansson, Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in 
reduced Ab levels in cellular models of Alzheimer’s disease. European Journal of Neuroscience, 
2007. 26: p. 882-889. 
202. P.C. Fraering, Structural and functional determinants of -secretase, an intramembrane protease 
implicated in Alzheimer’s Disease. Current Genomics, 2007. 8: p. 531-549. 
203. Walter J. Lukiw and N.G. Bazan, Docosahexaenoic Acid and the Aging Brain. The Journal of 
Nutrition, 2008. 138: p. 2510–2514. 
204. Hironobu Naiki, Kazuhiro Hasegawa, Itaru Yamaguchi, Hideki Nakamura, Fumitake Gejyo, and 
K. Nakakuki, Apolipoprotein E and antioxidants have different mechanisms of inhibiting 
Alzheimer's -amyloid fibril formation in vitro. Biochemistry, 1998. 37: p. 17882-17889. 
205. Charles Ramassamy, Diana Averill, Uwe Beffert, Stephane Bastianetto, Louise Theroux, 
Suzanne Lussier-Cacan, Jeffrey S. Cohn, Yves Christen, Jean Davignon, Remi Quirion, and J. 
Poirer, Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's 
disease is related to the apolipoprotein E genotype. Free Radical Biology & Medicine, 1999. 
27(5/6): p. 544-553. 
206. Hadi Kharrazi, Asad Vaisi-Raygani, Zohreh Rahimi, Haidar Tavilani, Mahdi Aminian, and T. 
Pourmotabbed, Association between enzymatic and non-enzymatic antioxidant defense mechanism 
with apolipoprotein E genotypes in Alzheimer's disease. Clinical Biochemistry, 2008. 41: p. 932-
936. 
207. Thomas Pham, Ahmer Kodvawala, and D.Y. Hui, The receptor binding domain of 
Apolipoprotein E is responsible for its antioxidant activity. Biochemistry, 2005. 44: p. 7577-
7582. 
208. Christopher M. Lauderback, Jaroslaw Kanski, Janna M. Hackett, Noboyo Maeda, Mark S. Kindy, 
and D.A. Butterfield, Apolipoprotein E modulates Alzheimer's A(1-42)-induced oxidative 
damage to synaptosomes in an allele-specific manner. Brain Research, 2002. 924: p. 90-97. 
209. Thomas B. Shea, Eugene Rogers, David Ashline, Daniela Ortiz, and M.-S. Sheu, Quantification 
of antioxidant activity in brain tissue homogenates using the "total equivalent antioxidant 
capacity". Journal of Neuroscience Methods, 2003. 125: p. 55-58. 
210. Quan Liu, Fang Xie, Raj Rolston, Paula I. Moreira, Akihiko Nunomura, Xiongwei Zhu, Mark A. 
Smith, and G. Perry, Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants. 
Mini-Reviews in Medicinal Chemistry, 2007. 7: p. 171-180. 
211. Resat Apak, Kubilay Guclu, Mustafa Ozyurek, and S.E. Karademir, Novel Total Antioxidant 
Capacity Index for Dietary Polyphenols and Vitamins C and E, Using Their Cupric Ion Reducing 
Capability in the Presence of Neocuproine: CUPRAC Method. Journal of Agricultural and Food 
Chemistry, 2004. 52: p. 7970-7981. 
 
 
114 
 
8    Appendices 
Appendix A – Full results for control cohort, two pages 
 
 
Appendix B – Full results Alzheimer cohort, two pages 
 
 
Appendix C – Graphs demonstrating the reason why age and post-mortem were not      
                        included in statistical analysis 
   
115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
p
p
en
d
ix
 A
 –
 R
es
u
lt
s 
fo
r 
th
e 
co
n
tr
o
l 
co
h
o
rt
 (
co
n
ti
n
u
ed
 o
n
to
 t
h
e 
n
ex
t 
p
ag
e)
 
F
 –
 f
ro
n
ta
l,
 T
P
 –
 t
em
p
o
ra
l,
 B
B
 N
o
 –
 S
am
p
le
 n
u
m
b
er
, 
D
H
A
 a
n
d
 A
A
 e
x
p
re
ss
ed
 a
s 
m
ea
n
 m
o
la
r 
p
er
ce
n
ta
g
e,
 I
P
 a
n
d
 N
P
 (
µ
g
/ 
w
et
 w
ei
g
h
t 
g
),
 C
D
 
(m
m
o
l 
d
m
-3
/ 
w
et
 w
ei
g
h
t 
g
),
 A
B
T
S
 (
T
E
A
C
/g
; 
µ
m
o
l/
 w
et
 w
ei
g
h
tg
),
 F
O
X
 (
C
H
P
E
/ 
w
et
 w
ei
g
h
t 
g
),
 T
B
A
R
s 
(n
m
o
l 
M
D
A
/ 
w
et
 w
ei
g
h
t 
g
).
 
 
116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
 –
 f
ro
n
ta
l,
 T
P
 –
 t
em
p
o
ra
l,
 B
B
 N
o
 –
 S
am
p
le
 n
u
m
b
er
, 
D
H
A
 a
n
d
 A
A
 e
x
p
re
ss
ed
 a
s 
m
ea
n
 m
o
la
r 
p
er
ce
n
ta
g
e,
 I
P
 a
n
d
 N
P
 (
µ
g
/ 
w
et
 w
ei
g
h
t 
g
),
 C
D
 
(m
m
o
l 
d
m
-3
/ 
w
et
 w
ei
g
h
t 
g
),
 A
B
T
S
 (
T
E
A
C
/g
; 
µ
m
o
l/
 w
et
 w
ei
g
h
tg
),
 F
O
X
 (
C
H
P
E
/ 
w
et
 w
ei
g
h
t 
g
),
 T
B
A
R
s 
(n
m
o
l 
M
D
A
/ 
w
et
 w
ei
g
h
t 
g
).
 
 
117 
 
 
F
 –
 f
ro
n
ta
l,
 T
P
 –
 t
em
p
o
ra
l,
 B
B
 N
o
 –
 S
am
p
le
 n
u
m
b
er
, 
D
H
A
 a
n
d
 A
A
 e
x
p
re
ss
ed
 a
s 
m
ea
n
 m
o
la
r 
p
er
ce
n
ta
g
e,
 I
P
 a
n
d
 N
P
 (
µ
g
/ 
w
et
 w
ei
g
h
t 
g
),
 C
D
 
(m
m
o
l 
d
m
-3
/ 
w
et
 w
ei
g
h
t 
g
),
 A
B
T
S
 (
T
E
A
C
/g
; 
µ
m
o
l/
 w
et
 w
ei
g
h
tg
),
 F
O
X
 (
C
H
P
E
/ 
w
et
 w
ei
g
h
t 
g
),
 T
B
A
R
s 
(n
m
o
l 
M
D
A
/ 
w
et
 w
ei
g
h
t 
g
).
 
A
p
p
en
d
ix
 B
 –
 R
es
u
lt
s 
fo
r 
th
e 
A
lz
h
ei
m
er
 c
o
h
o
rt
 (
co
n
ti
n
u
ed
 o
n
to
 t
h
e 
n
ex
t 
p
ag
e)
 
118 
 
 
F
 –
 f
ro
n
ta
l,
 T
P
 –
 t
em
p
o
ra
l,
 B
B
 N
o
 –
 S
am
p
le
 n
u
m
b
er
, 
D
H
A
 a
n
d
 A
A
 e
x
p
re
ss
ed
 a
s 
m
ea
n
 m
o
la
r 
p
er
ce
n
ta
g
e,
 I
P
 a
n
d
 N
P
 (
µ
g
/ 
w
et
 w
ei
g
h
t 
g
),
 C
D
 
(m
m
o
l 
d
m
-3
/ 
w
et
 w
ei
g
h
t 
g
),
 A
B
T
S
 (
T
E
A
C
/g
; 
µ
m
o
l/
 w
et
 w
ei
g
h
tg
),
 F
O
X
 (
C
H
P
E
/ 
w
et
 w
ei
g
h
t 
g
),
 T
B
A
R
s 
(n
m
o
l 
M
D
A
/ 
w
et
 w
ei
g
h
t 
g
).
 
 
119 
 
Appendix C – Age and post-mortem against assays conducted 
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